Global analysis of mRNA decay rates and RNA-binding specificity reveals novel roles for CUGBP1 and PARN deadenylase in muscle cells by Lee, Jerome Edward
DISSERTATION 
 
GLOBAL ANALYSIS OF MRNA DECAY RATES AND RNA-BINDING SPECIFICITY 





Jerome E. Lee 






In partial fulfillment of the requirements 
For the Degree of Doctor of Philosophy 
Colorado State University 






Advisor: Carol J. Wilusz 
Co-advisor: Jeffrey Wilusz 
 
Deborah M. Garrity 










GLOBAL ANALYSIS OF MRNA DECAY RATES AND RNA-BINDING SPECIFICITY 
REVEALS NOVEL ROLES FOR CUGBP1 AND PARN DEADENYLASE IN MUSCLE 
CELLS 
Type I Myotonic Dystrophy (DM1) is characterized by myotonia, cardiac 
conduction defects, muscle wasting, and insulin resistance. In patient muscle cells 
expression and function of the RNA-binding proteins CUGBP1 and MBNL1 are 
disrupted, resulting in altered mRNA metabolism at the levels of splicing and translation. 
Intriguingly, despite strong evidence for CUGBP1 being a regulator of mRNA turnover in 
humans and other organisms, the possibility that defects in mRNA decay contribute to 
DM1 pathogenesis has not been investigated to date.  
As such, we sought to further characterize the roles of CUGBP1 and its partner, 
the deadenylase PARN, in mRNA decay in mouse C2C12 muscle cells. The TNF 
message, which encodes a cytokine known to cause muscle wasting and insulin 
resistance when over-expressed, was stabilized by depletion of CUGBP1. The normally 
rapid decay of the TNF mRNA was also disrupted in cells treated with phorbol ester and 
this coincided with phosphorylation of CUGBP1.  
These findings provided impetus to undertake a global analysis of mRNA decay 
rates in muscle cells. Our investigation revealed that GU- and AU-rich sequence 
elements are enriched in labile transcripts, which encode cell cycle regulators, 
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transcription factors, and RNA-processing proteins. Transcripts specifically bound to 
CUGBP1 in myoblasts are linked with processes such as mRNA metabolism, protein 
targeting to the endoplasmic reticulum, cytoskeletal organization, and transcriptional 
regulation, all of which have implications for muscle cell biology. Consistent with this, 
CUGBP1 depletion profoundly altered the formation of myotubes during differentiation. 
Finally we investigated whether PARN, which interacts with CUGBP1 and 
mediates rapid deadenylation of TNF in HeLa cell extracts, also plays a role in mediating 
mRNA decay in muscle.  We identified 64 mRNA targets whose decay was dependent 
on PARN.  Moreover, deadenylation of the Brf2 mRNA was impaired in PARN knock-
down cells supporting that this mRNA is directly and specifically targeted for decay by 
PARN.   
Taken together our findings demonstrate that CUGBP1 and PARN are critical 
regulators of decay for specific sets of transcripts in muscle cells. It seems likely that 
some or all of the CUGBP1 targets we have identified may be affected in myotonic 
dystrophy.   Defective mRNA turnover could be linked with defects in myogenesis, TNF 
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Chapter 1: Introduction 
Gene expression, mRNA decay, and myotonic dystrophy 
 Gene expression is a multi-step process that must be carefully regulated. A 
significant proportion of this regulation takes place at the post-transcriptional level at 
steps such as splicing, polyadenylation, translation, and mRNA decay. Alteration of post 
transcriptional regulation is observed in the muscle of Myotonic Dystrophy (DM) patients. 
In this debilitating disease, mRNA metabolism is disrupted by expression of a toxic RNA 
molecule which results in altered function of two RNA-binding proteins, Muscleblind 
(MBNL1) and CUG-binding protein (CUGBP1). Herein, with the long term goal of gaining 
valuable insights into DM pathogenesis, we have examined the regulation of mRNA 
stability by CUGBP1 and associated factors in muscle cells. Specifically, this study 
focuses on global control of mRNA decay in muscle cells, the potent mRNA encoding 
the cytokine Tumor Necrosis Factor (TNF), the RNA-binding protein CUGBP1, and the 
Poly(A)-specific Ribonuclease PARN.  
 1.1 The life cycle of an mRNA 
In eukaryotes formation of a mature messenger RNA (mRNA) requires much 
more than mere transcription of a DNA template. During and after transcription many 
tightly regulated events must take place, each of which is associated with a unique array 
of proteins to form a fully competent mRNP (messenger ribonucleoprotein). Starting from 
the addition of a cap structure at the 5’ end of a nascent mRNA molecule, all the way to 
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translation and eventual decay of the transcript, proteins carefully chaperone mRNAs 
through their complex life cycle. 
1.1.1 Transcription 
Transcription is the first and an absolutely required step in gene expression. 
Transcription is the copying of a double-stranded DNA molecule into a single stranded 
RNA molecule by RNA polymerases. Most important here, RNA polymerase II (Pol II) is 
responsible for transcribing DNA to make mRNAs. This multi-subunit protein complex 
not only synthesizes RNA from DNA, but also brings many of the mRNA processing 
enzymes directly to their pre-mRNA substrate. Deposition of the mRNA processing 
factors is carried out by the carboxy-terminal domain (CTD) of the largest subunit of Pol 
II. In humans, the CTD is comprised of 52 copies of the hepta-peptide repeat 
Y1S2P3T4S5P6S7 (Hirose and Ohkuma, 2007). This domain undergoes a series of 
phosphorylation and dephosphorylation events as it proceeds from initiation, to 
elongation, to termination. The phosphorylation state of the CTD correlates with the RNA 
processing factors which are associated to it and deposited on the forming transcript. At 
initiation, Ser-5 is phosphorylated to ensure recruitment of the capping machinery (Gu 
and Lima, 2005). When transcription reaches the elongation phase, phosphorylation of 
the CTD increases at Ser-2 and decreases at Ser-5 (Bentley, 2005). This causes 
association of factors of the pre-mRNA splicing machinery. Finally, phosphorylation at 
Ser-2 further increases near the 3’ end of the nascent RNA, resulting in association of 
factors of the cleavage and polyadenylation machinery with the CTD and its subsequent 





The conventional 7-methylguanosine cap structure found on mammalian mRNAs 
consists of a non-templated guanosine residue with an unusual 5’-to-5’ linkage to the 
first templated base in the RNA molecule. Capping requires three distinct enzymatic 
activities, a triphosphatase, a guanylyl-transferase, and a methyltransferase (Wang et 
al., 1982). Cap addition must be carried out in an efficient manner to protect the mRNA 
from the cellular 5’3’ exoribonucleases XRN1 and RAT1 (Hsu and Stevens, 1993; 
Poole and Stevens, 1995), which will readily degrade RNA with a free 5’ mono-
phosphate. This cap structure is bound by the nuclear Cap-Binding Complex, Cap-
Binding Proteins 80/20 (CBP80/20; Izaurralde et al., 1994; Ohno et al., 1990), which 
protects from decapping, and promotes splicing and export (Lewis and Izaurralde, 1997). 
In addition, the 5’ cap is important for stimulating translation initiation in the cytoplasm 
(Both et al., 1975). Translation is accomplished by association of the cap with the 
eukaryotic translation initiation factor 4E (eIF-4E). eIF-4E interacts with eIF-4G which 
bridges to poly(A) binding protein, resulting in mRNA circularization and translation 
(Sachs and Varani, 2000). 
1.1.3 Splicing 
 Splicing is the process responsible for removing intervening portions of mRNA 
which are not to be translated, termed introns. Like capping, splicing also must be 
carried out in an efficient manner, and is promoted by associations between the CTD of 
Pol II and the serine-arginine rich (SR) proteins which interact with the spliceosome (Das 
et al., 2007). The spliceosome is comprised of well over 100 proteins and RNAs. In 
higher eukaryotes, CBP80/20, the spliceosome, regulatory RNA-binding proteins, 
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chromatin structure and transcription rate, all serve to regulate splice site choice (Nilsen 
and Graveley, 2010).  
At its core, splicing is carried out by ubiquitous small nuclear RNAs or U snRNAs 
complexed with proteins to form small nuclear ribonucleoprotein particles (snRNPs). 
Through base pairing between the U snRNAs and the unspliced pre-mRNA, the snRNPs 
are able to guide two nucleophilic attacks. The first attack is by the intron on to the pre-
mRNA itself, splitting the molecule in half. The second attack is from the free 3’OH of the 
mRNA which releases the intron and joins the two exons. Auxilary factors and RNA-
binding proteins, in complex with RNA molecules direct this highly specific process. 
(McManus and Graveley, 2011). 
 Completion of splicing is important not only for assembling the proper protein 
coding sequence, but also for forming a functional mRNP. Successful splicing leaves a 
specific array of proteins along the mRNA molecule termed exon-junction complexes 
(EJCs). The position of these EJCs on the mRNA serves as another important quality-
control mechanism. EJCs will trigger message decay if improperly positioned relative to 
the stop codon (Kim et al., 2001). Furthermore, proteins found in the EJC are important 
for promoting translation (Lee et al., 2009) and nuclear export via interactions with the 
factors, REF and p15/ALY (Le et al., 2001).  
RNA-binding proteins are essential regulators of the splicing process. Nucleotide 
sequences on the pre-mRNA molecule are specifically recognized by SR proteins, 
heterogeneous nuclear RNA-binding proteins (hnRNPs), and others (CELF, MBNL, 
FOX, NOVA, TIA-1, and so on). In general, splicing is enhanced by binding of SR 
proteins and CELFs (CUGBP and ELAV Like Factors), promoting exon inclusion and 
repressed by binding of hnRNPs and MBNLs, resulting in exon skipping though there 
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are many exceptions (McManus and Graveley, 2011). Predicting splicing patterns is very 
difficult, even with well-characterized binding sites for enhancer and repressor proteins 
(Barash et al., 2010).  
Splicing generates diverse RNA molecules from a limited DNA genome. 
Alternative splicing contributes to the large phenotypic differences between organisms 
like humans and mice which exhibit relatively minor differences in gene sequence (only 
2% unique at the DNA level; Graveley, 2001). Alternative splicing patterns give distinct 
tissues many of their unique properties in higher organisms (Graveley, 2001). For 
example, mis-splicing of the chloride channel-1 (Clcn1) mRNA by loss of MBNL1 
function, reverts the Clcn1 mRNA to the embryonic pattern. This results in the inability to 
quickly relax a muscle once contracted, as the grasp of many newborns exhibit (Mankodi 
et al., 2002). Shortly after birth the splicing patterns switch to the adult isoform allowing 
for both contraction and relaxation.  
1.1.4 Cleavage and polyadenylation 
The final steps in formation of a mature mRNA are cleavage and 
polyadenylation. When the last portion (the 3’ end) of the message has been 
transcribed, the 3’ end formation machinery, recruited by the CTD of Pol-II assembles 
and cleaves the newly transcribed RNA. This event is directed by 
Cleavage/Polyadenylation Specificity Factor  (CPSF), which binds the core (AAUAAA) 
upstream element, in combination with Cleavage Stimulation Factor (CStF) which binds 
a U-rich downstream element. Cleavage between the upstream and downstream 
elements is carried out by the 73 kDa subunit of CPSF (Mandel et al., 2006). Following 
cleavage, around 200 non-templated adenosine residues are added by poly(A) 
polymerase (Sheets and Wickens, 1989). This poly(A) tail has many important functions 
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from shielding the mRNA body from 3’5’ exoribonucleases like the exosome to 
enhancing translation and recruiting mRNA decay factors. In the nucleus the poly(A) tail 
is complexed with the nuclear Poly(A) Binding Protein (PABPN1) which also influences 
poly(A) tail length. In the cytoplasm the tail is bound by PABPC1-4, the cytoplasmic 
poly(A) binding proteins, which promote translation of the message by association with 
other proteins. The interaction between PABPC1, eIF-4G, and eIF-4E circularizes the 
mRNP and promotes translation. Following the cleavage event, Pol II continues to 
transcribe at a slower rate due to CTD phosphorylation. The uncapped nascent RNA is 
degraded by RAT1, which proceeds rapidly down the RNA triggering termination of 
transcription upon reaching the polymerase (Buratowski, 2005).  
 Polyadenylation, like splicing, can be used to produce multiple transcripts from a 
single gene. Predictive algorithms show nearly all genes possess alternative poly(A) 
sites, and studies estimate that about 50% of mRNAs exhibit alternative polyadenylation 
(APA; Tian et al., 2005).  Additional downstream poly(A) signals can act as a fail-safe 
mechanism to ensure 3’ end formation and transcription termination. Moreover cells can 
modulate gene expression by changing the 3’ end of a message. Although this can 
change the coding sequence of a gene, it more often allows for alternative regulatory 
information to be added or removed from an mRNA. Sequence features in the 3’UTR are 
bound by proteins and/or miRNAs which dictate how stable the mRNA is, where it 
localizes to, and how efficiently it is translated. The importance of APA was illustrated 
nicely by the observation that rapidly dividing cells tend to express short mRNA isoforms 
(choose the proximal poly(A) site). The reduced regulation of the short 3’UTR containing 
transcripts was correlated with cancerous cell types (Mayr and Bartel, 2009; Ji et al., 
2009; Sandberg et al., 2008). 
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1.1.4 The mature mRNA and nuclear surveillance  
A mature messenger RNA should have a 7-methyl guanosine cap, exon-exon 
junctions marked by EJCs, and a 3’ poly(A) tail of about 200 nucleotides, though the 
length of the tail has been shown to vary (Yang et al., 2011). The vast majority of our 
knowledge regarding mechanisms that monitor these features, termed nuclear 
surveillance, comes from studies in budding yeast. Relatively little work in this area has 
been done in mammals. During production of the mature mRNA if any of these 
processes fail there are a host of nuclear enzymes which will rapidly degrade the 
aberrant product. Starting at the cap, if addition of the 5’ guanosine residue fails or 
methylation is disrupted, the pyrophosphatase RAI1 will initiate decay of the nascent 
transcript, and the resulting 5’-monophosphate-containing RNA will be degraded by the 
RAT1 exoribonuclease (Jiao et al., 2010).  
If aberrant products are generated during splicing, specific enzyme complexes 
exist to destroy the messages.  Free 3’-ends which may result from incomplete joining of 
exons are rapidly degraded by the nuclear exosome (Callahan and Butler, 2010; see 
below for more discussion). The TRAMP complex enhances the efficiency of nuclear 
decay by catalyzing the addition of non-templated adenosine residues at the 3’ end. In 
addition to poly(A) polymerase activity, TRAMP also contains an RNA helicase for 
unwinding structured 3’ ends (LaCava et al., 2005). The addition of adenosines to a 
structured 3’ end is thought to create a “toe-hold” for decay to initiate. Thus in this 
instance, the polyadenylation machinery actually adds adenosines to promote decay as 




1.1.5 mRNA export 
Once the mature mRNA has been made, it must be transported to the cytoplasm 
where it can be translated. This is a process which requires energy in the form of 
adenosine triphosphate (ATP) and moving the RNA through a 10nm protein tunnel 
called the nuclear pore complex. The majority of cellular mRNAs leave the nucleus by 
association of SR proteins and other EJC components, which bind during processing, 
and interact with adaptor proteins like (REF/p15/ALY)  which in turn bind nuclear export 
factor 1 (NXF1), for a full review see Cook et al., (2007). This mRNP complex associates 
with the nucleoporin proteins or Nups on the nuclear side of the pore, and is moved into 
the cytoplasm (Rodriguez et al., 2004b). By linking processing factors deposited during 
mRNP formation to export, only fully processed mRNAs are efficiently trafficked to the 
cytoplasm. 
1.1.6 Translation 
Translation is the process of converting the open-reading frame of the mRNA into 
a polypeptide chain. It is carried out by the enormous ribonucleoprotein complex called 
the ribosome which is composed of a large 60S and small 40S subunit. Translation 
involves three basic steps, initiation, elongation, and termination.  
Initiation is achieved by association of initiation factors with the mRNA and 40S 
subunit which help to align the 40S subunit with the start codon, and promote large 
subunit joining for proper initiation, elongation, and eventual termination of the nascent 
polypeptide (Kapp and Lorsch, 2004). Interestingly, the conformation of the mRNA is 
important for efficient translation. Message circularization, by eIF-4G bridging the 
interaction of eIF-4E  with PABPC1, synergistically stimulates translation (Gray et al., 
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2000; Tarun, Jr. and Sachs, 1996). Initiation is the rate-limiting step in translation, and is 
extensively regulated, primarily through RNA-binding proteins. For example, the RNA-
binding protein ZBP1 binds the β-actin mRNA at its 3’UTR blocking translation initiation 
by inhibiting 60S subunit joining (Dahm and Kiebler, 2005). The ZBP1 protein also 
associates with myosin motors which travel along the microtubules carrying the β-actin 
mRNA to the edge of the cell, where the SRC kinase phosphorylates ZBP1 reducing its 
affinity for the mRNA. Release by ZBP1 allows the mRNA to be translated producing 
actin monomers, which polymerize to elongate the actin filaments (Huttelmaier et al., 
2005). 
1.1.8 Cross-talk in mRNA metabolism 
Every step along the assembly line of mRNA production seems functionally 
linked to the processes that precede and follow it. Quality control mechanisms are 
prevalent along the way. The cell has a multi-layered strategy in place to ensure that the 
information encoded in DNA is accurately represented in RNA and protein. 
Demonstrative of this cross-talk, transcription and decay are linked. In yeast, one of the 
small subunits of Pol II (Rpb4/7) is an RNA-binding complex that is co-transcriptionally 
loaded onto some mRNAs. Rpb4/7 promotes mRNA export, enhances translation by 
recruiting eIF-4G, and targets messages to processing bodies (P-bodies -which are 
thought to be sites of mRNA storage and decay), during stress (Harel-Sharvit et al., 
2010). Splicing and cleavage/polyadenylation are also coupled. Interactions between 
spliceosomal components (U2AF and U2 snRNP) and cleavage factors (CF1 and the 
CPSF complex) are necessary to allow for transcript release following the 
polyadenylation reaction (Rigo and Martinson, 2009). Cleavage and export are linked. 
Deposition of cleavage factor 1 (CF1m68) promotes nuclear export through interactions 
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with export factor NXF1/TAP (Ruepp et al., 2009). Further cross-talk has been observed 
between translation and mRNA decay. Decay can be initiated on mRNAs associated 
with translating ribosomes (polysomes). This decay is carried out in a specific fashion, 
first deadenylation, then decapping, and finally 5’3’ exoribonucleolytic decay. This 
ensures that the last ribosome will complete translation of an intact ORF before the 
coding sequence is destroyed and indicates a link between the two processes (Hu et al., 
2009). 
1.1.9 mRNP remodeling 
mRNPs are incredibly dynamic complexes that change dramatically as they 
move through their life cycle acquiring and losing proteins at each step. The proteins 
which bind an RNA molecule determine nearly everything about it, from how much 
protein is made to how long the message lasts. The sequence, structure, and 
modification of the RNA molecule determine what those proteins will be. Several 
examples of remodeling events are described below.  
Removal of the 3’-end cleavage and polyadenylation machinery is necessary for 
export to the cytoplasm and in yeast is promoted by the export factor Mex67p (Qu et al., 
2009). Recent studies have shown that the RNA helicase Dbp5p acts at the cytoplasmic 
surface of the nuclear pore complex where it is activated by Nup159p (a nuclear pore 
protein) to promote removal of nuclear RNA-binding proteins from the cytoplasmic-
bound mRNA (Noble et al., 2011). Furthermore, translation promotes the removal of 
PABPN1 and replacement by PABPC1 (Sato and Maquat, 2009).  The nuclear cap 
binding protein CBP80 is removed upon arrival to the cytoplasm by importin-β (Sato and 
Maquat, 2009). The EJCs deposited by splicing are removed during the first round of 
translation in the cytoplasm (Maquat, 2004). During mRNA decay, there is significant 
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remodeling to facilitate access of the mRNA decay enzymes. In the nonsense-mediated 
mRNA decay pathway (see Section 1.3.2.1) the RNA helicase activity of the UPF1 
protein is required to remove bound proteins before the transcript can be degraded 
(Franks et al., 2010). Association of various RNA-binding proteins with the 3’UTR 
regulates the translation  stability, and localization of the mRNA. Protein-mRNA 
associations are continually modulated based on external cues which can trigger post-
translational modifications, relocalization, chaperone interaction, or protein degradation 
(Parker and Sheth, 2007; Briata et al., 2005; Vlasova et al., 2008).  
1.1.10 mRNA decay 
Once a mature mRNA is no longer needed, perhaps due to a change in growth 
conditions or activation of cell signaling pathways, it is degraded. The process of 
degradation is carried out by two classes of ribonucleases. Endoribonucleases which 
can hydrolyze an RNA molecule internally and exoribonucleases which require a free 5’ 
or 3’ end for degradation. In addition, enzymes responsible for degrading the cap 
structure which exhibit special preference for the 5’-to-5’ linkage 
(pyrophosphohydrolases) are also needed. These aspects of mRNA metabolism are 
covered in detail below (Section 1.2). 
 1.2 Gene expression and the role of mRNA decay 
Messenger RNA is a requisite intermediate in the production of proteins and its 
abundance is an important factor in determining levels of gene expression 
(Schwanhausser et al., 2011).  Abundance for a given mRNA in the cytoplasm is 
dependent on the balance among its rates of synthesis (transcription), processing 
(capping, splicing, polyadenylation), export to the cytoplasm, and decay. Recently 
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mRNA decay has received significant attention and has been shown to play an important 
role in controlling gene expression. Several groups (Cheadle et al., 2005; Dolken et al., 
2008; Miller et al., 2011; Sharova et al., 2009; Rabani et al., 2011) have employed 
various transcriptome-wide technologies to determine the impact of mRNA stability on 
overall transcript levels in various cell types and conditions. Their findings vary 
significantly. One study attributed 50% of the changes in overall transcript abundances 
to alterations in mRNA decay rates (Cheadle et al., 2005). Another estimate predicted 
that altered decay is the more significant contributor to changes in message abundance 
for just 17% of mRNAs (Rabani et al., 2011).  
In general, these studies conclude that for some messages there is a good 
correlation between mRNA stability and abundance.  For example very stable 
“housekeeping” messages will be of relatively high abundance and very unstable 
mRNAs are often low abundance. There are classes of mRNAs where stability is 
dynamically regulated and does not necessarily correlate with abundance (Rabani et al., 
2011). Such regulated mRNAs tend to encode proteins like transcription factors, 
cytokines, and mRNA-binding proteins (Mukherjee et al., 2009). 
The TNF mRNA represents an excellent example of a transcript whose 
expression is exquisitely dependent on tightly controlled mRNA decay.  In unstimulated 
immune cells, TNF mRNA abundance is low, and the decay rate is high (Carballo et al., 
1998). Lipopolysaccharide (LPS) treatment causes TNF mRNA abundance to increase 
dramatically, through increased transcription and concomitant down-regulation of mRNA 
decay. Once the biological response has been elicited, transcription rates drop, and 
decay accelerates, rapidly returning the TNF mRNA to low levels (Hoffmeyer et al., 
1999). When appropriate regulation of TNF mRNA half-life is lost, disease ensues in the 
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form of rheumatoid arthritis, Crohn’s disease and other inflammatory conditions 
(Kontoyiannis et al., 1999). Thus, regulated mRNA decay allows for dramatic, rapid, and 
transient changes in gene expression necessary for eliciting a cellular response. Failure 
to appropriately modulate mRNA decay rates can have serious consequences, as 
mouse models lacking the RNA-binding proteins needed for modulating decay of specific 
transcripts have demonstrated (Stumpo et al., 2009; Carballo et al., 1998; Ghosh et al., 
2009; Kress et al., 2007). 
1.3 Mechanisms of mRNA decay  
Decay of mRNAs in the cytoplasm proceeds by two general pathways; the 
deadenylation-dependent pathway, and the deadenylation-independent (Figure 1). The 
process of poly(A) tail removal, initiates the deadenylation-dependent decay pathway 
which is employed for most cellular mRNAs (Garneau et al., 2007). Focus will be given 
to this primary pathway; however, other pathways will be described briefly to give 
perspective. 
 1.3.1 Deadenylation-dependent decay 
A brief overview of the deadenylation-dependent pathway is given here and 
followed by detailed information on the specific enzymes and factors required for each 
step. Deadenylation-dependent decay is unique among decay processes in that the first 
step is reversible. Poly(A) shortening is generally thought of as a way to destabilize 
and/or translationally silence a given message. Poly(A) tail lengthening is thought to 
have the opposite effect, increasing message stability and translatability. CCR4/NOT, 
PAN2/PAN3, and PARN are the best characterized of the many eukaryotic 
deadenylases that can shorten the poly(A) tail (Goldstrohm and Wickens, 2008).  
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Figure 1.  
 
The primary mRNA decay pathway. The majority of cellular mRNAs are decayed in a 
deadenylation-dependent manner. In this pathway, poly(A) tail removal is the first, and rate-
limiting step of message decay. This step is uniquely reversible and represents a key regulatory 
point for control of gene expression. The subsequent decay of the body of the transcript proceeds 
by 5’3’ and/or 3’5’ decay. 5’3’ decay relies association of the LSM1-7 complex and 
recruitment of the decapping enzyme DCP1/2 followed by exoribonucleolytic decay by XRN1. 
3’5’ decay is carried out by the RRP44 subunit of the exosome, and subsequent cap 
destruction by the scavenger decapping enzyme DCPS. 
 
Following deadenylation, transcripts can be degraded in both directions, 5’ 3’ and/or 
3’ 5’. In 5’3’ decay the LSM1-7 complex associates with the 3’ end of the mRNA and 
facilitates decapping by DCP1/DCP2 (Tharun et al., 2000). Once the cap has been 
removed, the transcript is susceptible to degradation by XRN1, which recognizes the 5’-
monophosphate. The 3’ 5’ decay pathway is mediated by the exosome, a 10-subunit 
complex (in mammals) containing one subunit, RRP44, with both 3’5’ exoribonuclease 
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and endoribonuclease activity (Schaeffer et al., 2009). The remaining cap is recycled by 
the scavenging enzyme DCPS (Liu et al., 2002).  
1.3.1.1 Deadenylation 
 Removal of the poly(A) tail is catalyzed by one or more of a family of enzymes 
termed deadenylases. Eukaryotic cells encode many deadenylases; 10 are predicted for 
humans. Thus far these enzymes fall into two categories based on the composition of 
their nuclease domains. The DEDD-type nucleases contain conserved aspartic and 
glutamic acid residues responsible for coordination of the Mg2+ ion needed for catalysis. 
CAF1/CNOT7/POP2, PAN2, and PARN deadenylases fall into this group. The second 
category is the Endonuclease-Exonuclease Phosphatases (EEP) which have conserved 
aspartic acid and histidine residues in their active site for Mg2+ coordination.  CCR4, 
Nocturnin, Angel, and 2’ Phosphodiesterase enzymes are EEPs. The action of these 
deadenylases can be directly opposed by poly(A) polymerases (Goldstrohm and 
Wickens, 2008).  
 1.3.1.1.1 PARN  
PARN is unique in that it is a cap-dependent deadenylase, meaning it 
deadenylates capped transcripts more efficiently than uncapped (Dehlin et al., 2000; 
Gao et al., 2000). It is also inhibited by cap-binding proteins (Gao et al., 2001; Balatsos 
et al., 2006). PARN has a cap-binding pocket and functions as a homodimer (Wu et al., 
2009). One monomer binds the cap, while the other degrades the tail. Due to this feature 
deadenylation by PARN is inhibited by the cap-binding protein CBP80 (Balatsos et al., 
2006). It is also inhibited by the Poly(A) Binding Protein PABPC1 (Korner and Wahle, 
1997). Furthermore, PARN is the predominant active deadenylase in cytoplasmic 
extracts derived from tissue culture cells (Gao et al., 2000). Knock-out of the PARN gene 
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in Arabidopsis, an organism with 26 predicted deadenylases, is lethal at the embryo 
stage (Reverdatto et al., 2004). An additional PARN-related gene, PARN-Like (PNLDC1) 
is also present in mammals, but has not been characterized. 
The best characterized biological role for PARN is in regulating maternal mRNA 
expression during oocyte maturation. In  Xenopus oocytes, PARN is required to keep 
maternally supplied mRNAs such as cyclin B1, Eg-5, and c-mos translationally silent 
(Kim and Richter, 2006; Paillard et al., 1998). Briefly, Cytoplasmic Polyadenylation 
Element Binding protein (CPEB) binds to an UUUUAAU motif in the Cyclin B1 3’UTR 
and forms a complex with GLD2, (a poly(A) polymerase) and PARN. Initially, PARN 
activity is dominant, the poly(A) tail of cyclin B1 is kept short, and translation is inhibited. 
Upon maturation of the oocyte, CPEB is phosphorylated, causing PARN to be expelled 
from the complex, GLD2 then polyadenylates the Cyclin B1 message and translation 
occurs to allow for cell division (Kim and Richter, 2006). 
PARN also plays a role in the nucleus. In response to UV-induced DNA damage, 
nuclear PARN is activated to prevent the accumulation of aberrant mRNAs. This process 
is mediated by the 50kDa subunit of Cleavage Stimulation Factor 50 (CSTF50) and the 
tumor suppressor BARD1.  CSTF50 and PARN form a complex which inhibits 3’ end 
formation of erroneous transcripts. Additionally, CSTF50/BARD1 alleviates the inhibition 
that CBP80 exerts on PARN. This promotes deadenylation and RNA decay (Cevher et 
al., 2010). Under similar DNA-damaging conditions the MK-2 kinase phosphorylates 
PARN in the cytoplasm resulting in stabilization of the Gadd45α mRNA whose gene 
product is necessary for cell cycle arrest to allow sufficient time for DNA repair to occur 
(Reinhardt et al., 2010). In addition, PARN is recruited by RNA-binding proteins including 
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CUGBP1 (Moraes et al., 2006), KSRP (Gherzi et al., 2004), and RHAU (Tran et al., 
2004) for poly(A) tail removal. 
To summarize, PARN is essential in plants (Reverdatto et al., 2004), and is 
important for regulation of translation of maternal mRNAs in vertebrates (Copeland and 
Wormington, 2001). The protein plays a general role in nuclear RNA surveillance 
following DNA damage (Cevher et al., 2010; Reinhardt et al., 2010). Lastly, PARN also 
has been shown to impact the stability of at least one mRNA important for cell cycle 
regulation following genotoxic stress (Reinhardt et al., 2010). Taken together, these 
findings indicate PARN function is important for control of cell division in higher 
eukaryotes.  Genetic studies are lacking as PARN is absent from yeast and Drosophila 
and there is no knockout mouse thus less is known about PARN function compared with 
some other deadenylases. 
 1.3.1.1.2 The CCR4/NOT complex 
In S. cerevisiae, genetic studies have revealed that the CCR4/NOT complex is 
the primary cytoplasmic deadenylase (Yamashita et al., 2005). In humans, this complex 
of proteins is very large (0.9-2.0 MDa; Bartlam and Yamamoto, 2010), consisting of the 
scaffold NOT proteins (CNOT1-5) along with CAF130 and CAF40, as well as the 
deadenylases (in humans) CNOT6 (CCR4a), CNOT6L (CCR4b), CNOT7 (CAF1) and 
CNOT8 (CAF2/POP2), which are homologues of the yeast proteins Ccr4p and Caf1p. 
Current models assert that CCR4/NOT complexes associate with mRNAs by interactions 
with other proteins. One interacting complex is Tob, which is known to have 
antiproliferative activities (Bartlam and Yamamoto, 2010). It appears that the association 
is mediated by mutually hydrophobic regions found on CNOT7 and Tob. In addition, Tob 
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also associates with PABPC1 and this mutual association with PABPC1 and CCR4/NOT 
serves to target the deadenylase to its substrate.  
Recent reports indicate that the CNOT proteins also promote deadenylation 
guided by microRNAs (miRNAs). This activity is mediated by direct recruitment of the 
deadenylase complex to the targeted mRNA by the protein GW182, a subunit of the 
RNA Induced Silencing Complex (RISC; Chen et al., 2009; Fabian et al., 2009).  
Recently, Tristetraprolin (TTP) was shown to recruit the deadenylase 
CNOT7/CAF1 through mutual associations with the scaffold protein CNOT1. This 
triggered poly(A) tail removal of an AU-rich element (ARE) containing reporter RNA 
(Sandler et al., 2011). Work with TTP has also shown that recruitment of cNOT7 is 
inhibited by TTP phosphorylation upon activation of the p38/MAPK pathway (Marchese 
et al., 2010).  Deadenylation by cNOT7 can be mediated directly through PABPC1 
interactions. Eukaryotic Release Factor 3 (eRF3) interacts with both PABPC1 and 
CNOT7. At translation termination, the mutual associations between eRF3, PABPC1, 
and CNOT7 facilitate transfer of the message to the deadenylase for poly(A) tail removal 
(Funakoshi et al., 2007). 
 1.3.1.1.3 PAN2/PAN3 
 Poly(A) Nuclease, PAN2/PAN3, is dependent on PABPC1 being associated with 
the poly(A) tail. As such, current models have it catalyzing the initial shortening of the 
poly(A) tail from 200 to ~80 residues (Yamashita et al., 2005). Interestingly, PAN2/PAN3 
also deadenylates transcripts following translation termination. In a similar mechanism to 
that described above for CNOT7/CAF1, mutual associations between PAN2/PAN3, 
PABPC1, and eRF3 facilitated the hand-off from the translation machinery to the 
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deadenylation machinery through PABPC1 (Funakoshi et al., 2007). In this way, 
PABPC1, functions as a destabilizing factor. 
1.3.2 Deadenylation-independent decay pathways   
 Deadenylation-independent decay pathways have two unifying themes. First, by 
definition they do not rely on poly(A) tail removal. Second, the primary 
endoribonucleolytic cleavage event permanently inactivates the mRNA. These pathways 
target both normal and aberrant transcripts and are reviewed in detail elsewhere 
(Garneau et al., 2007). 
1.3.2.1 Decay of aberrant mRNAs 
 Decay pathways for mRNAs which contain errors that disrupt appropriate 
ribosome travel have been classified based on the particular defect found in the 
transcript; nonsense-mediated, non-stop, and no-go decay. Nonsense-mediated decay 
(NMD) occurs when the ribosome encounters a premature termination codon (PTC). The 
PTC is detected due to inappropriate mRNP conformation; either prolonged association 
of the EJC with the transcript, or excessive distance between the stop codon and poly(A) 
tail (Isken and Maquat, 2007). NMD can trigger an endoribonucleolytic cleavage, 
(Huntzinger et al., 2008) or deadenylation-dependent decay (Lejeune et al., 2003). In a 
complex series of events, the stalled ribosome triggers phosphorylation of the UPF1 
helicase which initiates disassembly of the aberrant mRNP.  This results in recruitment 
of deadenylases, the decapping enzyme, and exonucleases to destroy the aberrant 
message (Franks et al., 2010).  
Non-stop decay is initiated when a message lacks a stop codon and the 
ribosome continues to translate to the 3’ terminal of the transcript. Upon reaching the 3’ 
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end of a “broken” mRNA the ribosome stalls, the SKI7 protein which resembles eRF-3, 
binds to the A-site along with the exosome. The ribosome is released and the message 
is decayed (Garneau et al., 2007).  
No-go decay also results from a stalled ribosome. In this case stalling is caused 
by strong secondary structure in the mRNA coding sequence. This halted ribosome 
triggers endoribonucleolytic cleavage by the DOM34 protein in yeast. Cleavage is 
followed by rapid degradation of the unprotected 5’ and 3’ fragments (Passos et al., 
2009). 
1.3.2.2 Endoribonucleolytic decay 
 One example of an endoribonucleolytic cleavage occurs during mitosis. Upon 
completion of cell division many of the cyclin mRNAs must be destroyed. The RNase 
MRP is a nucleolar localized RNA-protein complex, which initiates decay of the cyclin B2 
mRNA by endoribonucleolytic cleavage (Gill et al., 2004). Recent reports indicate that 
RNase MRP gains access to cytoplasmic mRNAs during nuclear envelope breakdown 
(Schneider et al., 2010). In another example, the role of the endoribonuclease L (RNase 
L) in muscle differentiation is quite dramatic. RNase L regulates stability of the MyoD 
mRNA, and other mRNAs that encode factors which regulate pluripotency. Over-
expression of RNase L inhibited muscle differentiation and promoted conversion to 
adipocytes (Salehzada et al., 2009).  
1.3.2.3 miRNA-mediated decay 
 miRNAs have garnered an enormous amount of attention in recent years for their 
ability to post-transcriptionally regulate gene expression (Bartel and Chen, 2004). This is 
in part due to their ubiquitous nature, and the potential for a single miRNA to 
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coordinately regulate many mRNA targets. miRNAs are short ~21 base RNA molecules, 
which are bound by RISC (Shruti et al., 2011). They use the associated RNA molecule 
(miRNA) as a guide and the Ago2 protein to carry out the endoribonucleolytic cleavage. 
It appears though that another primary mode of miRNA-initiated decay is through 
GW182 (a component of RISC) recruiting the deadenylation machinery by interaction 
with PAN2/PAN3 and CCR4/CAF1 deadenylases (Chen et al., 2009).  
 1.3.3 5’-to-3’ Decay 
Following poly(A) tail removal, or endoribonucleolytic cleavage, 5’3’ decay 
proceeds enzymatically by two basic steps. The first step is removal of the 7-
methyguanosine cap structure at the 5’ end. This is a critical step as it commits the 
transcript to destruction and is regulated by several enhancer and repressor proteins. 
The catalysis is carried out by some members of a super-family of proteins called Nudix 
proteins. They catalyze the hydrolysis of a diphosphate linkage attached to a larger 
molecule. There are 22 of these Nudix proteins present in mammals. Two have been 
verified as decapping enzymes: Dcp2 and Nudt16 (Song et al., 2010).  
In yeast, enhancers of decapping (Edc1 and Edc2) have been shown to bind 
RNA, and through interactions with Dcp1, bridge the enzymatic subunit Dcp2 to its 
substrate. These interactions increase rates of decapping 1000 fold (Borja et al., 2011). 
Not surprisingly, decapping is linked to other aspects of mRNA regulation. The yeast 
proteins Pat1p and Dhh1p enhance decapping and repress translation. Interestingly 
these proteins do this not only by recruiting the decapping enzyme Dcp1p, but also by 
recruiting the yeast deadenylase Pop2p (CAF1; Coller and Parker, 2005; Coller et al., 
2001). This may serve to coordinate the decay of a message with translational arrest.  
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There are many other proteins whose association has been shown to promote 
decapping. Following deadenylation, the heptameric Lsm1-7p complex associates with 
the 3’ end of mRNAs, which promotes decapping and subsequent decay (Tharun et al., 
2000). In metazoans the protein HEDLS/EDC4 (Human enhancer of decapping large 
subunit) associates with and stimulates the activity of the decapping complex 
(DCP1/DCP2; Simon et al., 2006). Furthermore, EDC3 has been shown to mediate 
interactions between GW182 of the RISC machinery and the decapping factors, 
providing a link between miRNA-mediated mRNA regulation and decay (Franks and 
Lykke-Andersen, 2008). Following decapping, the final step is hydrolysis of the 
remaining RNA body by the 5’3’ exoribonuclease XRN1.  
 1.3.4 3’-to-5’ Decay 
Once the poly(A) tail has been removed 3’5’ decay proceeds via the 3’5’ 
exoribonuclease called the exosome. The exosome is a 10-subunit protein complex that 
has endo- (Schaeffer et al., 2009) and exoribonucleolytic activities (Gatfield and 
Izaurralde, 2004). In yeast, the catalytically active subunit is Rrp44 (contains an RNase II 
domain) in the cytoplasm and Rrp44 and Rrp6 in the nucleus. Studies in yeast have 
demonstrated that one function of the nuclear exosome is as a quality-control enzyme in 
conjunction with the nuclear TRAMP complex (LaCava et al., 2005). In mammalian cells 
the exosome is also important for promoting decay of ARE-containing messages (Chen 
et al., 2001; Mukherjee et al., 2002), as well as for NMD (van Dijk et al., 2007). 
Transcriptome-wide studies in Drosophila indicate that 25% of exosome substrates 
contain premature stop codons (Kiss and Andrulis, 2010). Following completion of 3’5’ 




1.3.5 Sites of mRNA decay 
 Production of high-quality antibodies that recognize proteins which carryout RNA 
decay along with advances in fluorescence microscopy have allowed scientist to “see” 
where mRNA decay factors localize. Of the many RNA/protein bodies recorded two have 
gained significant attention within the mRNA turnover field, namely processing bodies 
(P-bodies) and stress granules (SGs). P-bodies are cytoplasmic RNA-containing 
granules which are characterized in mammalian cells by the presence of the AGO1 
protein, in addition to the DCP1, XRN1, and LSM proteins (Spector, 2006). P-bodies are 
hypothesized to be dynamic structures where mRNAs reside when translationally silent, 
stored, and decayed (Parker and Sheth, 2007). Evidence suggest it’s a two-way street 
and mRNAs also traffic from P-bodies back to polysomes (Brengues et al., 2005). 
However, P-bodies are yet to be biochemically purified and recent data indicates that 
mRNA decapping can occur on polysomes (Hu et al., 2009; Hu et al., 2010). As such P-
bodies are thought to be sites where mRNAs are stored and sorted during stress 
conditions requiring bulk movement of RNAs from ribosomes to the decay machinery 
(Parker and Sheth, 2007). Stress granules (SGs) are also ribonucleoprotein foci which 
are induced by heat shock and oxidative stressors. They contain mRNAs associated 
with the small 40S subunit of the ribosome, eIF-3 and other initiation factors. SGs are 
also thought to result when the macromolecular processing machinery of the cell is 
overwhelmed, as they are induced by heat-shock and oxidative stress. There is some 
dynamic exchange of proteins and mRNAs between the P-bodies and SGs indicating a 





1.4 Cis-acting determinants of mRNA stability 
Message decay, like transcription, is a highly regulated process. The primary 
sequence within a given message contains a great deal of information beyond encoding 
a polypeptide. Cis-acting elements are primary sequences which direct interaction of the 
mRNA with specific proteins and/or miRNAs. These cis-acting elements, and the factors 
they recruit, regulate every step in the life cycle of an mRNA from processing to decay. 
Sequences that specifically regulate mRNA decay can be found in the 5’ and 3’ UTRs 
and the coding sequence (CDS). The majority of these elements described to date are 
found in the 3’UTR. This is likely for two simple reasons: (1) the 3’UTR has less 
restriction on length and structure than the 5’UTR, as ribosomes do not have to traverse 
it, and (2) factors which associate in the CDS or 5’UTR would be displaced with each 
passing ribosome. Based on the factors they recruit, cis-acting elements influence 
mRNA decay rates (Misquitta et al., 2001). 
 1.4.1 The cap and poly(A) tail 
 The two most ubiquitous determinants of mRNA stability are the 5’ cap and the 3’ 
poly(A) tail. All cellular mRNAs have a 5’ cap structure. Nearly, all mRNAs have a 3’ 
poly(A) tail, the exception being some histone mRNAs which have a 3’ stem-loop 
structure that fulfills a similar role (Williams and Marzluff, 1995). These features are 
important as their presence serves as a binding platform for the cytoplasmic cap and 
poly(A) binding proteins, eIF-4E and PABPC1 respectively. The presence of these 





 1.4.2 3’UTR regulatory elements 
The 3’ UTR is generally the first place one looks for sequence elements which 
regulate the life span of an mRNA. The best characterized instability elements are AU-
rich elements, GU-rich elements, and UGUA motifs, all which recruit RNA-binding 
proteins.  In addition, the presence of miRNA target sites modulates stability. Cis-acting 
elements are context-dependent. The mere presence of a destabilizing element does not 
mean a message will be unstable. Other factors influence the efficacy of the element 
such as cellular conditions, RNA secondary structure, mRNP conformation, and the 
presence of other elements within the transcript. 
 1.4.2.1 AU-rich elements 
One of the best characterized mRNA stability elements in the 3’UTR are the AU-
rich elements (AREs) which interact with a plethora of trans-acting factors including 
Tristetraprolin (TTP/ZFP36) and the related BRF1/ZFP36L1 and BRF2/ZFP36L2 
(Carballo et al., 1998), AU-rich binding factor (AUF1; Zhang et al., 1993), embryonic 
lethal abnormal vision like protein, HuR/ELAVL1 (Ma et al., 1996), KH-type splicing 
regulatory protein (KSRP; Gherzi et al., 2004), and CUGBP1 (CELF1;  Moraes et al., 
2006). It has been estimated that AREs are present in 5-8% of human transcripts 
(Bakheet et al., 2006). AREs were subdivided into three classes based on the 
arrangement of canonical AUUUA pentamers (Wilusz et al., 2001). Class I AREs contain 
one pentamer flanked by U-rich sequences. Class II contains multiple tandem repeats of 
the pentamer motif. Class III AREs are generally U-rich and lack AUUUA pentamers 
(Peng et al., 1996), and in some cases may be GREs (see below). AREs are commonly 
found in the 3’UTRs of cytokine, growth factor, and transcription factor mRNAs (Caput et 
al., 1986) where they mediate large changes in expression in response to specific 
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stimuli. The TNF ARE is an excellent example of the potency of AREs in modulating 
gene expression. The ARE is absolutely essential for stabilization, decay, and 
translational de-repression of the TNF mRNA in response to cellular stimuli 
(Kontoyiannis et al., 1999). 
 1.4.2.2 GU-rich elements  
In addition to the ARE, cis-acting elements called GREs (GU-rich elements) were 
recently identified (Vlasova et al., 2008). GREs were originally defined as UGUUUGU 
repeats (Vlasova et al., 2008), but during the course of our study UG-repeats were 
included in this class (Rattenbacher et al., 2010). GREs are instability elements very 
similar to AREs. The principle differences are in the proteins which associate with the 
two types of elements. GREs specifically interact with the RNA-binding protein CUGBP1 
(CELF1; Lee et al., 2010; Rattenbacher et al., 2010; Vlasova et al., 2008). HuR has 
affinity for these types of sequences as well (Lopez et al., 2004). GREs are commonly 
found in mRNAs encoding transcription factors as well as cytokines (GREs and AREs 
can often be found on common mRNAs). It is very likely that other uncharacterized 
proteins also interact with GREs to modulate mRNA metabolism. 
 1.4.2.3 UGUA elements 
 The UGUA element also confers instability to mRNAs through association with 
RNA-binding proteins in the Pumilio family. Like AREs and GREs, UGUA elements are 
found on transcription factor, cytokine, and cyclin mRNAs (Morris et al., 2008). These 
three, AREs, GREs, and UGUA elements, are commonly thought of as instability 
elements, but this function can be reversed when a stability factor like HuR associates 
with them (Lopez et al., 2004). 
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1.4.2.4 miRNA-binding sites 
Another class of instability elements commonly found in the 3’UTR are miRNA 
target sites. These show sequence specificity on a case by case basis for the specific 
miRNA-mRNA target pair. From the standpoint of the miRNA, the most important region 
for determining interactions is the 7 base seed sequence at positions 2-8. Efficacy is 
enhanced by adjacent miRNA target sites, AU-richness near the target, proximity to the 
stop codon (>15 bases away), and not being in the middle of a long 3’UTR (Grimson et 
al., 2007).  Regulation of gene expression by miRNAs is important in development and 
in adult tissues (Williams et al., 2009). miRNAs regulate gene expression through 
translational repression (Wu and Belasco, 2008), endoribonucleolytic cleavage by the 
AGO2 protein (Yekta et al., 2004), promoting deadenylation (Chen et al., 2009; Fabian 
et al., 2009), or by translational activation (Vasudevan et al., 2007).  
1.5 Trans-acting factors influence mRNA decay rates 
As mentioned AREs are a regulatory elements that commonly promote instability. 
Instability is brought about by trans-acting factors that recognize primary sequence 
elements (or secondary structure) within the transcript and promote rapid decay. This is 
often achieved by recruiting deadenylases followed by rapid poly(A) tail shortening and 
consequent entry into the mRNA decay pathways (Figure 1). Similarly, RISC-associated 
miRNAs can bind to mRNAs and either induce endoribonucleolytic cleavage or trigger 
deadenylation. Tethering experiments have revealed that it is not the cis-acting element 
per se that causes stability or instability, but the trans-regulatory factors which recognize 
it (Chou et al., 2006). Thus, the function of the element can be rapidly altered in 
response to cellular cues that modulate activity of trans-acting factors. 
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 1.5.1 Destabilizing factors 
 Destabilizing factors generally exert their effects by directly binding an mRNA 
substrate, and recruiting (directly or indirectly) components of the decay machinery. 
They can cause an mRNA to localize to a P-body, sites where decay factors are in close 
proximity. Finally, destabilizing factors can also displace a stabilizing factor. Each trans-
acting factor has its own unique mode of action and regulatory mechanisms.  Some 
examples are discussed below. 
AUF1- AU-rich binding factor 1 The AUF1 protein binds to AREs. There are four splice-
isoforms of AUF1 (37, 40, 42, and 45kDa) and the best characterized 37kDa isoform 
mediates instability by binding directly to the exosome (Chen et al., 2001). AUF1 activity 
can be disrupted by the peptidyl-prolyl isomerase PIN1. PIN1 action inhibits AUF1 
binding and stabilizes ARE-containing mRNAs (Esnault et al., 2006).  Recent reports 
have identified heat shock protein 27 (HSP27) as part of the ARE destabilizing AUF1 
complex. Interestingly, activation of the mitogen activated protein kinase (p38/MAPK) 
pathway causes HSP27 phosphorylation, ubiquitination of AUF1 and its destruction by 
the proteosome, resulting in stabilization of the ARE-containing TNF mRNA (Knapinska 
et al., 2011).  This mechanism is very similar to that described in previous reports linking 
HSP70 to AUF1, and  its destruction following heat-shock (Laroia et al., 1999). 
TTP-Tristetraprolin is an RNA-binding protein which exhibits strong preference for AREs 
(Emmons et al., 2008).  TTP is the most studied member of the Tis11 family of RNA-
binding proteins, which also includes BRF1 and BRF2. BRF1 has been shown to interact 
with the decay machinery and promote P-body formation (Franks and Lykke-Andersen, 
2007). TTP has extensive interactions with the mRNA decay machinery including DCP1 
and 2, XRN1, the CCR4/NOT complex of deadenylases, and the exosome (Lykke-
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Andersen and Wagner, 2005). One important target of TTP-mediated regulation is the 
TNF mRNA. TTP restricts TNF production in resting immune cells, but is phosphorylated 
in response to LPS stimulation. Phospho-TTP associates with a 14-3-3 chaperone 
leading to stabilization of the TNF mRNA and a large increase in protein production (Sun 
et al., 2007). Interactions between TTP and cytokine and growth factor messages are 
very important as a TTP knockout mouse is embryonic lethal due to failed 
haematopoiesis (Taylor et al., 1996), and derived knockout cell lines exhibit a 
tumorigenic phenotype (Sanduja et al., 2010). Finally, the TTP homolog ZFP36L1 is 
increased during muscle differentiation, further underscoring the importance of these 
RNA-binding proteins ('t Hoen et al., 2011).  
KSRP- KH-type splicing regulatory protein is also an ARE-binding protein. It confers 
instability to its bound mRNAs by recruiting the decay factors PARN, DCP2, and the 
exosome (Chou et al., 2006). KSRP plays an important role in muscle differentiation 
keeping ARE-containing mRNAs unstable in proliferating myocytes. Upon differentiation, 
p38/MAPK  phosphorylates KSRP, disrupting its RNA-binding activity, and resulting in 
stabilization of transcripts such as myogenin, p21, and MyoD which encode factors 
essential for myoblast differentiation (Briata et al., 2005).  
KSRP also indirectly influences the expression of many genes. In the nucleus 
KSRP promotes the biogenesis of a subset of microRNAs by binding to AREs in the 
primary transcript (pri-miRNA) and promoting processing to mature forms through 
interactions with the pre-miRNA processing factors Drosha and Dicer (Trabucchi et al., 
2009). There appears to be an antagonistic relationship between KSRP and hnRNPA1. 
The two compete for pri-miRNA-binding and the winner appears to be determined by the 
levels of each protein. In somatic cells KSRP wins out and miRNAs predominate, in 
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proliferative cells hnRNPA1 wins out and miRNA biogenesis is suppressed (Michlewski 
and Caceres, 2010). 
Pumilio or Pum1 is a member of the Puf family of RNA-binding proteins which recognize 
UGUA motifs. Pufs are the best characterized RNA-binding proteins from the standpoint 
of RNA-binding as crystal structures in complex with their substrate RNAs have been 
solved at high resolution (Wang et al., 2009b). The alpha-helical domain of the protein 
forms a long half-moon shape where individual bases of the RNA intercalate forming 
base-stacking interactions between amino acid side-chains. With this information 
researchers are now constructing sequence specific RNA-binding proteins (Lu et al., 
2009). Though their biological roles in yeast and some vertebrates have been well 
characterized, relatively little is known of Pum function in mammalian cells. In Xenopus, 
Pum2 binds the 3’UTR of the RINGO/SPY mRNA. In this context it also binds the cap, 
thereby repressing translation by inhibiting association of translation initiation factors 
(Cao et al., 2010). In general, Pumilio proteins confer instability to their mRNA targets, 
and cause relocalization to P-bodies (Morris et al., 2008).   
CUGBP1/CELF1 CUG-binding protein 1 (CUGBP1) belongs to a family of six RNA-
binding proteins called CELF (CUGBP and ELAV like factors).  CELF proteins bind 
GREs, and AREs, and confer instability on mRNAs they target (Paillard et al., 2002; 
Mukhopadhyay et al., 2003). CUGBP1 is a major focus of this thesis and will be 
discussed in detail later (Section 1.12). 
miRNAs microRNAs are a class of small regulatory RNAs whose influence is exerted by 
canonical Watson-Crick base pairing, and non-canonical G-U base pairing to mRNA 
targets. miRNAs are expressed as a primary transcript  and processed, or result from 
processing of intronic sequences (Rodriguez et al., 2004a). The pri-miRNA transcript is 
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processed in the nucleus by Drosha and DGCR8 to form the pre-miRNA, which is a 60-
100nt stem-loop. This is exported to the cytoplasm where Dicer processing trims it down 
to a 22nt. duplex. Loading of the guide strand into RISC forms the mature complex. 
Target recognition by miRNAs generally results in inhibition of gene expression by 
translational repression, or in cases of high sequence complementarity between the 
miRNA and its target, endoribonucleolytic cleavage or deadenylation and mRNA decay 
(Grimson et al., 2007). 
1.5.2 Stabilizing factors 
 The binding of stabilizing factors with an mRNA generally promotes translation, 
and disfavors interaction with the RNA decay machinery. Additionally, their association 
can cause relocalization, out of P-bodies and onto polysomes (Bhattacharyya et al., 
2006). Below are two examples of RNA-binding proteins regarded as stability factors. 
HuR or Embryonic Lethal Abnormal Vision (ELAV) is the most studied mRNA-binding 
protein. It has been shown to associate with both AREs and GREs (Yoon et al., 2008; 
Mukherjee et al., 2011). In general HuR binding displaces instability factors to promote 
stabilization and translation (Fan and Steitz, 1998). Competition by HuR for target sites 
is generally accomplished by translocation from the nucleus to the cytoplasm (Atasoy et 
al., 1998), or by signaling events which disrupt instability factor binding (Kawai et al., 
2006). HuR is an essential factor but inducible knockout mice show that it is specifically 
important for regulation of p53-mediated apoptosis (Ghosh et al., 2009). HuR function is 
critical for stabilizing many mRNAs which harbor AREs and GREs when their encoded 
factors are needed. 
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PCBP Poly(C) Binding Proteins are also well-characterized stability factors. This protein 
binds poly(C) tracts in the 3’UTR of mRNAs it regulates. This binding is responsible for 
stabilizing the α-globin mRNA, which must be translated throughout the life of an 
erythrocyte (Kiledjian et al., 1995). 
 1.6 Modulation of mRNA decay rates 
 Decay of mRNA molecules is a dynamic process mediated by the proteins and/or 
miRNAs which associate with each transcript. One way responsiveness is achieved in 
this system is by modulating the function, abundance, and/or access of regulatory RNA-
binding proteins as discussed below. 
Regulation of RBP abundance This is the most basic method employed to modulate 
function of RNA-binding proteins. Several examples exist, for instance the RNA-binding 
protein LIN28 is a pluripotency marker expressed in embryonic stem (ES) cells. This 
protein is responsible for keeping the expression of differentiation promoting miRNAs, 
including let7a, very low as such it is highly expressed in ES cells, but drops dramatically 
as distinct cell types arise (Viswanathan et al., 2008). In addition, production of miRNA 
let7a is inhibited by the RNA-binding protein hnRNPA1, and promoted by KSRP binding.  
The levels of hnRNPA1 and KSRP correlate with the amount of mature let7a produced 
in various tissue types (Michlewski and Caceres, 2010). Expression of the ARE-binding 
protein TTP is induced by growth factors, insulin, and the phorbol-ester TPA. Upon 
induction TTP can promote the rapid decay of ARE-containing transcripts by association 
with deadenylases (Sanduja et al., 2010). Finally, AUF1 abundance can be down-
regulated by ubiquitination and proteasomal degradation upon activation of the 
p38/MAPK pathway, stabilizing ARE-containing reporter RNAs (Laroia et al., 1999). 
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Localization This is perhaps the most dramatic from a visual standpoint. Common 
cellular conditions where RBPs rapidly relocalize include during muscle formation (Lal et 
al., 2004), viral infection (Sokoloski et al., 2010), and T-cell stimulation (Atasoy et al., 
1998). In all of these instances the RNA stability factor HuR can be visualized 
translocating from the nucleus to the cytoplasm where it stabilizes mRNAs for increased 
protein production. In addition, activation of the p38/MAPK pathway results in TTP 
phosphorylation, and association with 14-3-3. This excludes TTP from stress granules, 
and results in stabilization of ARE containing mRNAs (Stoecklin et al., 2004). 
Phosphorylation/other post-translational modifications Post-translational modifications 
are an effective, reversible, and rapid way to modulate activity of RNA-binding proteins. 
Phosphorylation of TTP reduces both its affinity for RNA substrates and its ability to 
interact with the decay machinery (Sanduja et al., 2010). Similarily, reduction of eIF-4E 
phosphorylation triggered by nutrient deprivation reduces its affinity for the cap and 
consequently promotes deadenylation by PARN (Seal et al., 2005). Activation of the PI3-
Kinase/AKT pathway triggers KSRP phosphorylation reducing its ability to bind the 
exosome and stabilizing β-catenin mRNA (Gherzi et al., 2006). Finally, perhaps the most 
intuitive modification is ubiquitination (which causes proteasomal mediated degradation 
of the RNA-binding protein itself) as mentioned above for AUF1 promoting cytokine 
expression (Laroia et al., 1999).  
Chaperone interactions A final way in which the function of RNA-binding proteins 
appears to be regulated is through interaction with other proteins. These chaperones 
can remove an RBP from its substrate or prevent it from recruiting decay factors (as was 
the case with TTP and 14-3-3). This type of interaction, along with phosphorylation, can 
also be used to expel a deadenylase from a complex as is the case for PARN in oocytes 
34 
 
(Kim and Richter, 2006). A final example, isomerization by a prolyl-isomerase reduces 
the affinity of AUF1 for an ARE-containing mRNA  promoting HuR association and 
protein expression (Esnault et al., 2006). 
1.7 Competition between trans-acting factors  
ARE-mediated instability can be dramatically reversed by external cues, like 
infection or altered growth conditions, which require changes in gene expression. One 
way this is achieved is through replacement of an instability factor, with a stability factor 
like HuR. This was observed in stimulated immune cells when HuR moved from the 
nucleus to the cytoplasm and its movement was closely correlated with increased 
translation and stability of ARE-containing mRNAs (Atasoy et al., 1998).  Another 
mechanism is by post-translational modification of the instability factor, commonly 
phosphorylation, resulting in abrogation of its activity. Phosphorylation of trans-acting 
factors has been reported upon activation of the p38/MAPK, and AKT/PI3 pathways (Lal 
et al., 2004; Li et al., 2000). Another instance of this comes from differentiating muscle. 
In this example, nuclear HuR and AUF1 were found on common mRNAs. However, 
upon reaching the cytoplasm, association of HuR with the cyclin dependent kinase 1A 
(CDKN1A/p21) mRNA increased as differentiation progressed, and association of AUF1 
decreased, promoting translation of the message and cell differentiation (Lal et al., 
2004).  
1.8 Muscle biology  
Muscle is a unique tissue type. By mass, it is the most abundant tissue in the 
body, and its ability to coordinately contract and relax upon membrane depolarization 
and polarization allows for movement, breathing, and digestion amongst higher 
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organisms. Calcium (Ca2+) signaling is central to muscle contraction and stretching, and 
many of the transcriptional programs in muscle are influenced by Ca2+ signaling 
(Berridge et al., 2003). Ca2+/Calmodulin Kinase signaling promotes nuclear export of 
repressive histone deacetylases, allowing for transcription of Myocyte Enhancer Factor-2 
(MEF2) regulated genes (McKinsey et al., 2002). MEF2 pairs with the transcription factor 
MyoD to activate many muscle specific genes (Black and Olson, 1998).  
Muscle does more than move. It is sensitive to signaling molecules like insulin 
and cytokines. Treatment of muscle with insulin causes uptake of glucose for energy 
metabolism (Kewalramani et al., 2010). Muscle produces low levels of TNF for 
para/autocrine signaling (Li and Reid, 2001). Exposure of myoblasts to low levels of the 
cytokine TNF promotes myogenesis by activation of the p38/MAPK pathway, whereas 
high levels inhibit myogenesis (Chen et al., 2007). Chronic exposure to high TNF levels 
causes muscle wasting (Flores et al., 1989) and insulin resistance (Li and Reid, 2001).  
1.9 Muscle differentiation 
During development some mesodermal cells will go on to become muscle tissue. 
This developmental process has been correlated with expression of muscle-specific 
transcription factors; MyoD, Myf5, and Pax3.  Expression of these factors results in 
conversion of pluripotent cells into myoblasts. Myoblasts can then fuse to become 
multinucleate myotubes by reduced growth factor stimulation, and/or activation of the 
p38/MAPK signaling pathway, followed by expression of the transcription factors 
myogenin and MEF2 (for review see; Molkentin and Olson, 1996). Differentiation is also 
coupled with the expression of p21 which promotes cell cycle withdrawal (Parker et al., 
1995). Early myotubes mature through expression of the transcription factor MRF4 
coincident with innervation (Patapoutian et al., 1995). The murine C2C12 myoblast 
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model has been useful for studying a portion of the differentiation process, as they are 
proliferative myoblasts that become differentiated myotubes upon serum withdrawal 
(Blau et al., 1983).  
Importantly, muscle has the ability to regenerate. Upon injury, myogenic satellite 
cells differentiate to myoblasts, and fuse to form myotubes, adjacent myotubes then fuse 
to form a myofiber. Chronic conditions of muscle injury indicate that depletion of satellite 
cells has dire consequences (Briata et al., 2005; Wagers and Conboy, 2005).  
Figure 2.  
 
Muscle differentiation requires post-transcriptional gene regulation. Efficient differentiation 
of myoblasts to myotubes requires dynamic changes in message stability. Shown are 
destabilizing factors (red), with their corresponding unstable target mRNAs (blue), and stabilizing 
factors (black) with their stabilized target mRNAs (green).  
 
1.10 Role of mRNA decay during muscle differentiation 
The process of muscle differentiation is one that requires dynamic and concerted 
regulation of gene expression at the post-transcriptional level (Figure 2; Bisbal et al., 
2000; Figueroa et al., 2003; Jin et al., 2010; Naguibneva et al., 2007; Briata et al., 2005; 
Gong et al., 2009). The onset of muscle differentiation is marked by increases in the 
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abundance of the muscle specific transcription factors MyoD and myogenin mediated in 
part through post-transcriptional mechanisms (Figueroa et al., 2003). RNase L activity 
must drop for expression of MyoD (Bisbal et al., 2000). HuR must relocalize transiently 
from the nucleus to the cytoplasm where it displaces AUF1 (Lal et al., 2004) to stabilize 
p21, myogenin, and MyoD mRNAs (Figueroa et al., 2003). RBM24 binds to and 
promotes the stability of the myogenin mRNA (Jin et al., 2010). MiR181 levels increase 
to down-regulate the proliferation-promoting HoxA11 mRNA (Naguibneva et al., 2007). 
Phosphorylation of KSRP by p38 disrupts binding to ARE-containing mRNAs promoting 
the stability of pro-myogenic mRNAs (Briata et al., 2005). Finally, the levels of RNA-
binding protein Staufen increase, promoting decay of the Pax3 mRNA and favoring 
differentiation (Gong et al., 2009). Altered mRNA decay rates and increases in the 
mRNAs which encode transcription factors result in production of many muscle specific 
transcripts. Indeed, exogenous expression of MyoD is sufficient to convert fibroblasts 
into myoblasts (Davis et al., 1987). Additionally, miRNAs have a crucial role to play in 
the regulation of gene expression in muscle for proper tissue function (Kalsotra et al., 
2010; Naguibneva et al., 2007). These findings highlight the importance of modulating 
mRNA decay in muscle differentiation.  mRNA decay is critical for more than just 
keeping the abundance of certain messages low. Altering the stability of low abundance 
messages permits a burst of gene expression observed in muscle differentiation.  
1.11 Myotonic Dystrophy (DM) 
The myotonic dystrophies are dominant heritable neuromuscular diseases, 
caused by microsatellite repeat expansions in the non-coding region of the affected 
gene. DM1 is caused by CTG repeat expansion in the 3’UTR of the dystrophia 
myotonica protein kinase (DMPK) mRNA (Buxton et al., 1992), while DM2 results from a 
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CCTG repeat expansion in intron 1 of the ZNF9 mRNA (Mankodi et al., 2003).  DM is the 
most common form of adult onset muscular dystrophy affecting 1 in 8,000 individuals 
(Harper et al., 2001). The disease state has been strongly correlated with the production 
of toxic RNA molecules.  As both DM1 and DM2 repeat expansions lie in untranslated 
regions of mRNAs they affect protein function only minimally (Lee and Cooper, 2009).   
Here we will focus on DM1, as aberrant CUGBP1 expression is a clear contributor to 
pathogenesis in DM1 (Kuyumcu-Martinez et al., 2007) whereas it’s role, if any, in DM2 is 
unclear (Margolis et al., 2006). 
1.11.1 Disease symptoms  
Symptoms of DM1 include myotonia (the ability to contract but not relax a 
muscle), insulin resistance (failure of muscle tissue to take up glucose in response to 
insulin), cardiac conduction defects (failure to coordinate an action potential through the 
cardiac tissue in an efficient manner), muscle wasting (reduced muscle tissue volume 
and increased protein catabolism of skeletal muscle), and cataracts (clouding of the lens 
of the eye; Harper et al., 2001). Congenital DM1patients exhibit reduced mental capacity 
and mental retardation in addition to all of the above symptoms, many of which are more 
severe (Modoni et al., 2004). The congenital form is typically fatal by early adulthood. 
1.11.2 Repeat expansion, anticipation, disease severity, and toxic RNA 
 DM1, like other repeat expansion diseases, exhibits anticipation, meaning that it 
tends to get worse with each subsequent generation that harbors the mutation (Harper 
et al., 2001). This effect is due to repeat expansion in the germline. A grandmother, who 
experiences mild symptoms such as cataracts late in life, may have few repeats (50-80 
CTGs). Her affected child may experience muscle weakness in mid-adulthood and have 
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100-500 repeats. A grandchild born with congenital DM1 will likely have over 1000 CUG 
repeats.  
Expansion of the CUG repeat in the DMPK 3’UTR beyond 50-100 repeats results 
in formation of toxic RNA (Musova et al., 2009).  Many primary symptoms of the disease 
result from the presence of the repeat RNA. Analysis by fluorescence microscopy has 
indicated that the repeat accumulation in nuclear foci containing mRNAs, and that the 
RNA-binding protein and splicing factor MBNL1 is bound to them (Jiang et al., 2004). 
This sequesters MBNL1 from its natural mRNA targets, perturbing the antagonistic 
relationship between CUGBP1 and MBNL1 resulting in many mis-splicing events (Ladd 
et al., 2001; Philips et al., 1998; Du et al., 2010). The length and context of the CUG 
repeats, and the abundance of the toxic RNA species are important determinants of 
disease severity (Logigian et al., 2004).  
1.11.3 Phosphorylation and over-expression of CUGBP1 in DM1 
 Increased abundance of CUGBP1 in DM1 patient muscle was noted quite soon 
after identification of the DMPK gene (Philips et al., 1998). However the mechanisms 
behind over-expression are only now coming to light. Expression of repeat RNA results 
in elevated Protein Kinase C (PKC) activity through an uncharacterized pathway 
(Kuyumcu-Martinez et al., 2007). PKC activation leads to hyperphosphorylation of 
CUGBP1. One effect of hyperphosphorylation is increased stability of the CUGBP1 
protein, leading to its over-expression in the nucleus (Kuyumcu-Martinez et al., 2007). It 
is of note that to date CUGBP1 over-expression has been observed only in mouse 
models of DM1 that exhibit the muscle wasting phenotype (Kuyumcu-Martinez et al., 
2007; Mahadevan et al., 2006). In one such mouse model, elevated CUGBP1 levels are 
observed in as little as 6 hours after tamoxifen induction of CUG repeat expression 
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indicating that in this case CUGBP1 over-expression is a primary effect and not due to 
long term damage of the muscle (Wang et al., 2007). Moreover, over-expression of 
CUGBP1 in the absence of repeat-containing toxic RNAs is sufficient on its own to 
induce many symptoms of DM1 (Ward et al., 2010; Timchenko et al., 2004). 
1.11.4 Aberrant splicing regulation by CUGBP1 and MBNL1  
Much effort has been invested in characterizing the nuclear roles of MBNL1 and 
CUGBP1 with respect to splice site selection in muscle-specific transcripts (Kalsotra et 
al., 2008; Ladd et al., 2001).  Indeed, many observed symptoms of DM1 are likely due to 
mis-splicing. Documented mis-splicing events include: myotonia (chloride channel 1, 
intron 2 retention, β-tropomyosin exon 6B inclusion), insulin resistance (insulin receptor 
exon 11 skipping), and cardiac conduction defects (cardiac troponin T exon 5 inclusion). 
(Ladd et al., 2001; Charlet et al., 2002; Philips et al., 1998; Kalsotra et al., 2008; Philips 
et al., 1998; Savkur et al., 2001). In DM1, MBNL1 loss of function and CUGBP1 gain of 
function are both thought to contribute to splicing changes. Comparisons between CUG-
repeat expressing mice and MBNL1 knock-out mice indicate that loss of MBNL1 function 
is responsible for 80% of the splicing changes in DM1. However, the authors noted that 
50% of the mRNA abundance changes are currently inexplicable (Du et al., 2010).    
1.11.5 Aberrant translational regulation by CUGBP1 in DM1  
There have been few studies conducted to address the possible roles of altered 
activity of CUGBP1 from the standpoint of mRNA translation. Studies looking at stress 
granules found CUGBP1 was a component of them (Fujimura et al., 2008). Further work 
with purified components of SGs from DM1 patient cells, found evidence for activation of 
protein kinase R (PKR) and reduction in protein synthesis by phosphorylation of eIF-2 
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(Huichalaf et al., 2010). These studies indicate that translation may be impacted in by 
aberrant CUGBP1 function DM1.  
1.11.6 Unexplained symptoms of DM1  
Muscle wasting is a common symptom in severe cases of DM1. However, no 
molecular defect, splicing or otherwise, has been identified to explain the muscle wasting 
symptom. One study found elevated serum TNF levels in DM1 patients (Mammarella et 
al., 2002). TNF is known to cause muscle wasting (Flores et al., 1989), is expressed by 
muscle and its expression is extensively regulated at the level of mRNA stability 
(Carballo et al., 1998; Garnon et al., 2005; Lai et al., 1999).  
The insulin resistance observed in DM1 patients is often attributed to mis-splicing 
of the insulin receptor (Savkur et al., 2001). However, this study merely identified a 
correlation between the mis-splicing event and insulin resistance. Exposure of muscle 
cells to elevated levels of TNF also causes insulin resistance (Li and Schwartz, 2001). 
Currently it is unclear which molecular changes are responsible for insulin resistance in 
DM1 patients. 
1.11.7 Modifiers of DM phenotype  
Several DM1 models have been generated in both mice and Drosophila and 
have greatly aided in characterizing the disorder. Interestingly, over-expression of the 
MBNL1 protein in CUG-repeat expressing mice alleviates the phenotype (Kanadia et al., 
2006). These findings have been corroborated in Drosophila models of the disease. The 
muscle wasting phenotype in DM1 flies (express 480 CUG repeats introduced by 
targeted mutagenesis) worsened in MBNL1-depleted lines, and improved in MBNL1 
over-expressing lines (De Haro et al., 2006).  Additionally, over-expression of CUGBP1 
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in DM1 flies further worsened the phenotype (De Haro et al., 2006). DM1 flies also 
showed improvement in phenotype in conjunction with over-expression of the RNA 
export factor ALY, consistent with the finding that the repeat-containing mRNAs are less 
toxic when located in the cytoplasm (Garcia-Lopez et al., 2008). All told, these findings 
indicate that RNA metabolism and the levels of CUGBP1/MBNL1 are important 
determinants of disease severity in DM1. 
Figure 3. 
 
Defects in RNA metabolism are hallmarks of DM1. CUG-repeat containing RNA is primarily 
confined to the nucleus of DM1 cells. MBNL1 is strongly associated with repeats and unable to 
carry out normal functions including splicing regulation, while nuclear CUGBP1 levels are 
increased. Disruption of repeat RNA/MBNL1 complexes improves conditions, through correcting 
splicing, perhaps enhancing decay of repeat containing mRNAs, and returning CUGBP1 to 
normal function. 
 
1.11.8 Therapeutic approaches  
Currently there is no therapy or cure for DM1, but mouse models have 
demonstrated that the effects of toxic CUG RNA are reversible (Mahadevan et al., 
2006). Development of therapies is focused on destruction or inactivation of the toxic 
RNA. One idea is to introduce a morpholino that binds to the CUG-repeat RNA and 
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releases MBNL1 (and any other sequestered factors ) to carry out its normal function 
(Figure 3). Attempts at this have been successful at improving phenotype in mouse 
models, showing a reduction in RNA-foci and corrected splicing defects (Mulders et al., 
2009). The biggest challenge with this approach is getting the morpholino into the tissue, 
and bringing the cost down. As direct targeting of nucleic acids is challenging, one 
alternative might be treating with PKC inhibitors. These inhibitors correct the CUGBP1-
mediated defects, but not the MBNL1-mediated defects (Wang et al., 2009a). A 
drawback of this approach in humans may be off-target effects. This would likely not 
correct all the splicing defects, but may alleviate the muscle wasting phenotype. As 
such, approaches to degrade the toxic RNA are most promising. 
1.12 CUGBP1 
The trans-acting factor of primary interest in this study is the CELF-family protein 
CUGBP1. CELF proteins are well-characterized regulators of mRNA metabolism (Ladd 
et al., 2005; Timchenko et al., 2005; Vlasova et al., 2008; Zhang et al., 2008; Goraczniak 
and Gunderson, 2008). The protein has three tandem RNA recognition motifs (RRMs) 
with RRMs two and three separated by a linker region (Figure 4). This layout is common 
for all six proteins of the human CELF family, and is also found in ELAV family members 
including HuR/ELAVL1. The human CUGBP1 protein was originally identified in vitro 
(HeLa cell lysates) based on its ability to cause a shift in the migration pattern of (CUG)8 
RNA during gel electrophoresis (Timchenko et al., 1996). While the affinity of CUGBP1 
for CUG repeats has since been refuted (Marquis et al., 2006; Vlasova et al., 2008), the 
protein has remained associated with the human disease DM1, as its function is 
dramatically altered in the presence of CUG repeat containing mRNAs (Kuyumcu-
Martinez et al., 2007). 
44 
 
 1.12.1 RNA-binding properties of CUGBP1 
Based on early studies implicating CUGBP1 in DM1, many have sought to further 
define the role of CUGBP1 in cells. Firstly, multiple studies have examined the binding 
preferences of CUGBP1 (Marquis et al., 2006; Vlasova et al., 2008; Graindorge et al., 
2008; Mori et al., 2008; Takahashi et al., 2000; Graindorge et al., 2008; Tsuda et al., 
2009). Most have found a strong preference for U-rich regions interspersed with G 
residues. CUGBP1 protein also exhibits strong affinity for UG repeats, primarily by 
RRM3 association with RNA (Graindorge et al., 2008; Tsuda et al., 2009). Quantitative 
experiments looking at binding to CUG repeats revealed that the protein has 100-fold 
lower affinity for them than UG repeats (Mori et al., 2008). 
 1.12.2 Nuclear roles of CUGBP1 
From a molecular standpoint, CUGBP1 has been most thoroughly characterized 
as a splicing enhancer. CUGBP1 association with pre-mRNAs promotes exon inclusion 
for a subset of muscle transcripts (Kalsotra et al., 2008). CUGBP1 expression is 
decreased during muscle development by miRNA targeting the CUGBP1 message 
(Kalsotra et al., 2010) Reduction in CUGBP1 protein levels in muscle correlated with 
observed splicing changes in target transcripts that favor expression of adult splice 
isoforms over embryonic ones. As muscle develops, reduction of CUGBP1 levels favors 
MBNL1 activity and promotes exon-skipping (Ladd et al., 2001). In addition to 
modulating alternative splicing events, binding of CUGBP1 to GREs near a viral poly(A) 





 1.12.3 Cytoplasmic roles of CUGBP1 
 In addition to roles in the nucleus mediating alternative splicing, CUGBP1 has 
important cytoplasmic functions as detailed below. 
1.12.3.1 mRNA Decay 
 Work with the Xenopus homolog of CUGBP1, EDEN-BP, demonstrated that 
binding of this factor triggered deadenylation of the c-mos transcript (Paillard et al., 
1998). Similar findings have been made in mammalian systems as well (Graindorge et 
al., 2008; Moraes et al., 2006; Mori et al., 2008; Rattenbacher et al., 2010; Vlasova et 
al., 2008). Previous work in the Wilusz lab has demonstrated that CUGBP1 binds to the 
3’UTR of the TNF mRNA, where it recruits PARN to initiate poly(A) shortening (Moraes 
et al., 2006). In support of these findings, array studies conducted in T-cells 
demonstrated that a significant proportion of regulated mRNAs contained GREs. These 
GREs bind CUGBP1 and thereby destabilize reporter transcripts in transfected HeLa 
cells (Vlasova et al., 2008). 
1.12.3.2 Translational regulator 
 Additional reports imply that CUGBP1 associates with the 5’UTR of the C/EBP-β 
mRNA and enhances translation initiation by recruiting initiation factors (Timchenko et 
al., 2005), as well as modulating translational start site selection (Timchenko et al., 
1999). Under certain conditions CUGBP1 is associated with translationally repressive 
stress granules (Fujimura et al., 2008). In support of a repressive role in translational 
control, the Drosophila CUGBP1 homologue, Bruno inhibits translation of the oskar 
mRNA in oocytes through association with the 3’UTR. Repression was achieved by two 
mechanisms, first by binding Cup, an eIF-4E binding protein that represses 40S subunit 
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joining. Secondly, in the absence of Cup, Bruno was capable of mediating mRNA 
oligomerization of large translationally repressed complexes (Chekulaeva et al., 2006). 
1.13 Heritable neuromuscular diseases and CUGBP1 disruption 
Several heritable neuromuscular diseases show disruption of CUGBP1 
expression: Oculopharyngeal Muscular Dystrophy (OPMD), Spinal Bulbar Muscular 
Atrophy (SBMA), Fragile-X Tremor Ataxia Syndrome (FXTAS), and DM1. In DM1 
CUGBP1 disruption is a direct effect of the disorder (Wang et al., 2007). For the others, 
that remains an open question. Nevertheless, the link remains that a common feature of 
these diseases is misregulation of CUGBP1. Future studies must address if this is a 
primary symptom of each disease, or due to the continual regenerative process of  the 
affected muscle (Orengo et al., 2011). 
1.13.1 OPMD-Oculopharyngeal Muscular Dystrophy 
OPMD is an adult-onset muscular dystrophy caused by a (GCN)12-17 expansion in 
the open-reading frame of the nuclear poly(A) binding protein (PABPN1). This results in 
a polyalanine expansion in the N-terminus of the protein. Expression of this mutant 
PABNP1 causes formation of intranuclear inclusions, which contain many other RNA-
binding proteins, one of which is CUGBP1 (Corbeil-Girard et al., 2005). 
1.13.2 SBMA-Spinal Bulbar Muscular Atrophy 
Like DM1, SBMA is caused by a trinucleotide repeat expansion, this time CAG 
repeats in the androgen receptor mRNA resulting in a receptor containing a 
polyglutamine tract (La Spada et al., 1991). Interestingly, mouse models of SBMA exhibit 
over-expression of CUGBP1, but not muscle wasting. These mice also exhibit mis-
splicing events consistent with CUGBP1 overexpression. In this case, CUGBP1 
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overexpression likely results from muscle denervation rather than being a direct 
consequence of repeat expression (Yu et al., 2009).  
1.13.3 FXTAS-Fragile-X Tremor Ataxia Syndrome  
FXTAS is found in older individuals who carry a premutation allele (CGG)60-200 in 
the 5’UTR of the fragile-X mental retardation gene (FMRP(Jacquemont et al., 2003). 
This disease is thought to be caused in part by toxic CGG RNA sequestering RNA-
binding proteins (Iwahashi et al., 2006). A Drosophila model of FXTAS which expresses 
the CGG repeat RNA (in the context of the 5’UTR of the FMRP mRNA) found the RNA 
was associated with hnRNP A1/B2 (Sofola et al., 2007). CUGBP1 was also found in this 
complex through interactions with hnRNP A1/B2. Over-expression of CUGBP1 alleviated 
the neural degeneration phenotype in the transgenic fly model of FXTAS (Sofola et al., 
2007). 
In summary, defects in RNA metabolism are common in expanded repeat 
neuromuscular disorders. Furthermore, there is a significant body of evidence 
implicating CUGBP1 in these muscle diseases. The predominantly muscular symptoms 
of these RNA-mediated defects are demonstrative of the importance of proper control of 
mRNP dynamics in muscle cells. When those dynamics are disrupted, the results are 
severe. 
1.14 Rationale and hypotheses 
1.14.1 TNF mRNA decay in muscle cells 
 A previous report identified CUGBP1 and PARN as direct mediators of rapid 
deadenylation of a TNF reporter RNA in HeLa cytoplasmic extracts (Moraes et al., 
2006). TNF is a significant modulator of muscle differentiation (Li and Schwartz, 2001), 
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and over-expression triggers muscle wasting (Taylor et al., 1996). Aberrant myogenesis 
and muscle wasting are hallmarks of myotonic dystrophy (Lee and Cooper, 2009). 
Moreover, although TNF is primarily produced by immune cells it is also secreted at low 
levels by muscle and other cell types (Hotamisligil et al., 1995; Li and Reid, 2001). 
However, no prior studies have examined the post-transcriptional regulation of TNF in 
muscle. We hypothesized that in muscle cells, where CUGBP1 appears to have a 
unique influence on mRNA metabolism, CUGBP1 and PARN collaborate to 
promote rapid decay of the TNF message. 
1.14.2 Global rates of mRNA decay of in muscle cells 
 By mass, skeletal muscle is the most abundant tissue type in the body, and it 
exhibits its own distinct pattern of gene expression that can change dramatically during 
development and in response to extracellular cues (Molkentin and Olson, 1996). Several 
transcription factors which control myogenesis (MyoD, myogenin, and PAX3)  are 
encoded by short-lived mRNAs (Figueroa et al., 2003; Gong et al., 2009). For these 
mRNAs, and likely for numerous other transcripts, post-transcriptional control is 
essential for robust and transient response to differentiation cues (Wagers and Conboy, 
2005). 
Establishment of basal rates of mRNA decay on a global scale is a necessary 
step to permit the discovery and characterization of novel post-transcriptional regulatory 
pathways in muscle cells. We hypothesized that global mRNA decay profiling would 
identify characteristic features of mRNAs that influence decay in muscle, reveal 
cellular processes impacted by regulated mRNA decay, and identify those 
transcripts which are degraded through CUGBP1-dependent mechanisms. 
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1.14.3 Identification of CUGBP1 substrate mRNAs 
CUGBP1 influences many aspects of mRNA metabolism including splicing, 
translation and mRNA decay.  CUGBP1 function is disrupted in DM1 and other 
neuromuscular diseases and over-expression of CUGBP1 is sufficient to induce many 
aspects of DM1 pathogenesis in mice (Timchenko et al., 2004).  The contribution of 
altered splicing to DM1 pathogenesis has been studied extensively (Du et al., 2010; 
Jiang et al., 2004; Mankodi et al., 2002), but nothing is known about the impact of 
aberrant CUGBP1 expression on mRNA decay in this debilitating muscle disease. We 
reasoned that identification of direct targets of CUGBP1 in muscle would uncover 
novel mechanisms that may be disrupted in DM1 and contribute to pathogenesis. 
1.14.4 mRNA decay and deadenylation by PARN in muscle cells 
 Many sequence-specific RNA-binding proteins specifically recruit components of 
the decay machinery to accelerate mRNA turnover. CUGBP1 (Moraes et al., 2006), 
KSRP (Gherzi et al., 2004), RHAU (Tran et al., 2004), and TTP (Sandler and Stoecklin, 
2008) all interact directly with the deadenylase PARN. Some of these RNA-binding 
proteins also interact with other deadenylases; for example, TTP binds the CAF1 
deadenylase (Lykke-Andersen and Wagner, 2005).  However, it is not known whether 
the many eukaryotic deadenylases each show preference for different mRNA substrates 
or are redundant in function and can each be recruited to any transcript destined for 
decay. Given that CUGBP1 and PARN directly collaborate for TNF message destruction 
in vitro, we predicted that they would also extensively collaborate to initiate decay of 
other transcripts in vivo.  We hypothesized that assessment of the rates of mRNA 
decay in the absence of PARN would reveal the full extent to which PARN 
influences this process in muscle cells.   
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The overarching goal of this study was to fully characterize the targets of post-
transcriptional control mediated by CUGBP1 and PARN in muscle cells.  We anticipated 
that the results would also provide essential insights into transcripts and processes that 























Chapter 2: Materials & methods 
 
2.1 Bacterial expression plasmids 
2.1.1 CUGBP1 
A bacterial expression vector to produce recombinant N-terminal GST-tagged H. 
sapiens CUGBP1 protein was generated by PCR amplification using primers CUGBP S 
and CUGBP AS (see Table 2.1) from the pcDNA3.1CUG-BP (transcript variant 3 
accession # NM_001025596.2) which was a gift from Dr. T.A. Cooper (Baylor College of 
Medicine). PCR amplicons were digested with BamH1 and EcoR1 and ligated into 
pGex2TZQ vector (Qian and Wilusz, 1994) which had been digested with the same 
enzymes. Locations of primers for generation of mutant vectors are indicated with arrow 




Note: Underlined sequence correspondes to the CUGBP1 cDNA sequence, bold indicates 
translation stop codon. 
 
Name Primer Name (restriction site) Nucleotide Sequence (5' to 3')
CUGBP-S CUGBP S (BamH1) GCTGGATCCATGAACGGCACCCTGGACC
CUGBP-AS CUGBP AS (EcoR1) GCTGAATTCTCAGTAGGGCTTGCTGTCA
CUGBP-A CUGBP A (EcoR1) ACAGAATTCCTAAGCAGGTTTCATCTGT
CUGBP-B CUGBP B (EcoR1) ACAGAATTCCTAAGCAAATTTTACCACC
CUGBP-C CUGBP C (EcoR1) ACAGAATTCCTATCCAGCAGCACCAATA
CUGBP-D CUGBP D (BamH1) ACAGGATCCAGCCAGAAGGAAGGTCCAG
CUGBP-E CUGBP E (BamH1) ACAGGATCCGCTGATACACAGAAGGACA
CUGBP-F CUGBP F (BamH1) ACAGGATCCAGTGAGAAGAACAATGCAG







Experimental design for generating GST-tagged CUGBP1 and deletion mutants. PCR 
primers are represented as arrow heads, RNA recognition motifs (RRM) as boxes and the linker 




A bacterial expression vector to produce recombinant N-Terminal 6 histidine 
(6XHis) tagged H. sapiens PARN protein was generated as follows. The PARN cDNA 
was PCR amplified using pcDNA3.1+hPARN as template (a kind gift from J. Anderson) 
and the primers listed below in Table 2.2. Amplified product was digested and cloned 








A bacterial expression vector to produce recombinant 6XHis tagged mouse HuR 











Primer Name Primer Name (restriction site) Nucleotide Sequence (5' to 3')
PARN-S PARN S (Xho1) GTCGAGAACCTCGAGATGGAGATAATCAGGA
PARN-AS PARN AS (Kpn1) GGTACCCAAGGTACCTTACCATGTGTCAGGAA




2.2 Plasmids for lentivirus expression of shRNAs targeting CUGBP1 and PARN 
 
2.2.1 CUGBP1 
CUGBP1 targeting lentivirus vectors were obtained from the Broad Institute 
Mission collection and were purchased as bacterial stocks from Sigma Aldrich 
(NM_198683.1-868s1c1, NM_198683.1-869s1c1, NM_198683.1-1279s1c1, 
NM_198683.1-1320s1c1, and NM_198683.1-1739s1c1). The numbers in bold indicate 
the first nucleotide of the region targeted within the CUGBP1 transcript (accession# 
NM_198683.1).   
 
2.2.2 PARN 
PARN targeting shRNA vectors were generated by subcloning oligos (see Table 
2.3 below) into the empty pLKO.1puro plasmid (a gift from R. Schneider; Stewart et al., 
2003). Oligonucleotide sequences were chosen by selecting the 6 highest scoring hits 
from the Broad Institute’s RNAi Consortium database. Briefly, the plasmid was digested 
with Age1 and EcoR1 and phosphatased. Annealed oligonucleotide pairs bearing 
compatible cohesive ends were kinased and ligated into the vector using T4 DNA ligase. 
pCMVRΔ8.2 and pCMV-VSVG plasmids for packaging and pseudotyping lentiviruses 
were described previously (Stewart et al., 2003) and were obtained from R. Schneider of 








2.3 Plasmids for in vitro transcriptions 
2.3.1 pGemT-p21 
Total RNA from C2C12 myoblasts was isolated and subjected to RT-PCR (using 
p21 3’UTR F and p21 3’UTR R in Table 2.4). The 1290bp PCR product represents the 
majority of the p21 3’UTR (20nt. at the 5’end and 18nt. at the 3’ end were omitted). This 
amplicon was ligated into the pGemT-Easy vector (Promega). The clone was sequenced 
and found to match the Genbank sequence. This plasmid pGemTp21 was used as a 
template (linearized with EcoRV) for transcriptions to generate RNA for use in ultra-violet 
(UV) crosslinking assays (Section 2.26). Additionally, this plasmid served as a template 
for generating short 120bp PCR amplicons which were then used as a template for 





























Name Gene Name (accession #) Oligonucleotide Sequence (5' to 3')
p21 3'UTR F CCTCTTCTGCTGTGGGTCAG
p21 3'UTR R ATTGAGCACCAGCTTTGGG 
p21 T7 F TAATACGACTCACTATAGAGGCCTCTTCCCCATCTTC
p21 T7 R GACTGGGAGAGGGCAGGCAG
Cdkn1a/p21 
(NM_007669.4)




2.3.2 pGemT-Zfp36l2 (Brf2), pGemT-Actin 
Plasmids used as transcription templates to generate probes for RNase H 
northern blots were generated as follows. Total RNA was isolated from proliferating 
C2C12 cells, and the poly(A) tails were removed by RNase H and oligo dT18 treatment 
(Section 2.29). An RNA linker (Integrated DNA Technologies Linker 3) was ligated to the 
3’ ends of the RNAs using T4 RNA ligase treatment as described previously (Garneau et 
al., 2008). Ligated RNAs were subjected to reverse transcription using a specific primer 
complementary to the RNA linker (Table 2.5). The resulting cDNA, which corresponded 
to the 3’ ends of the actin or Brf2 mRNAs, were then PCR amplified using the linker 
complement and the DNA oligo originally designed for the Poly(A) Tail (PAT) assay and 
ligated into the pGemT Easy vector as described above. This process generated the 
pGemT-Brf2 and pGemT-Actin plasmids which encode the 3’-most 300nt of the Actin 





2.4 In vitro transcription reactions 
Internally radio-labeled RNAs were generated by in vitro transcription (20U T7 or 
SP6 RNA polymerase, 10U RNase inhibitor, 40mM Tris pH7.9, 6mM MgCl2, 10mM DTT, 
10mM NaCl, 2mM spermidine, 500µM ATP, GTP, CTP, 50µM UTP and 4.0µl/10µl 
reaction [α-32P]UTP(4.5µCi/µl), 716Ci/mmol). Reactions were carried out for 3 hours at 
Primer Name Gene ID Gene name Nucleic Acid (5' to 3') Type
Linker - RNA Linker ApppTTTAACCGCGAATTCCAGddC RNA
RT-Linker - Linker complement CTGGAATTCGCGGTTAAA DNA
Actin-PAT 109711 Actin CACTCCTAAGAGGAGGATGGTCGCGTC DNA
Zfp-PAT 12193 Zfp36l2 (Brf2) CAGTTGGAGCACCGCGTGTG DNA
Oligonucleotides for generation of 3'UTR probes
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37°C, using 100ng of PCR template or 1µg of plasmid template. For the 
RNaseH/northern blot probes, the pGemT-Brf2 construct was linearized with SpeI and 
transcribed with T7 RNA polymerase. The pGemT-Actin construct was linearized with 
SacII and transcribed with SP6 RNA polymerase. Restriction enzymes were purchased 
from New England Biolabs, and plasmids digested according to the manufacturer’s 
instructions. The p21 RNA was transcribed with T7 RNA polymerase, run at ~10V/cm on 
a 5% polyacrylamide gel containing 7M urea, excised and eluted overnight in 400mM 
NaCl, 50mM Tris-Cl pH7.5, and 0.1% SDS (w/v) at 22°C. RNA was precipitated and 
resuspended in H2O. Typical reactions yielded 3-5million counts per minute. 
 
2.5 Purification of GST-tagged CUGBP1 proteins 
 
500ml of log phase culture of E.coli BL21 (DE3) cells containing the pGex2TZQ-
CUGBP1 plasmid (Section 2.1.1) was grown at 30°C in Luria Broth (LB) containing 
100µg/ml ampicillin. The bacteria were induced to express N-terminal tagged human 
CUGBP1 protein by addition of isopropyl β-D-1-thiolgalactopyranoside (IPTG) to 1mM 
for 3 hours. Cells were harvested by centrifugation at 2,500xg for 10 minutes at 4°C, 
resuspended in 10ml lysis buffer (50mM HEPES pH 7.9, 150mM KCl, 1mM MgCl2, 0.1% 
triton-X 100, 0.1mM phenylmethylsulfonylfluoride (PMSF), and Complete Protease 
Inhibitor Cocktail (Roche)) and lysed  via sonication on ice (Fisher Scientific Sonic 
Dismembrator Model 100; three 10 second pulses at level 7). Debris was pelleted via 
centrifugation at 11,000xg for 20 minutes at 4°C, and supernatants were then added to 
2mls of 50% slurry of glutathione-agarose in lysis buffer. Beads were rocked with lysates 
for 1 hour at 4°C, then washed 5 times with 10ml of lysis buffer. GST-CUGBP1 protein 
was eluted by adding 1ml of lysis buffer containing 50mM reduced glutathione and 
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rocking on ice for 10 minutes. Elution was repeated two more times and the eluates 
were pooled, dialyzed into lysis buffer containing 20% glycerol and stored at -80°C. 
Deletion mutants were prepared in a similar manner. 
 
2.6 Purification of 6XHis-tagged PARN protein 
 
500ml of log phase E.coli BL21 (DE3) culture containing the pTrcHisA hPARN 
plasmid was grown in LB with 100µg/ml ampicillin at 30°C.  Cells were induced to 
express 6XHis tagged human PARN protein for 4 hours by addition of IPTG to 1mM. 
Cells were harvested by centrifugation at 2,500xg for 10 minutes at 4°C, resuspended in 
lysis buffer and lysed  by sonication on ice (three 10 second pulses at level 7). Debris 
was pelleted via centrifugation at 25,000xg for 10 minutes at 4°C. Supernatant was 
incubated with pre-charged Ni-NTA resin (Invitrogen R901-01) which had been pre-
equilibrated in lysis buffer for 1 hour at 4°C. Resin was washed three times in 10mls of 
lysis buffer containing 20mM imidazole, then three times with 60mM imidazole, and 
finally three times with 80mM imidazole also in lysis buffer. 6XHis-hPARN was eluted by 
rocking for 10 minutes at 4°C with 1ml of 250mM imidazole. Purified protein was 
dialyzed in lysis buffer with 20% glycerol and stored at -80°C. 
 
2.7 Purification of 6XHis-tagged HuR protein 
 
500ml of log phase E.coli BL21 (DE3) culture containing the pET21aHuR plasmid 
was grown in LB with 100µg/ml ampicillin at 30°C.  Cells were induced to express 6XHis 
N-terminal tagged mouse HuR protein for 4 hours by addition of IPTG to 1mM. Cells 
were harvested by centrifugation at 2,500xg for 10 minutes at 4°C, resuspended in 10ml 
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lysis buffer and lysed  via sonication on ice (three 10 second pulses at level 7). Debris 
was pelleted via centrifugation at 50,000xg for 20 minutes at 4°C. Supernatant was 
loaded onto a column containing 1ml Ni-NTA resin (Invitrogen R901-01) which had been 
pre-equilibrated in lysis buffer containing 10mM imidazole for 1 hour at 4°C. Unbound 
material was allowed to flow through the resin, and the column was then washed 3 times 
with 4mls of lysis buffer containing 50mM imidazole. HuR protein was eluted by the 
addition of 1ml of lysis buffer containing 250mM imidazole, and then with 1M imidazole 
in lysis buffer. The eluates were collected separately, dialyzed into lysis buffer with 20% 
glycerol (without imidazole), aliquoted, and stored at -80°C. 
 
2.8 GST-pulldown assays 
 
20µl of 50% slurry of glutathione-agarose pre-equilibrated in 1X phosphate 
buffered saline (PBS) was incubated with 5µg of rGST-CUGBP1 or deletion variant for 2 
hours at 4°C. Beads were washed three times in 1.1X PBS (10% more salt than 
conventional 1XPBS), and then incubated with 1µg of r6XhisPARN in 1.1X PBS 
containing 0.3% triton-X 100 (1.1XPBS-T) for 1 hour at 4°C. Beads were washed 4 times 
with 1.1X PBS-T, then resuspended in 6X protein loading dye (600mM Tris-Cl pH 6.8, 
10% sodium dodecyl sulfate (SDS), 30% glycerol, 0.6M dithiothreitol (DTT) and 0.001% 
w/v bromophenol blue) , boiled, and resolved on 10% Tris-Glycine SDS-polyacrylamide 
gels. Proteins were detected by western blotting (Section 2.14). Blots were probed for 
the presence of rPARN using rabbit anti-PARN serum (generated in-house; Moraes et 
al., 2006) at 1:20,000 dilution and goat anti-rabbit horseradish peroxidase conjugated 




2.9 Cell culture 
Murine C2C12 myoblasts (ATCC# CRL1772) cultures were maintained at or 
below 60% confluency in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% 
fetal bovine serum (FBS), penicillin (10 units/ml) and streptomycin (10µg/ml) in 5% CO2 
at 37°C. Cells were detatched from culture flasks by rinsing two times with sterile PBS, 
and adding 0.25% trypsin. Cells were diluted in complete culture medium and split at a 
ratio no greater than 1:20. 
2.10 Differentiation of C2C12 cells 
3.0x105 C2C12 myoblasts were seeded on 60mm dishes in DMEM growth media 
(described above). Once cells had reached a density of ~90% confluency (typically 12-
16 hours later) the media was replaced with differentiation media (DMEM, 2% donor 
equine serum, penicillin 10 units/ml, and streptomycin 10µg/ml). Differentiating cells 
were cultured for 0 to 7 days in 5% CO2 at 37°C, with fresh media each day.   
2.11 Phorbol-ester treatment of C2C12 cells 
For experiments involving phorbol-ester treatment, 100 ng/ml of 12-O-
tetradecanoyl-phorbol-13-acetate (TPA Sigma Aldrich) or an equivalent volume of 
DMSO was added, to cells. Cells were incubated for 3 h prior to either lysis for 
immunoprecipitation or Trizol collection for RNA analyses.  
2.12 Generation of lentivirus particles for shRNA expression 
Infectious lentivirus was generated by cotransfection of 10µg each of packaging 
(pCMVRΔ8.2), pseudotyping (pCMV-VSVG), and targeting plasmids 
(pLKO.1puro+shRNA) into 293T cells by the calcium phosphate method (Jordan et al., 
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1996). Twelve hours post-transfection 6mls (for 75cm2 dishes) of fresh culture media 
(DMEM, 10% FBS, penicillin (10 units/ml), and streptomycin (10µg/ml)) was added 
containing 60µl of a 5% butyric acid solution in PBS.  Virus-containing supernatants 
were collected every day for three days following syncytia formation (Stewart et al., 
2003), and stored in 1.5ml aliquots at -80°C. 
2.13 Immunofluorescence Microscopy  
Cells were grown on glass coverslips for the indicated period of time, fixed and 
permeabilized in PBS containing 0.05% triton-X 100 and 1% paraformaldehyde for 15 
minutes at room temperature. Fixed cells were washed 3 times in PBS with 0.05% triton-
X 100 (wash buffer) and blocked in wash buffer containing 3% bovine serum albumin 
(BSA). Primary antibodies were added to block solution at the following dilutions: myosin 
heavy chain 1:20 (MF20), myogenin 1:20 (F5D), CUGBP1 1:1000 (3B1), and HuR 
1:1000 (3A2) for 1 hour at room temperature. Following incubation coverslips were 
washed 3 times, probed with fluorophore conjugated  donkey anti-mouse Cy-2 (Jackson 
Labs Cat # 715226020), goat anti-mouse Texas Red (Santa Cruz Cat.# sc-3797), or 
donkey anti-mouse Dylight-488™ (Cat.# 715486150). They were then washed 3 times 
and mounted on a glass slide in DAPI containing ProLong-Gold (Invitrogen). Actin was 
visualized using Texas-Red conjugated phalloidin (Invitrogen Cat.# T7471; 1:1000). 
2.14 Determination of fusion index 
Nuclei residing within myosin heavy chain positive cells were counted and 
represented as a ratio of total number of nuclei per field of view. Random fields of view 




2.15 Generation of PARN and CUGBP1 knock-down cells 
2.15.1 PARN 
Wild type C2C12 myoblasts were transfected as described in Mercer et al., 
(2005) using Lipofectamine 2000 (Invitrogen) with the six PARN targeting vectors from 
Table 2.3. Two days post-transfection cells were switched to media containing 4.0µg/ml 
puromycin. Once puromycin resistance had been established, PARN expression was 
evaluated by qRT-PCR using primers listed in Table 2.6, and by western blot using 
rabbit anti-PARN antibodies. Constructs #1520 and #2211 gave the best knock-down 
(consistently around 90%). These vectors were therefore chosen for generation of 
infectious lentivirus particles. Wild type C2C12 cells were transduced with PARN-
targeting or LKO-1 control lentivirus and puromycin resistant cell pools were selected. 
From these pools single clones were isolated by seeding ~10 cells per 100mm dish. Five 
to ten clonal cell lines were isolated using glass cloning rings, grown up and re-screened 
for gene knock-down by western and/or qRT-PCR.  All experiments involving PARN 
Knock Down (KD) cells, were conducted with a clonal cell line stably expressing #2211, 
as those expressing #1520 failed to differentiate.  
2.15.2 CUGBP1 
Glycerol stocks of lentivirus vectors bearing shRNAs targeting CUGBP1 were 
purchased from Sigma Aldrich (SHCLNG-NM 198683). Plasmids were transfected into 
C2C12 cells and selected with 4.0μg/ml puromycin. CUGBP1 expression was evaluated 
by qRT-PCR using CUGBP1-specific primers listed below (Table 2.6) and by western 
blotting.  Of the five constructs supplied, #1320 and #1739 gave the best knock-down 
and #1739 was used for the majority of experiments.  These constructs were used to 
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generate knock-down cell lines by transfection and subsequent selection of stable 
clones with puromycin. For later experiments involving differentiation, pools of CUGBP1 
knock-down cells were generated by infecting with lentivirus and selecting stable pools 
of CUGBP1-depleted cells. Stable pools were generated with both construct #1739 and 
#1320.  
Control cells were generated in a similar fashion as described for PARN (Section 
2.15.1). For experiments involving clonal cell lines, controls were generated by 
transfection of empty pLKO.1puro vector, selection of puromycin resistant pools, and 
selection of clonal cell lines. Clones were tested for the ability to differentiate and line 6-3 
was utilized for all experiments involving clonal CUGBP1 and PARN KD cells (including 
the global half life analysis).  For experiments involving CUGBP1 knock-down pools, 
cells were infected with virus containing empty pLKO.1puro. Puromycin-resistant pools 
were then selected in an identical fashion. 
2.16 Western blotting 
For CUGBP1 western blots, 40 µg of whole cell lysate was prepared by lysis of 
cells in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1.0% deoxycholate, 1% 
triton-X 100, 1mM EDTA, and 0.1% SDS). The lysates were boiled in 6X protein loading 
buffer, and resolved on a 10% SDS-polyacrylamide gel. Gels were blotted to 
Polyvinylidene Fluoride (PVDF) membrane, using Bio-Rad Semi-Dry transfer apparatus 
at 18V for 25 minutes in Transfer Buffer (25mM Tris-HCl, 190mM Glycine, and 15% 
methanol). Membranes were blocked for one hour in PBS-T (PBS containing 0.05% 
Tween-20) and 5% (w/v) non-fat dry milk. Primary antibodies were added directly to 
blocking solution. Following one hour incubation with primary antibody, membranes were 
washed three times with PBS-T, 5 minutes per wash, fresh blocking solution was added, 
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secondary antibody added for one hour at room temperature, membranes again washed 
three times for five minutes each in PBS-T, and signal detected using Pierce Pico 
Chemiluminescent detection kit. CUGBP1 was detected using monoclonal antibody 3B1 
(1:20,000 dilution; Santa Cruz Biotechnology), HuR was detected using monoclonal 
antibody 3A2 (1:10,000 dilution; Santa Cruz Biotechnology), phospho-PKC was detected 
with rabbit polyclonal antibody SC-12356-R (1:2000 dilution; Santa Cruz Biotechnology) 
PARN was detected using rabbit anti-sera (1:20,000; Moraes et al., 2006). GAPDH was 
used as a loading control (1:20,000 dilution; Chemicon mAB374). Differentiation 
markers, namely myogenin and myosin heavy chain were detected using hybridoma 
supernatants F5D and MF20 respectively at 1:20 dilution (Developmental Studies 
Hybridoma Bank, University of Iowa). Quantification was performed using QuantityOne 
software (BioRad). Reported values are a measure of the pixel intensity of the band of 
interest relative to the pixel intensity of the loading control (GAPDH in most cases). 
These ratios were then normalized relative to control samples. 
2.17 Cytoplasmic and nuclear fractionation of C2C12 cells 
Cells were collected by trypsinization and washed three times in ice-cold PBS. 
Cells were pelleted by centrifugation at 500xg for 5 minutes at 4°C. Cell pellets were 
resuspended in an equal volume of Buffer A (10mM HEPES pH 7.5, 10mM NaCl, 1.5mM 
MgCl2, 0.5mM DTT, and Complete Protease Inhibitor Cocktail (Roche)) and swollen on 
ice for 10 minutes with intermittent mixing. Cells were pelleted by spinning at 500xg for 5 
minutes at 4°C. Supernatant was removed and the cell pellet was resuspended in an 
equal volume of Buffer A containing 0.5% (v/v) Nonidet-P40 (NP-40). Cells were lysed 
by vigorously passage through a 25-gauge needle about 20 times. Cytoplasmic lysis 
was confirmed by microscopy. Nuclei were pelleted by centrifugation at 4,000xg in a 4°C 
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bench top microcentrifuge. Cytosolic supernatant was collected and stored at -80°C. 
Pellets containing nuclei were subjected to 4 washes in Buffer A containing 0.5% NP-40, 
each of which was approximately 4 packed nuclei volumes. Nuclear pellets were 
resuspended in an equal volume Buffer C (20mM HEPES pH7.9, 420mM NaCl, 0.2mM 
EDTA, 1.5mM MgCl2, 0.5mM DTT, 25% glycerol, and Complete Protease Inhibitor 
Cocktail (Roche)) and incubated on ice for 30 minutes with intermittent vortexing. The 
mixture was then centrifuged at 16,000xg at 4°C in a bench top microcentrifuge for 10 
minutes. Supernatant containing nucleoplasm was stored at -80°C for future use. 
2.18 Half-life analysis 
C2C12 cells were grown in 100mm dishes to 60-70% confluency. Transcription 
was shut off by treating cells with Actinomycin-D (8µg/ml Sigma-Aldrich) for 20 minutes. 
Cells were collected in Trizol™ (Invitrogen) at the indicated time points post transcription 
shutoff. Total RNA was isolated according to the manufacturer’s instructions. Equivalent 
amounts (1-2µg) were reverse transcribed, and analyzed by real-time PCR (BioRad 
MyIQ or, BioRad CFX96) using the ΔΔCt method (Vandesompele et al., 2002). Primer 
sets were designed using qPrimer Depot (Cui et al., 2007) or Primer3 plus (Untergasser 
et al., 2007) and are shown in Table 2.6 below. Except where otherwise noted, graphed 
data represents the mean values from at least three independent experiments; error 
bars represent the pooled standard deviations.  
For microarray experiments RNA concentration, purity, and quality were 
assessed via Bioanalyzer (Agilent). Transcription shut-off was confirmed using 1µg of 
total RNA from each time point in qRT-PCR assays (described previously Section 2.16) 
for either MyoD or myogenin, using GAPDH as a reference mRNA. Samples displaying 




For reverse transcriptase reaction (RT) 1-4µg of total RNA was annealed to 
500ng of random hexamers (for TNF, 1µl of 10µM gene-specific primer was used) in 5µl 
total volume by heating to 70°C for five minutes then cooling on ice. Reverse 
transcriptions were done in the following reaction mixture (35mM Tris-Cl pH8.3, 50mM 
NaCl, 5mM MgCl2, 5mM DTT, 500ng random hexamers, 10U RNase Inhibitor, 1µl 
Improm II Reverse Transcriptase (Promega)). Following the RT step, 2.5µl of cDNA 
template was used for qPCR with BioRad Supermix (170-8860) according to 
manufacturer’s instructions. A two-step amplification protocol was used with an 
annealing temperature of 60°C for 30 seconds and a melting temperature of 95°C for 30 
seconds for 40 cycles. A melt curve was generated by starting at 65°C and heating 
0.5°C every 30 seconds until a temperature of 95°C was reached. Primer pairs were 
standardized by amplifying six 5-fold serial dilutions (each done in triplicate) of cDNA 
reactions and fitting the data to a line. Primer pairs which generated a PCR efficiency 







Note: N/D indicates that the PCR efficiency was not measured as these primer pairs were used 
in traditional end-point RT-PCR assays. 
 
2.20 RNA immunoprecipitation 
 
Cell lysates were collected from proliferating C2C12 cells (~70% confluency) as 
previously described (Tenenbaum et al., 2002). This involved rinsing the cells three 
times in ice cold PBS, and collecting the cells by trypsinizing. Cells were then pelleted by 
Name Gene ID Gene name Left Primer (5' to 3') Right Primer (5' to 3') Efficiency
Actin 109711 Actin AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT 108.8%
Adora2b 11541 Adora2b TGCTCACACAGAGCTCCATC TGTCCCAGTGACCAAACCTT 108.2%
Ankrd54 223690 Ankrd54 CAATGCCAACGACGTAGAAA ATTGCAGGAAGCAAAATGGA 105.3%
Arl8a 68724 Arl8a CAGTACTCGGGCAAGACCAC CCTTTGGTGATTTTTCGCAT N/D
Bcl6 12053 Bcl6 AGTTTCTAGGAAAGGCCGGA GATACAGCTGTCAGCCGGG 103.5%
p21 12575 Cdkn1a CTCAGGTAGACCTTGGGCAG GTGTGCCGTTGTCTCTTCGG 89.2%
cJun 11767 cJun AAAACCTTGAAAGCGCAAAA GTTTGCAACTGCTGCGTTAG 99.8%
Myc 17869 cMyc CTGTCCATTCAAGCAGACGA TCCAGCTCCTCCTCGAGTTA N/D
Cox-2 19225 Ptgs2 CAAGACAGATCATAAGCGAGGA GGCGCAGTTTATGTTGTCTGT 116.0%
CUGBP 13046 Cugbp1 GATCAGTGCAGCGTCTGTGT GTGTTGAGGTTCCCAGAGGA 107.1%
GAPDH 14433 GAPDH TCACCACCATGGAGAAGGC GCTAAGCAGTTGGTGGTGCA 98.8%
Gata4 14463 Gata4 CTGGAAGACACCCCAATCTC CAGGCATTGCACAGGTAGTG 107.2%
Gnb1l 54584 Gnb1l AGCGGAGCCTCTGATCCT GACAAATCTGGGACCAGGC 112.6%
GPSM 67839 Gpsm1 CTGACTAGCCCAGCAGCAG TCTCGGCACTCAGCCTCT 98.4%
Gemin4 276919 Gemin4 GAACTGCAGGACATGCTCAA AGCTCCAAGTTTTGGCTGAA 106.3%
Id2 15902 Id2 GTCCTTGCAGGCATCTGAAT AGAAAAGAAAAAGTCCCCAAATG 99.5%
Il-6 16193 Il6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 99.9%
Infγ 16173 Il18 ACGGCACAGCTATTGAAAGCCTA CTCACCATCCTTTTGCCAGTTCC 97.9%
JunD 16478 JunD GACCCTCAAAAGCCAGAACA GTTGACGTGGCTGAGGACTT N/D
Lsm7 66094 Lsm7 CATCGATAAGACCATTCGGG AGCACCAGGTTGAGCAGTG N/D
MyoD 17927 Myod TGGGATATGGAGCTTCTATCGC GGTGAGTCGAAACACGGATCAT 107.1%
Myogenin 17928 Myog ACTCCCTTACGTCCATCGTG CAGGGCTGTTTTCTGGACAT 110.4%
Ncoa5 228869 Ncoa5 GGCAGCGGAAAGAAGAAATA TCTCCTTGGACTTCCTCGAA 112.5%
Net1 56349 Net1 TGTTCCCATTCTAGCACCAAG CAGCTCTGCGTCGAGTTTTT N/D
PARN 74108 PARN CTCAGCCAGCCAGAACAAGT TGCTTGCCTTTCTGCTTCTT 98.3%
Plk2 20620 Plk2 GGCAAGAAGGACAAAGCAAG TTGCTAGGCTGCTGGGTTAT N/D
Ppp1r15b 108954 Ppp1r15b GTGAGGCTCTTGCTGGAGAA TCCTTTGCGATCCTCATCAC 110.1%
Rnd3 74194 Rnd3 CACTGCCAGTTTTGAAATCG GGTAAGAGAGTGGACGGACG 114.5%
Smad7 17131 Smad7 GAACGAATTATCTGGCCCCT GACACAGTAGAGCCTCCCCA 113.2%
Sox9 20682 Sox9 AGGAAGCTGGCAGACCAGTA TCCACGAAGGGTCTCTTCTC 118.1%
TNF 21926 TNF CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 94.9%
Xist 213742 Xist CCAGGAACCATTCTTGCCTA GGAAAGCCCCAAGTAAAAGG N/D
Zfp36l2 12193 Zfp36l2 (Brf2) CCTCCTTTGTGGTGGTTGTT ACACTACGTGGTGGCAATGA 109.1%
List of primers used for (q)RT-PCR experiments 
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centrifuging at 500xg for 5 minutes at 4°C, and washing thrice in PBS. Cells were lysed 
by resuspension of the pellet in an equal volume of Polysome Lysis Buffer (100mM KCl, 
5 mM MgCl2, 10 mM HEPES, pH 7.0, 0.5% Nonidet P-40, 1 mM DTT, 100 units/ml 
RiboLock RNase Inhibitor (Fermentas), 0.2% vanadyl ribonucleoside complexes (New 
England Biolabs), 0.2mM PMSF, and 1X Complete Protease Inhibitor Cocktail (Roche)) 
and snap freezing to -80°C. Immunoprecipitates were isolated by incubating 100µl of 
cleared lysate with 7µl mouse control IgG (Santa Cruz sc-3877) or αCUGBP1 antibody 
(Santa Cruz sc-3B1) for 1 hour on ice. Following centrifugation at 16,000x g for 3 
minutes at 4°C, the reaction was transferred to a tube containing 100µl of a 10% slurry 
of Protein-G sepharose beads (Sigma) in NT-2 buffer (50 mM Tris-Cl, pH 7.4, 150 mM 
NaCl, 1 mM MgCl2, and 0.05% Nonidet P-40) and rocked for 1 hour at 4°C. Beads were 
washed two times with 250µl of NT-2 buffer, transferred to a micro-spin column (Pierce 
Cat.# 89879) and washed four more times with 200µL of NT-2 buffer. Beads were 
collected, divided in half, and analyzed for associated RNAs or proteins, by qRT-PCR or 
western blot respectively. For array validations, RNA was eluted by vortexing beads in 
60µl of Trizol (Invitrogen). RNA was purified according to manufacturer’s 
recommendations and resuspended in 5µl of water. 1 µl of RNA was reverse-transcribed 
with random hexamers, subjected to 30-40 cycles of PCR and run on a 2% agarose gel. 
Proteins were collected by elution with 10µl 6X protein loading buffer, boiled for 5 
minutes, resolved by SDS-PAGE (10% gels) and analyzed by western blot. For co-
immunoprecipitation, lysates were prepared as described above except cells were 






2.21 Preparation of RNA samples and microarray hybridization 
RNA samples were isolated from Trizol™ (Invitrogen). 300ng of total RNA for 
half-life, and 100ng of immunoprecipitated RNA were used to generate labeled cDNA 
fragments for hybridization to Affymetrix Gene 1.0 ST Arrays (Cat.# 901168) following 
the manufacturer’s protocols for the Sense Target Labeling Kit (cat.# 900652).  Half life 
experiments were conducted in triplicate, using a total of 45 arrays. For 
immunoprecipitation the experiment was conducted in duplicate and input RNA, control 
IgG precipitated RNA, and α-CUGBP1 precipitated RNA samples were assayed. 
2.22 Half-life analysis by microarray  
Relative fluorescence unit (RFU) values for each probe were normalized to the 
5th percentile value of the range of RFUs on each array. Array probes exhibiting signal 
that was above background in the 0 time point (P-value <0.05) were considered present. 
Half-lives were calculated in R (Dessau and Pipper, 2008) using a non-linear model fit to 
the normalized RFU values and time points. The calculated value for the mRNA half-life 
was considered reliable if it met the following two criteria in at least two of the three 
experimental replicates. First, the data points had to fit the decay curve within the 
acceptable error range (P-value <0.05). Second, the range of the 95% confidence 
intervals must be less than twice the calculated half-life.  For comparisons between 
control and CUGBP1 KD and control and PARN KD cells only mRNAs which yielded 
reliable half-lives in both sets were used. 
 2.23 CUGBP1 target identification by RIP-Chip and comparison to other datasets 
Probe intensities and expressed genes were normalized and determined as 
described in the preceding section. The data from the Input RNA arrays was not used for 
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the final analysis. The ratio of the log2 values of the CUGBP1 IP sample over the log2 
values of the normal mouse IgG sample were calculated for each gene and the genes 
were ranked by this value. Genes in the top 95th percentile were considered significantly 
associated with CUGBP1. The significantly associated genes were compared to other 
datasets for Pum1 (Morris et al., 2008) and HuR (Mukherjee et al., 2009) using Ingenuity 
Pathway Analysis (Ingenuity® Systems, www.ingenuity.com). 
 2.24 Cis-element analysis 
In order to identify sequence elements significantly enriched in unstable and 
stable transcripts the following approach was taken. mRNAs with reliable half-lives in 
C2C12 LKO-1 cells were ranked from shortest to longest. The transcripts with the 
shortest (10th percentile and below) and longest (90th percentile and above) half-lives 
were selected for comparison. Each set contained 739 mRNAs. The 3’UTR of each 
mRNA from both sets was examined for the occurrence of each of 4096 possible 
hexamers. Hexamer occurrence for the unstable and stable sets were compared by 
Fisher’s exact test to identify those that were significantly over-represented in one set as 
compared to the other (P-values <0.05 were considered significant). Related hexamers 
were clustered, and used to generate sequence logos via a Position Specific Scoring 
Matrix using Perl. In the sequence logo the probability for a particular nucleotide to be 
found in that position is represented by character height, where full height equals >99%. 
Sequence logos were generated by Web Logo Tool (Crooks et al., 2004). This process 





2.25 Gene ontology analysis 
Gene Ontology (GO) analyses were performed on various sets of mRNAs (e.g. 
unstable transcripts, transcripts bound by CUGBP1, transcripts affected by PARN knock-
down) in order to identify functional relationships within each set. Significantly over-
represented GO terms were identified using R script and Perl script by Dr. Ju Youn Lee, 
University of Medicine & Dentistry of New Jersey Medical School. 
2.26 Electrophoretic mobility shift assays 
The 120nt p21 RNA (Section 2.3.1) was in vitro transcribed from 100ng of PCR-
generated template in the presence of (α-32P) UTP (4.0µl in 10µl total) using 10U T7 
RNA polymerase in 1X transcription buffer (40mM Tris-HCl (pH 7.9), 6mM MgCl2, 10mM 
DTT, 10mM NaCl, and 2mM spermidine) containing 0.5mM NTPs. Precipitated RNA was 
gel purified on a 5% denaturing polyacrylamide gel (see section 2.3 for electrophoresis 
conditions). Increasing amounts of recombinant human GST-CUGBP1, mouse 6XHis 
HuR, or both were incubated with 3 fmol of RNA in the presence of 20 units of RNase 
inhibitor, 0.15mM spermidine, 20 mM HEPES (pH 7.9), 8% glycerol, 100 mM KCl, 1mM 
DTT and 2 mM MgCl2 for 5 min at 30 °C in a total volume of 10 µl. Low molecular weight 
heparin (Sigma Cat.# H2149) was added to a final concentration of 4mg/ml. Samples 
were chilled on ice for an additional 5 min, and 2 µl of loading buffer (0.5% bromophenol 
blue, 0.5% xylene cyanol, 30% glycerol) was added, followed by electrophoresis at room 
temperature on 5% native polyacrylamide gels in 1X TBE buffer (89mM Tris-Cl, 89mM 
boric acid, and 1mM EDTA) at 10 V/cm for 90 minutes. Dried gels were exposed to 
storage phosphor screens and visualized by Phosphor-Imaging using a Typhoon Trio 
Imager (GE Healthcare) and Image Quant software. The fraction of RNA bound was 
calculated by quantifying the amount of RNA associated with protein and dividing it by 
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the total amount of RNA in each lane. Excel (Microsoft) was used to plot the graphs 
shown, and dissociation constants (KD) were defined as the protein concentration 
required to achieve half-maximal binding at equilibrium. Reported KDs are the average of 
at least three experiments ± the standard deviation. 
2.27 UV cross-linking assays 
The p21 3’UTR RNA substrate was generated using EcoRV digested pGemTp21 
as a template for transcription (Section 2.4). The RNA contains the first 395nt of the 
murine p21 3’UTR. 0.3 fmols of RNA were incubated for 20 minutes at 22°C with the 
indicated concentration of recombinant proteins in binding buffer (20mM HEPES pH 7.9, 
100mM KCl, and 1mM DTT) as described previously (Sureban et al., 2007). Heparin 
was then added to a final concentration of 5mg/ml. After 5 minutes reactions were 
crosslinked at 250mJ/cm2 at a wavelength of 254nm, and were subsequently treated 
with 5 units of RNase One (Promega) for 10 minutes at 37°C, mixed with 6X protein 
loading dye and resolved by SDS-PAGE (10% gels). Dried gels were exposed to storage 
phosphor screens and imaged on the Typhoon Trio Imager (GE Healthcare). 
2.28 2D protein gels 
Total protein from RIPA lysed C2C12 cells (0.2mg) was precipitated in 4 volumes 
acetone at -20°C for 20 minutes followed by centrifugation for 20 minutes at 5,000 x g at 
4°C. Pellets were wash four times in 80% acetone, air dried, and resuspended in IEF 
sample buffer (8M urea, 2M thiourea, 2% w/v CHAPS, 0.3% DTT, 0.2% triton-X 100, 1% 
bromophenol blue, and 2.5% carrier ampholytes). For calf-intestinal phosphatase (CIP) 
treated samples 0.2mg of protein was resuspended in 1X CIP buffer containing: 50 mM 
Tris-HCl pH7.9, 100 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol, and 100 units CIP 
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(New England BioLabs) and incubated at 37°C for two hours. Mock samples were 
incubated in identical conditions lacking enzyme. First dimension focusing was done on 
Bio-Rad Ready Strips pH 3-10 following 12 hours of active rehydration (in IEF sample 
buffer) at 50V, focusing was done initially at 250V for 15 minutes, then for a total of 
30kV-hours using the BioRad Protean IEF Cell. Strips were equilibrated for 15 minutes 
in equilibration buffer (6M urea, 30% glycerol, 2% SDS, and 25mM Tris pH 6.8) first 
containing 2% DTT, then containing 2.5% iodoacetamide.  Second dimensions were 
resolved on 10% SDS-PAGE, and blotted to PVDF membrane at 18V for 40 minutes, 
which were probed and visualized as described Section 2.16. 
2.29 RNaseH/northern blotting 
In order to shorten mRNAs to facilitate analysis of mRNA poly(A) tail lengths 
10µg of total RNA was incubated with 2µM DNA oligos (sequence listed in Table 2.7), 
heated to 95°C for 3 minutes and slow cooled (drop of 1.5°C/minute) to 4°C. RNaseH (7 
units) and RNase Inhibitor (20 units) were added in the supplied reaction buffer 
(Fermentas Cat.# EN0201). For generating poly(A) tail minus (A0) controls 100ng/µl of 
oligo dT18 was included. Reactions were incubated at 37°C for 30 minutes. RNAs were 
then resolved on a 5% denaturing polyacrylamide gel (7M urea, 1X TBE), electroblotted 
to nylon membrane (Hybond-XL GE Healthcare) at 700mA for 30 minutes in 1X TBE. 
Nucleic acids were immobilized by UV-crosslinking (Stratalinker, Auto-Crosslink 
Feature). Membranes were pre-hybridized for 1 hour at 60°C in 25ml hybridization buffer 
(50% formamide, 750mM NaCl, 75mM sodium citrate, 1% SDS, 0.1mg/ml salmon sperm 
DNA, 1mg/ml polyvinylpyrrolidone, 1mg/ml ficoll, 1mg/ml bovine serum albumin (BSA)).  
Membranes were then hybridized to radio-labeled probe over night at 60°C, also in 
hybridization buffer. Blots were washed two times in 25ml non-stringent wash buffer 
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(0.1% SDS, 300mM NaCl, 30mM sodium citrate) and two times in 25ml stringent wash 
buffer (0.1% SDS, 30mM NaCl, 3mM sodium citrate) for 20 minutes each time at 60°C. 
Membranes were exposed to storage phosphor screens and imaged on the Typhoon 
Trio Imager (GE Healthcare). Results were analyzed using Image Quant software (GE 
Healthcare). α32P-labeled RNA probes were generated by in vitro transcription reactions 
as described (Section 2.4). Briefly pGemTZfp36l2 (Brf2) was linearized with Spe1 and 
transcribed with T7 RNA polymerase to generate RNA complementary to the Zfp36l2 
message.  The pGemTActin plasmid, was linearized with SacII and transcribed with SP6 
RNA polymerase. In some experiments, cells were treated with Actinomycin-D (8µg/ml 





Gene ID Gene name DNA oligo (5' to 3')
109711 Actin AAGCAATGCTGTCACCTTCC
12193 Zfp36l2 (Brf2) CGCGGTGCTCCAACTGTACCTA







Chapter 3: CUGBP1 regulates stability of TNF mRNA in muscle 
cells 
Many of the results presented in Chapter 3 appeared in: The RNA-binding Protein CUGBP1 
Regulates Stability of Tumor Necrosis Factor mRNA in Muscle Cells: Implications for Myotonic 
Dystrophy Journal of Biological Chemistry Vol. 283, No. 33, pg. 22457–22463, August 15, 2008. 
  
A previous study in the Wilusz lab sought to address the mechanism by which 
ARE-mediated decay of TNF mRNA is achieved (Moraes et al., 2006). A cell-free RNA 
decay system which can be used to accurately assess rates of deadenylation was 
employed (Ford and Wilusz, 1999). Through UV-crosslinking and competition assays, it 
was demonstrated that CUGBP1 specifically binds to a fragment of the 3’UTR of TNF 
mRNA in cytoplasmic extracts. Later experiments showed CUGBP1 was not associated 
exclusively with the ARE, but also recognized a UGUU element adjacent to the ARE. 
Additional experiments demonstrated that the TNF 3’UTR RNA was rapidly 
deadenylated in cytoplasmic extracts. This activity was dependent on CUGBP1 binding 
and PARN was the enzyme responsible. Finally, evidence was presented that PARN 
and CUGBP1 could directly interact, and that this interaction was RNA-independent. 
Unfortunately, attempts to further characterize the interaction between PARN and 
CUGBP1 have been unsuccessful to date (Appendix 1). Overall, these in vitro results 
demonstrate that direct recruitment of a deadenylase to an RNA substrate by CUGBP1 
enhances mRNA decay. 
 TNF is a potent cytokine produced primarily in immune cells (Tracey and 
Cerami, 1994), but also in other cell types, including adipocytes (Prins et al., 1997) and 
myocytes (Li and Schwartz, 2001).  Importantly, TNF over-expression has many 
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pathogenic effects; it has been directly linked with muscle wasting (Reid and Li, 2001), 
rheumatoid arthritis (Kontoyiannis et al., 1999), and Crohn’s disease (Kontoyiannis et al., 
2002). Moreover, TNF is commonly over-expressed in skeletal muscle diseases like 
Duchenne Muscular Dystrophy, DM1, and polymyositis (Mammarella et al., 2002; Saito 
et al., 2000; Shimizu et al., 2000).   
As stated above, the TNF mRNA is a probable target of CUGBP1, which likely 
regulates decay of several mRNAs in immune cells (Vlasova et al., 2008). However, 
CUGBP1 appears to play a more significant role in muscle than in immune and other cell 
types as its function is disrupted in the neuromuscular disorders including DM1, OPMD, 
FXTAS, and SBMA (Corbeil-Girard et al., 2005; Sofola et al., 2007; Yu et al., 2009; 
Mammarella et al., 2002). Based on these observations we hypothesized that disruption 
of CUGBP1 function in DM1 leads to stabilization of TNF mRNA and TNF over-
expression, which might promote muscle wasting. We therefore examined whether the 
CUGBP1-mediated regulation of TNF mRNA decay observed in HeLa extracts (Moraes 
et al 2006) could be recapitulated in proliferating muscle cells. 
 
3.1 CUGBP1 destabilizes TNF mRNA in C2C12 myoblasts 
We chose to use C2C12 muscle cells for this study because they are a well-
characterized and easily cultured model that can be induced to differentiate in vitro (Blau 
et al., 1983). In order to examine the role of CUGBP1 in regulating TNF expression in 
C2C12 cells we first generated a knock-down cell line. Five commercially available 
lentivirus vectors containing shRNAs predicted to target CUGBP1 were tested for 
efficacy by transient transfection into C2C12 cells (Figure 5A). Cell pools which exhibited 
the best knock-down when compared to empty vector (LKO-1), as assessed by qRT-
PCR and western blot, were used for selection of clonal lines. Two cell lines were 
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selected for further experiments – LKO-1 (bearing empty vector) and CUGBP1 knock-
down (KD; bearing construct #1739, which targets all splice isoforms of CUGBP1) 
(Figure 5A). As shown in Figures 5B and C, CUGBP1 expression was reduced 
approximately 90% at the mRNA and protein levels in the CUGBP1 KD cell line. 
Figure 5. 
 
Knock-down of CUGBP1 by shRNA triggers TNF mRNA abundance and half-life increases.  
(A) Schematic of CUGBP1 mRNA, ORF as box, lines as UTRs, red line indicates approximate 
position of targeting shRNA, numbers indicate nucleotide boundaries of described features. (B) 
Abundance of CUGBP1 mRNA in CUGBP1 KD and control (LKO-1) cells determined by qRT-
PCR, normalized to GAPDH mRNA. (C) Western blot for CUGBP1 and GAPDH (loading control) 
of extracts from LKO-1 and CUGBP1 KD cell lines. (D) TNF mRNA levels in LKO-1 and CUGBP1 
KD cell lines assessed by qRT-PCR normalized to GAPDH. (E) Rate of decay for TNF mRNA in 
the LKO-1 (solid line) and CUGBP1 KD cell lines (dashed line) was assessed following 
actinomycin-D treatment. mRNA levels were measured at each time point and normalized to 




As an initial experiment, the levels of TNF mRNA were measured by qRT-PCR in 
both LKO-1 and CUGBP1 KD cell lines (Figure 5D). In CUGBP1 KD cells the relative 
abundance of the TNF transcript was, on average, increased 4-fold over the levels in the 
control cells, consistent with an increase in mRNA stability. Next, TNF mRNA stability 
was assessed in control and CUGBP1 knock-down cell lines (Figure 5E) by treating cells 
with the transcription inhibitor actinomycin-D, isolating total RNA at each time point, and 
measuring the abundance of both a stable reference mRNA (GAPDH) and TNF mRNA 
for each sample.  The measured half life for TNF mRNA in control cells was 
10.0±1.0min. This is slightly less stable than previously reported in lymphocytes and 
macrophages where the message had a half-life of 15-20 minutes for lymphocytes and 
30-40 minutes for macrophages (Garnon et al., 2005; Wang et al., 2006). This may be 
due to muscle not being a primary TNF producer, or be indicative of the sensitive nature 
of muscle to TNF levels. 
In the CUGBP1 KD cells the half-life of the TNF mRNA was markedly increased 
(27.0±3.5min). This result conforms nicely with the in vitro data generated in the 
previous study (Moraes et al., 2006) which first suggested that decay of TNF was 
regulated by CUGBP1. This finding adds CUGBP1 to the growing list of RNA-binding 
proteins which post-transcriptionally regulates TNF mRNA, which currently includes: 
TIA-1 (Piecyk et al., 2000), FXR1(Garnon et al., 2005), TTP (Carballo et al., 1998), and 
HuR (Rajasingh et al., 2006). This is the first study to identify an RNA-binding protein 
that regulates TNF mRNA decay in muscle. Previous studies focused on the TNF 
expression in immune responses of haematopoetic cells (Garnon et al., 2005; Wang et 




 3.2 PARN deadenylase is dispensable for rapid decay of TNF mRNA in C2C12 cells 
In vitro, CUGBP1 initiated rapid poly(A) tail removal by directly interacting with 
PARN (Moraes et al., 2006). We were therefore interested to learn whether PARN 
influences TNF mRNA decay in proliferating myoblasts. To test this, six oligo pairs 
encoding sequences predicted by The Broad Institute’s RNAi Consortium to specifically 
target the PARN mRNA were subcloned into the pLKO.1puro vector. Again, these were 
transfected into C2C12 cells, and cells were screened by qRT-PCR and western blot for 
those exhibiting the best knock-down. The two most effective vectors (#1520 and #2211) 
from Table 2.3 were chosen for production of infectious lentiviral particles. C2C12 cells 
were then transduced with PARN-targeting lentivirus, and clonal cell lines were selected. 
As shown in Figure 6B and C for construct #2211, PARN mRNA and protein levels were 
both reduced about 85%. We focused our efforts on construct #2211, because cells 
generated by #1520 failed to differentiate upon serum withdrawal (data not shown). 
In the PARN KD cells, there was no detectable difference in TNF mRNA 
abundance (Figure 6D). As mRNA half-life and abundance do not necessarily correlate 
(Dolken et al., 2008; Rabani et al., 2011), the rate of TNF mRNA decay was measured in 
LKO-1 and PARN KD cells. TNF mRNA consistently decayed at the same rate in both 
cell types (Figure 6E; half-life around 11 minutes in both cases).  The fact that PARN 
knock-down does not affect TNF mRNA half life could be for several reasons. First, it is 
possible that another deadenylase is acting in its place. As mentioned earlier, there are 
multiple deadenylases (10 encoded in humans; Garneau et al., 2007). Secondly, PARN 
was chosen for study based on observations from HeLa cytoplasmic extracts where it is 
the major active deadenylase, but this may not be the case for C2C12 muscle cells.   





Knock-down of PARN by shRNA does not change TNF mRNA abundance or half-life.  (A) 
Schematic of PARN mRNA, ORF as box, lines as UTRs, red line indicates position of targeting 
shRNA. (B) Abundance of PARN mRNA in (PARN KD) and empty vector (LKO-1) expressing 
cells determined by qRT-PCR and normalized to GAPDH. (C) Western blot for PARN and 
GAPDH (loading control) of extracts from LKO-1 and PARN knock-down cell lines. (D) TNF 
mRNA levels assessed by qRT-PCR from LKO-1 and PARN KD cell lines normalized to GAPDH. 
(E) Rate of decay for TNF mRNA in the LKO-1 (solid line) and PARN KD cell line (dashed line) 
was assessed following actinomycin-D treatment. mRNA levels were measured at each time 
point and normalized to GAPDH. 
 
myoblasts. Finally, the level of PARN knock-down may simply be insufficient to elicit an 
effect on the half life of the TNF mRNA. On a related note the PARN KD cells generated 
using shRNA construct #1520 (which showed similar levels of knock down) did exhibit 
significant stabilization of the TNF mRNA, by about 2-fold (Appendix 2). However, the 
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validity of these results is questionable as the finding (1) was not corroborated by an 
add-back experiment showing a return to normal decay rates and (2) could be the result 
of an off-target effect as the cells generated using shRNA #1520 failed to differentiate 
(data not shown).  
3.3 Protein Kinase C activation increases TNF mRNA abundance and stability 
The experiments described above indicated that PARN is dispensable for rapid 
TNF mRNA decay. As CUGBP1 was found necessary for rapid decay of the TNF mRNA 
additional experiments were focused there. We were drawn to a report by the Cooper 
lab which indicated that CUGBP1 function is altered in DM1  by phosphorylation via 
activation of the Protein Kinase C (PKC) pathway (Kuyumcu-Martinez et al., 2007). We 
therefore hypothesized that either expression of CUG-repeat containing mRNAs or PKC 
activation by treatment with the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate 
(TPA) would impact TNF mRNA stability by inducing phosphorylation of CUGBP1. 
Experiments conducted in our lab by Dr. Libin Zhang showed that transfection of C2C12 
cells with an expression plasmid bearing 960 CUG repeats (CUG960) within the DMPK 
3’UTR (Philips et al., 1998) triggers CUGBP1 phosphorylation, whereas an otherwise 
identical control plasmid bearing zero CUG repeats (CUG0) does not (Figure 7A).  
Additionally treatment of C2C12 myoblasts with TPA triggers PKC activation (Figure 7B) 
and a reduction in isoelectric point (pI) of CUGBP1. Interestingly, both repeat RNA and 
TPA treatment apparently result in multiple phosphorylation events, however the exact 
number could not be precisely determined as no isoelectric focusing standard was 
included with the samples. These data are consistent with a phosphorylation event (Dr. 
Libin Zhang Figure 7A). In DM1 patient cells CUGBP1 is increased in abundance in the 
nucleus (Kuyumcu-Martinez et al., 2007) but we saw no effect on abundance or 
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localization of CUGBP1 in C2C12 cells expressing CUG repeat RNA (Dr. Libin Zhang, 
data not shown). 
Figure 7.  
 
CUG-repeat RNA expression and TPA treatment result in CUGBP1 phosphorylation. (A) 
Extracts from C2C12 cells treated with DMSO or TPA or transfected with 0 or 960 CUG repeat 
expressing plasmids were subjected to 2D-PAGE followed by western blot for CUGBP1. (B) 
Western blot of extracts from untreated, DMSO, and TPA treated C2C12 myoblasts probed for 
active (pPKC) and transferring receptor as loading control.  
3.4 CUGBP1-mediated decay of TNF mRNA is disrupted upon TPA treatment 
To address the effect of PKC activation on TNF mRNA levels and stability we 
first treated the control LKO-1 myoblasts with TPA or DMSO (solvent only control). TPA 
treatment resulted in TNF mRNA abundance being increased 10-fold over the levels in 
DMSO treated myoblasts (Figure 8A). This large increase in mRNA levels indicated that 
TPA induces TNF expression in C2C12 cells as was reported previously for monocytes 
(Kelker et al., 1985) but does not distinguish between regulation at transcriptional and 
post-transcriptional levels. To determine the contribution of changes in mRNA decay to 
this large increase in steady-state TNF mRNA levels, we assessed TNF mRNA half-life 
in myoblasts which had been pre-treated for 3 hours with TPA or DMSO. In myoblasts 
treated with DMSO, the TNF mRNA half-life was 14.9±1.2minutes, which was slightly 
longer that in the untreated control myoblasts (Figure 5E). For the TPA treated control 
cells the TNF mRNA half-life was 32.7±2.8 minutes (Figure 8B). 
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The two-fold change in stability of the TNF message indicated that upon TPA 
treatment, at least some of the ten-fold increase in mRNA abundance was due to an 
increase in mRNA stability.  The remainder of the increase in abundance can be 
attributed to increased rates of transcription. Indeed, TPA treatment has been shown to 
increase TNF transcription rates in T-lymphocytes (Hoffmeyer et al., 1999) by activating 
the transcription factor,  Activator Protein-1 (AP-1 or Jun; Lee et al., 1987). 
Figure 8. 
 
TNF mRNA abundance and stability are increased upon PKC activation in a CUGBP1-
dependent manner. (A) TNF mRNA levels were assessed following TPA or DMSO (carrier) 
treatment in control, and CUGBP1 knock-down myoblasts by qRT-PCR.(B) TNF mRNA half life 
following treatment of control cells with TPA or DMSO, and (C) TNF mRNA half life in CUGBP1 





To test whether CUGBP1 phosphorylation plays a role in stabilizing TNF mRNA 
upon TPA treatment we repeated these experiments in our CUGBP1 KD myoblasts. 
When TPA was added to CUGBP1 KD cells, there was a large increase in TNF mRNA 
levels (Figure 8A) much as was seen in the LKO1 controls. However, the TNF mRNA 
half-life was identical in both DMSO and TPA treated CUGBP1 KD cells (31.4±4.1 
minutes for DMSO and 33.3 ±3.0 minutes for TPA treated cells, Figure 8C).  
This result indicates that the TNF transcript was fully stabilized by CUGBP1 
depletion, and could not be further stabilized by TPA treatment. Thus phosphorylation or 
depletion of CUGBP1 have similar effects on TNF mRNA stability. These observations 
strongly support the idea that phosphorylation of CUGBP1 abrogates its destabilizing 
activity. Furthermore, it indicates that the ten-fold increase in TNF mRNA abundance 
observed in TPA treated control cells (Figure 8A) was due to both a transcriptional 
increase, and disruption of CUGBP1-mediated mRNA decay. The idea that the ten-fold 
increase is caused by changes in transcription and stabilization, is supported by similar 
experiments in the CUGBP1 knock-down cells. In the KD cells the TNF mRNA is already 
stabilized, so the five-fold abundance increase would represent just the transcriptional 
induction. The effect of TPA treatment on TNF mRNA could be mediated through loss of 
CUGBP1 binding, or could require recruitment of a stability factor like HuR. This is 
plausible as HuR has been shown to bind the TNF 3’UTR and regulate mRNA stability in 
NIH 3T3 fibroblasts (Stoecklin et al., 2003).  
Exhaustive attempts were made to measure TNF protein levels in control and 
CUGBP1 KD myoblasts, DMSO and TPA treated myoblasts, differentiated myotubes, 
and in media supernatants both by western blot and enzyme-linked immunosorbent 
assay (ELISA). The levels of TNF protein expressed in C2C12 cells were too low to 
84 
 
permit detection of TNF in these cells. In the future, it would be interesting to determine 
whether the changes we observed at the mRNA level are reflected in increased TNF 
protein levels. 
3.5 Protein kinase C activation disrupts interaction of CUGBP1 with substrate 
mRNAs 
  As we had demonstrated that TPA treatment of cells results in stabilization of an 
mRNA target of CUGBP1, and that this event is correlated with CUGBP1 
phosphorylation, we next sought to address the possible mechanism by which CUGBP1 
loses its ability to destabilize TNF mRNA. One hypothesis was that phosphorylation of 
CUGBP1 resulted in loss of RNA-binding ability and consequently decreased 
association with mRNA targets. Alternatively, it could be that phospho-CUGBP1 no 
longer efficiently recruits PARN and/or other mRNA decay factors. We focused on 
testing the first hypothesis –that CUGBP1 association with its RNA targets is decreased 
upon phosphorylation. 
We chose an RNA immunoprecipitation (RIP) approach that has been successful 
for others (Schmidt et al., 2011; Galban et al., 2008; Kawai et al., 2006; Jin et al., 2010). 
For these experiments we were forced to examine mRNA targets other than TNF, as it 
was expressed at too low a level for reliable detection in this assay (data not shown). 
The Jun mRNA was selected because it is bound avidly by the Xenopus homolog of 
CUGBP1, and by human CUGBP1 (Paillard et al., 2002).  Myogenin was selected as a 
muscle-specific and post-transcriptionally regulated mRNA which has extensive UG-rich 
elements in its 3’UTR (Figueroa et al., 2003; Jin et al., 2010). These elements strongly 
resemble those previously identified as CUGBP1 binding sites (Vlasova et al., 
2008(Rattenbacher et al., 2010). 
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C2C12 myoblasts were pre-treated for 3 hours with TPA or DMSO, lysed, and 
the extracts subjected to immunoprecipitation with αCUGBP1 antibody (3B1) or an 
equivalent volume of control IgG. Efficient isolation of CUGBP1 from both DMSO and 
TPA treated cells was confirmed by western blot, (Figure 9A). Associated mRNAs were 
detected by qRT-PCR.  
Figure 9.  
 
Myogenin and Jun mRNAs are associated with CUGBP1 and treatment with TPA reduces 
CUGBP1 association. (A) Western blot of lysates from DMSO and TPA treated cells probed for 
CUGBP1 and GAPDH (loading control). Shown is the relative quantitation of CUGBP1 in each 
fraction following immunoprecipitation. (B) Levels of Jun and myogenin mRNAs were assessed 
by qRT-PCR from total RNA samples isolated from DMSO and TPA treated myoblasts. (C) qRT-
PCR of bound fractions from negative control IgG and α-CUGBP1 immunoprecipitation reactions 
show abundance of each mRNA associated with CUGBP1 normalized to GAPDH mRNA. These 
experiments were repeated in triplicate and the average of the three independent trials is shown, 
where error bars represent the pooled standard deviations. 
 
For Jun mRNA the results in cells treated with DMSO were promising in that the 
transcript was enriched in the CUGBP1 immunoprecipitate, as expected, based on 
published results from another lab (Paillard et al., 2002). In fact, Jun mRNA shows on 
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average a ten-fold enrichment in the CUGBP1 immunoprecipitate over the control IgG 
precipitated samples. There is a marked reduction in the amount of Jun mRNA 
associated with CUGBP1 in TPA treated extracts (Figure 9C) despite that the overall 
abundance of Jun mRNA is not affected by TPA treatment (Figure 9A). 
Myogenin mRNA also associated with CUGBP1 (Figure 9C). In DMSO treated 
C2C12 cells, myogenin mRNA was enriched on average 30-fold in the CUGBP1 
immunoprecipitate over control IgG. This is exciting as myogenin is a potent transcription 
factor necessary for muscle differentiation (Parker et al., 1995), which has been shown 
to be regulated at the post-transcriptional level by the RNA-binding proteins HuR 
(Figueroa et al., 2003) and RBM24 (Jin et al., 2010). Our result indicates that CUGBP1 
may also regulate expression of myogenin and thus impact muscle differentiation. 
Interestingly, the pretreatment of myoblasts with TPA dramatically reduced the amount 
of myogenin mRNA associated with CUGBP1 (Figure 9C) even though TPA treatment 
had a negligible effect on myogenin mRNA abundance (Figure 9B). This indicates that 
PKC activation may disrupt muscle differentiation through CUGBP1. 
As CUGBP1 bound specifically to Jun and myogenin mRNAs, we measured the 
half-life of these transcripts in our control and CUGBP1 KD myoblasts, but found no 
significant differences. Jun had a half life of ~12 minutes in both KD and control cell 
types, and myogenin had a half life of ~1.3 hours in both. CUGBP1 may impact other 
aspects of mRNA metabolism for these two messages, such as translational efficiency. 
Alternatively, instability of these critical transcripts may be maintained through multiple 
redundant pathways such that CUGBP1 knock-down is not sufficient on its own to 
disrupt their degradation. The fact that multiple RBPs are known to associate with both 
of these transcripts to regulate their decay is consistent with this possibility (Figueroa et 
al., 2003; Jin et al., 2010; Paillard et al., 2002). 
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In summary, we have demonstrated that TNF mRNA has a very short half-life 
(~10 minutes) in C2C12 cells. This rapid decay requires CUGBP1 activity, as knock-
down experiments showed marked stabilization of the TNF transcript. However, PARN 
depletion had no significant impact on the TNF mRNA. Following activation of PKC, 
which results in CUGBP1 phosphorylation, TNF mRNA is induced and stabilized in a 
CUGBP1-dependent fashion. Activation of PKC, a condition observed in DM1 
(Kuyumcu-Martinez et al., 2007), disrupts CUGBP1 association with Jun and myogenin 
mRNAs. Taken together this work underscores a critical gap in the understanding of 
DM1 and other diseases of muscle. Inappropriate expression of CUGBP1 is strongly 
correlated with muscle disease, yet the cytoplasmic mRNA targets for which CUGBP1 









Chapter 4:  Global analysis of mRNA decay reveals the 
importance of CUGBP1 in muscle cells 
Many of the results presented in Chapter 4 appeared in: Systematic Analysis of Cis-Elements in 
Unstable mRNAs Demonstrates that CUGBP1 Is a Key Regulator of mRNA Decay in Muscle 
Cells. PLoS ONE 5(6): e11201. 
 
 
As we had now demonstrated that CUGBP1 regulated TNF mRNA stability in 
muscle cells, we sought to identify additional mRNA targets of CUGBP1 in these cells. 
Our focus was on the role of CUGBP1 in muscle, primarily because it is misregulated in 
several muscle disorders (FXTAS (Sofola et al., 2007), SBMA (Yu et al., 2009), OPMD 
(Corbeil-Girard et al., 2005), and DM1 (Philips et al., 1998)). In one mouse model of 
DM1, a global approach revealed that approximately half of the changes in mRNA 
abundance were due to sequestration of MBNL1 by CUG-repeat RNA (Du et al., 2010). 
We hypothesized that some of the remaining changes could be due to aberrant 
CUGBP1 function. Thus identifying the mRNA targets of CUGBP1 in muscle was a 
primary goal.  
The methods we chose to identify additional mRNA targets of CUGBP1 utilized 
whole genome microarrays. The approach is two-pronged, employing microarrays to 
measure mRNA decay rates on a global scale in both control and CUGBP1 KD cells. 
Comparison of half-life datasets revealed mRNAs exhibiting CUGBP1-dependent decay 
kinetics. The second approach involves an RNA ImmunoPrecipitation followed by 
microarray (RIP-Chip) to identify mRNA targets bound by CUGBP1.  
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Microarray-based strategies have been successful for measuring mRNA decay 
rates on a global scale in bacteria (Bernstein et al., 2002), yeast (Wang et al., 2002), and 
mammalian cells (Raghavan et al., 2002; Sharova et al., 2009). These studies have 
found that abundance and mRNA half-life do not necessarily correlate (Bernstein et al., 
2002), that functionally related mRNAs decay with similar kinetics (Wang et al., 2002), 
and that functionally related messages are co-regulated in response to external cues 
(Raghavan et al., 2002; Sharova et al., 2009).   
The RIP-Chip approach has identified mRNA targets for regulation by HuR 
(Mazan-Mamczarz et al., 2008), Pum1(Morris et al., 2008), TTP (Emmons et al., 2008), 
and Ago2 (miRNAs; Wang et al., 2010). These studies have yielded significant insight to 
the cellular roles of mRNA-binding proteins. HuR was implicated in transformation of 
cells to a tumorigenic phenotype (Mazan-Mamczarz et al., 2008). Pum1 was found to be 
important for cell cycle regulation (Morris et al., 2008). TTP was associated with many 
mRNAs encoding factors important for regulating protein synthesis (Emmons et al., 
2008). By applying these global approaches to study CUGBP1, significant progress 
should be made towards understanding mRNA decay in muscle cells in general as well 
as better characterizing the role of CUGBP1 as a regulator of mRNA decay in this tissue. 
 4.1 Global assessment of mRNA decay in muscle cells 
A microarray-based approach (Wang et al., 2002) was used to measure mRNA 
decay rates in C2C12 LKO-1 muscle cells in triplicate. Similar to the TNF mRNA half-life 
experiments described in Chapter 3, we utilized actinomycin-D for transcriptional arrest, 
collected cell samples at 0, 10, 40, 100, and 230 minutes post drug treatment, and 
isolated RNA (Figure 10A). Total RNA samples were used to generate probes for 
hybridization to the arrays. This time course was chosen for two reasons: First, 
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prolonged transcriptional inhibition is toxic to cells (Reich et al., 1961), and second, other 
studies indicated many post-transcriptionally regulated genes have shorter half-lives 
(Vlasova et al., 2008; Dolken et al., 2008; Rabani et al., 2011).  
Figure 10.  
 
Experimental design for estimation of mRNA half-lives. (A) Proliferating myoblasts were 
treated with transcription inhibitor and collected in Trizol at the indicated time points. Total RNA 
was isolated and used to prepared cDNA probes which were hybridized to Affymetrix Gene 1.0 
ST Arrays. (B) Criteria applied to probe intensities for determining reliable half-lives. 
 
For all of the arrays, generation of biotinylated cDNA probes, hybridization, and 
detection were performed by Erin Petrilli of the Colorado State University Genomics and 
Proteomics Core.  Drs. Bin Tian and Ju Youn Lee at the University of Medicine and 
Dentistry of New Jersey (UMDNJ)-New Jersey Medical School performed the majority of 
the bioinformatic analyses described below. Drs. Tian and Lee calculated mRNA half-
lives by monitoring diminished fluorescence on each spot on the arrays over the 
experimental time course, and fitting to a non-linear model as described previously 
(Wang et al., 2002). 
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 4.2 Global mRNA decay features in myoblasts 
In total, 17,080 transcripts were expressed in the C2C12 myoblasts (signal 
significantly above background in the 0 time point for all three replicates). Half-lives were 
determined by fitting the data to a first order exponential curve.  Highly selective criteria 
(Fig 10B) were applied to each gene to ascertain that only reliable half lives were 
reported.  First, the decay curve had to be a good fit to the exponential (p<0.05).  
Second, the range of the 95% confidence interval had to be less than twice the 
calculated half life. These two criteria had to apply for at least two of the three replicates. 
17,008 transcripts met the first criterion (fit well to the exponential curve) and 7,398 of 
these also met the second criteria (acceptable confidence interval). This represents 41% 
of the detected mRNAs.  
Examples of calculated mRNA decay curves for an unstable (Fbxo5) and stable 
message (Gdpd3) are shown in Figure 11A. The median half-life of all 7,398 mRNAs 
was 2.9 hours (Figure 11B) which is somewhat shorter than expected, as other global 
mRNA decay studies reported medians of ~10 hours for fibroblasts and hepatocytes 
(Yang et al., 2003), and 7.1 hours for embryonic stem cells (Sharova et al., 2009). We 
attribute these differences to the stringent criteria that we have used (many genes we 
have excluded had long half-lives), differences in cell types, and our shorter 
experimental time course. The lower and upper 10th percentiles, at 0-1.6 hours and 




Figure 11.  
 
Global decay assay yields 7,398 mRNA half-lives in muscle cells. (A) Change in abundance 
of representative mRNAs over time as determined by microarray for an unstable (Fbxo5) and 
stable (Gdpd3) transcript. (B) Distribution plot of the 7,398 reliable half lives from C2C12 cells, 
red dashed lines indicate the upper and lower 10th percentiles and solid line indicates the median. 
 
4.3 mRNAs involved in cell cycle and ion transport are enriched in short and long-
lived mRNAs respectively 
To identify functional relationships between transcripts with similar half-lives 
Gene Ontology (GO) analyses were performed. For this we focused on the least and 
most stable transcripts (lower and upper 10th percentiles Figure 11B). GO analysis was 
performed by retrieving assigned GO terms from the NCBI database and comparing the 
normalized frequency of occurrence for each term in the lowest 10th percentile with its 
normalized frequency in the entire dataset. P-values for GO terms were calculated by 
Fisher’s exact test. Terms with a p-value of <0.05 were considered significantly enriched.  
The top 20 GO terms (by significance) for the least and most stable transcripts 
are listed in Table 4.1. Short half-life messages were enriched for factors involved in cell 
cycle, transcriptional regulation, and mRNA metabolism. The longest-lived transcripts 
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were enriched for factors involved in ion transport. These results are similar to those 
reported in other global mRNA decay experiments which concluded that short half-life 
mRNAs frequently encode factors which mediate rapid responses to external cues 
(Miller et al., 2011; Mukherjee et al., 2009; Vlasova et al., 2008). Conversely, long half-
life mRNAs encode factors that are typically involved in “house-keeping” functions (Miller 
et al., 2011).  
We were most interested in the unstable messages as they were likely to be 
dynamically regulated at the level of mRNA stability. For muscle short-lived mRNAs are 
involved in cell cycle, transcriptional regulation, and mRNA metabolism. As other studies 
have shown, it is common for mRNAs whose gene products need to be regulated 
dynamically to have a short half-life (Miller et al., 2011; Vlasova et al., 2008). Global half-
life experiments conducted in embryonic stem (ES) cells found that short half-life 
mRNAs encode factors involved in conversion of stem cells into differentiated cell types 
(Sharova et al., 2009). For T-cells, short half-life mRNAs encode factors involved in 
eliciting an immune response (Mukherjee et al., 2009; Vlasova et al., 2008).  In yeast, 
short half-life mRNAs encode factors critical for response to heat-shock or osmotic 
stress (Miller et al., 2011).  
4.4 Identification of cis-acting elements enriched in the 3’UTRs of short and long-
lived transcripts 
To identify sequence elements within the short and long lived transcripts which 






Table 4.1  
 
GO analysis reveals important processes associated with short and long half-life mRNAs. 
The top 20 GO terms are shown for the short and long half-life mRNAs. Calculation of p-values 
was done by Fisher’s exact test. The first number in parentheses corresponds to the number of 
mRNAs for the indicated half-life category, and the second number corresponds to the number of 
mRNAs for the category of the opposite half-life group. 
 
P-value GO ID, GO Term
Short half life mRNAs
6.30E-07 (56,14) GO:0007049,cell cycle
6.07E-06 (31,4) GO:0006325,establishment or maintenance of  chromatin architecture
1.19E-05 (55,17) GO:0006366,transcription f rom RNA polymerase II promoter
3.49E-05 (51,16) GO:0006357,regulation of  transcription f rom RNA polymerase II promoter
6.51E-05 (31,6) GO:0051276,chromosome organization
1.64E-04 (40,12) GO:0009892,negative regulation of  metabolic process
1.64E-04 (40,12) GO:0031324,negative regulation of  cellular metabolic process
2.78E-04 (16,1) GO:0016071,mRNA metabolic process
3.39E-04 (35,10) GO:0010629,negative regulation of  gene expression
3.39E-04 (35,10)
GO:0045934,negative regulation of  nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process
4.00E-04 (38,12) GO:0010605,negative regulation of  macromolecule metabolic process
4.08E-04 (18,2) GO:0048534,hemopoietic or lymphoid organ development
4.83E-04 (29,7) GO:0045892,negative regulation of  transcription, DNA-dependent
4.83E-04 (29,7) GO:0051253,negative regulation of  RNA metabolic process
4.96E-04 (20,3) GO:0006396,RNA processing
5.56E-04 (24,5) GO:0000122,negative regulation of  transcription f rom RNA polymerase II promoter
5.56E-04 (24,5) GO:0000278,mitotic cell cycle
7.39E-04 (17,2) GO:0006333,chromatin assembly or disassembly
8.45E-04 (33,10) GO:0016481,negative regulation of  transcription
9.87E-04 (14,1) GO:0006397,mRNA processing
Long half life mRNAs
1.63E-08 (36,4) GO:0006811,ion transport
1.45E-04 (12,0) GO:0006820,anion transport
1.63E-04 (20,3) GO:0006812,cation transport
3.06E-04 (11,0) GO:0015698,inorganic anion transport
1.35E-03 (9,0) GO:0015674,di-, tri-valent inorganic cation transport
2.82E-03 (8,0) GO:0006816,calcium ion transport
2.82E-03 (8,0) GO:0006817,phosphate transport
2.82E-03 (8,0) GO:0006887,exocytosis
3.11E-03 (17,4) GO:0007610,behavior
3.11E-03 (17,4) GO:0044255,cellular lipid metabolic process
3.17E-03 (15,3) GO:0030001,metal ion transport
4.68E-03 (10,1) GO:0006836,neurotransmitter transport
4.68E-03 (10,1) GO:0007268,synaptic transmission
4.68E-03 (10,1) GO:0008610,lipid biosynthetic process
5.49E-03 (12,2) GO:0007626,locomotory behavior
5.90E-03 (7,0) GO:0006631,fatty acid metabolic process
9.08E-03 (15,4) GO:0046903,secretion
9.82E-03 (13,3) GO:0019226,transmission of  nerve impulse
9.82E-03 (13,3) GO:0032940,secretion by cell
1.23E-02 (6,0) GO:0007601,visual perception
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Briefly, this involved scanning the 3’UTR with a 6 nucleotide window and counting each 
occurrence of the 4,096 possible hexamers. From there, frequencies of occurrence were 
compared between the least and most stable mRNAs (bottom 10th percentile and the 
most stable 90-100th percentile). P-values were calculated from these observed 
frequencies using Fisher’s exact test (Figure 12A). Significant hexamers were clustered 
by relatedness of sequence (Appendix 3). Sequence logos were generated (Figure 12B) 
for clustered hexamers using WebLOGO, as described previously (Hu et al., 2005). 
These logos are hereafter referred to as Destabilizing or Stabilizing Elements base on 
the transcripts there were identified from. 
Encouragingly, we found that the transcripts with the shortest half-lives (0-10th 
percentile or a half-life of less than 1.6 hours) contained a high frequency of AU and GU-
rich sequences within their 3’UTRs (Figure 12A and B). This was promising for several 
reasons. Firstly, AU-rich elements (AREs) were one of the first mRNA cis- elements to 
be discovered (Shaw and Kamen, 1986) and are often found within notoriously unstable 
cytokine mRNAs, among others (Emmons et al., 2008; Caput et al., 1986; Miller et al., 
2011). Identifying ARE-like sequences (Figure 12, Destabilizing Element (DE)1 and 2) 
via our hexamer analysis indicated the method was both specific and sensitive.  
Identifying GU-rich sequences (DE3-DE6) was even more encouraging. GREs, 
though more recently discovered than AREs, appear to have an analogous function as 
regulators of mRNA stability. In addition, GREs are bound by CUGBP1 (Paillard et al., 
1998; Vlasova et al., 2008; Goraczniak and Gunderson, 2008). Identification of GREs 
correlating significantly with mRNA instability in muscle cells potentially links muscle 




Figure 12.  
 Hexamer analysis of unstable and stable mRNAs reveals potential mRNA decay 
determinants in muscle cells. (A)The top 20 hexamers (ranked by P-value) enriched in the 
least and most stable mRNA 3’UTRs. (B) Sequence logos of significantly enriched cis-elements 
in the least stable transcripts (half life ranking in the bottom 10th percentile) and sequence 
elements associated with the most stable transcripts (top 10th percentile). (C) Standardized 





support for the idea that post-transcriptional control may be disrupted in DM1 and other 
neuromuscular diseases. 
In contrast to the short-lived mRNAs, the longest lived transcripts (90 -100th 
percentile, or a half life greater than 5.0 hours) harbored GA (Stabilizing Element (SE)1), 
CA (SE2 and 4), and CU (SE5 and 6) containing elements. These results were exciting 
as there was literary precedent for each element promoting stabilization of mRNAs. CA 
elements have been shown to bind the stability factor hnRNP L (Hui et al., 2003), CU 
repeat-containing mRNAs are stabilized by PCBP1/PCBP2 and the stability factor HuR 
(Kong et al., 2006; Wein et al., 2003), and GA-containing elements have been shown to 
stabilize the elastin mRNA (Hew et al., 2000). Overall, the hexamer approach was a 
specific and sensitive systematic approach to identify putative 3’UTR stability elements 
in muscle cells.  
Next we investigated whether the occurrence of putative stabilizing and 
destabilizing elements correlated with mRNA half-life (Figure 12C). The occurrences of 
all significant hexamers (Figure 12A and Appendix 3) were normalized for 3’UTR length 
and grouped based on what cis-element they mapped to in Figure 12B. The resulting 
normalized frequency of occurrence was plotted as a function of mRNA half-life. Half-
lives were grouped as indicated in Figure 12C. This analysis showed that Destabilizing 
elements are enriched in the 3’UTRs of the shortest lived mRNAs, and occur at a much 
decreased frequency in very stable mRNAs. Stabilizing elements show the opposite 
trend. Interestingly, the intermediated half-life mRNAs (1.6-5.0 hours) show some 
enrichment of both destabilizing and stabilizing elements, indicating that the elements 
may act combinatorially. This finding is supported by the observation that in some very 
unstable mRNAs, destabilizing elements are generally repeated multiple times. For 
98 
 
instance the TNF 3’UTR has a Class II ARE consisting of 4 overlapping repeats of 
AUUUA (Caput et al., 1986).  
The process of scanning for enriched hexamers was repeated in the 5’UTR and 
the coding-sequence. However, no significant enrichment was observed between the 
identified elements and their frequencies in other regions of the mRNAs. This 
observation strongly supports the accepted idea that elements which regulate transcript 
stability are most prevalent in the 3’UTR. 
 4.5 CUGBP1 knock-down impacts mRNA decay rates in muscle cells 
At the same time as we conducted the half-life analysis with the control 
myoblasts, we also performed a parallel analysis with CUGBP1 KD myoblasts. Our goal 
in doing this was to compare half-lives between the two cell lines to reveal novel mRNAs 
whose stability was regulated by CUGBP1. Identification of these targets would aid in 
understanding the CUGBP1-related pathology of DM1. A similar array-based approach 
revealed CUGBP1 may be important in modulating mRNA stability in stimulated immune 
cells (Vlasova et al., 2008).  
The CUGBP1 KD dataset was generated and analyzed in an identical fashion to 
the control myoblast dataset described previously. There were 14,619 transcripts 
present; half-lives were calculated for 14,505 mRNAs (good match to the exponential 
curve p< 0.05 for two out of the three replicates). Transcripts were omitted, where the 
range of the 95% confidence intervals was greater than twice the half-life (Criterion 3 
Figure 10B) leaving just 959 mRNAs half-lives. This was just 6.5% of the mRNAs 
present and far fewer than the 7,398 half-lives obtained for the control. Finally, only 924 
genes had reliable half-lives in both the control and CUGBP1 KD dataset. Reasons for 
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the increased variability in the CUGBP1 KD dataset are not clear, as the experiment was 
done in parallel with the control set. One possibility is that the knock-down cells were 
differentiating precociously leading to unwanted variations in gene expression between 
the replicates.  This idea is based on the fact that we later found dramatic differences in 
differentiation of the knock-down cells (see below).  
Differentially stabilized genes were identified by comparing the average 
calculated half-lives from the three CUGBP1 KD replicates to the average obtained from 
the three control cell replicates. Student’s T-test was used to calculate p-values within 
similar sets and significant differences in half-life were noted when the p-value was less 
than 0.05. In total, we identified 480 transcripts whose half-lives had increased 
significantly in the CUGBP1 KD cell line compared to the control (Appendix 4) These 
half-life increases ranged from 5.3-fold stabilized to 1.2-fold stabilized. Surprisingly, no 
mRNAs showed a significant decrease in half-life in the CUGBP1 KD cells. 
 From the analysis of our control data, we had identified a set of short lived 
transcripts bearing GREs. We hypothesized that these GREs could be functioning as 
CUGBP1 binding sites. As such, these GRE-containing transcripts were likely to be 
stabilized by CUGBP1 KD. To test this hypothesis and to validate the microarray data, 
stabilities of 13 transcripts were examined by qRT-PCR. In total, 9 out of 12 mRNAs 
stabilized in the CUGBP1 KD cells by microarray analysis were also stabilized by qRT-
PCR (Figure 13 and Appendix 5). Of the 9 stabilized genes, 5 of them (MyoD, Rnd3, 
Smad7, Ppp1r15b, and Id2) bear hexamer sequences that match to the GU-rich DEs 




Figure 13.  
 
CUGBP1 knock-down stabilizes a subset of mRNAs in muscle cells. Half-lives of indicated 
mRNAs were determined in LKO-1 and CUGBP1 KD cell lines by linear regression of qRT-PCR 
data from half-life experiments. Error bars represent the standard deviation. Myogenin was 
chosen as a negative control as it showed no change in stability by array, and here, by qRT-PCR.  
Decay curves for each mRNA can be found in Appendix 5. 
These results demonstrate that CUGBP1 impacts the decay of mRNA targets 
other than TNF in muscle. MYOD, ID2, RND3, and SMAD7 all are factors important for 
myogenesis (Fortier et al., 2008; Melnikova et al., 1999; Miyake et al., 2010; Rudnicki et 
al., 1993), and our results show that decay of the mRNAs encoding them is dependent 
on CUGBP1. We conclude that CUGBP1 has a significant role in regulating gene 
expression in muscle. However, since only five of the nine stabilized mRNAs we 
examined had GU-rich elements in their 3’UTRs, CUGBP1 KD may also have indirect 
effects on mRNA decay or be recruited to other sequence elements. 
4.6 Identification of direct mRNA targets of CUGBP1 in muscle cells 
In the preceding section, comparisons between half-life data sets from CUGBP1 
KD and control cells identified 480 transcripts stabilized in the CUGBP1 KD cells. The 





























indirect mRNA targets of CUGBP1. We therefore sought to identify direct mRNA targets 
of CUGBP1 in muscle cells.  To do this on a global scale we performed a well 
characterized RIP-Chip protocol (Tenenbaum et al., 2002).  
RNAs bound by CUGBP1 were immuno-purified from C2C12 cytoplasmic lysates 
using anti-CUGBP1 monoclonal antibody 3B1 (Santa Cruz Biotechnology). As a 
negative control an equal volume of non-specific mouse IgG antibody was used. Column 
resins were washed extensively in ice cold NT-2 buffer (Chapter 2) and RNAs were 
eluted by addition of Trizol. Following confirmation of specific and efficient pull-down (by 
western blot and qRT-PCR for Jun and myogenin mRNAs), total RNA was prepared 
from input, CUGBP1 bound, and control IgG bound samples. RNA (100ng each) from 
two independent experiments was used to generate probes for hybridization to 
microarrays (Affymetrix Gene 1.0 ST).  RNAs that were bound in the α-CUGBP1 
immunoprecipitate were compared to those in control mouse IgG immunoprecipitate. 
Transcripts were ranked by ratio of the α-CUGBP1 signal to control mouse IgG signal 
(Signal to Negative, Figure 14A).  The top 5% of these (881 transcripts see Appendix 6) 
were defined as being bound specifically by CUGBP1 (Figure 14B).  Several of these 








Figure 14.  
 
 
Identification of novel mRNA targets of CUGBP1 in muscle cells. (A) Experimental approach 
to identify direct mRNA targets of CUGBP1 from myoblast lysates. (B) Gene densities were 
plotted as a function of the mean ratio of the CUGBP1 immunoprecipitate signal to control IgG 
immunoprecipitate signal (Signal to Negative). 95th percentile is indicated by a dashed line, 
corresponding colored dots indicate where RT-PCR samples from D lie in the analysis.  (C) 
Western blot probed for CUGBP1 and GAPDH (loading control) indicates specificity and 
efficiency of protein pull-down. (D) Ethidium bromide stained 2% agarose gels of RT-PCR from 
CUGBP1 and control mouse IgG immunoprecipitation (remaining panels). Colored boxes 




4.7 CUGBP1 binds GU-rich element containing and unstable mRNAs in muscle 
cells 
We used a hexamer analysis similar to that described above to identify enriched 
sequences in the CUGBP1 associated transcripts. The 3’UTRs of the transcripts 
associated with CUGBP1 (upper 95th percentile of the Signal to Negative ratio) were 
scanned using a 6-base window. The number of occurrences of each hexamer was 
counted. Fisher’s exact test was used to identify hexamers significantly enriched in the 
“bound” set as compared to the unbound set of transcripts. This approach identified 
enriched hexamers which are generally U-rich within the CUGBP1 associated 3’UTRs 
(Figure 15A). The top 50 significant hexamers were clustered and the highest ranking 
group (by mean of p-values) was used to generate a sequence logo using WebLOGO 
(Figure 15B and Appendix 7). The hexamers and the sequence logo shown in Figure 
15B very closely match with  CUGBP1 binding sites identified in other cell types 
(Marquis et al., 2006; Rattenbacher et al., 2010; Vlasova et al., 2008). We hypothesized 
that a significant fraction of the 480 transcripts stabilized in the CUGBP1 KD half-life 
arrays were stabilized due to loss of CUGBP1 binding. Shared transcripts between the 
significantly stabilized group from the CUGBP1 KD dataset, and the top 5% of the signal 
to negative ratio of the CUGBP1 RIP-Chip dataset were identified. In total 88 transcripts 
were common between the two groups (Appendix 8). Hexamer analysis, clustering, and 
a sequence logo were generated from this set of transcripts as well (Appendix 9). The 
resulting sequence logo (Figure 15C) is nearly identical to those generated from the 
CUGBP1 IP dataset. We conclude that this represents the canonical CUGBP1 binding 
site in muscle. The 88 transcripts common between datasets are mRNAs that are both 
bound by CUGBP1 and regulated at the level of mRNA stability. These are likely only a 
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subset of the CUGBP1 targets given the small size of the CUGBP1 KD half-life dataset, 
but nevertheless are highly likely to be regulated by CUGBP1 in muscle cells. 
Figure 15.  
 
CUGBP1 binds GU-rich element containing mRNAs, correlating with rapid decay in muscle 
cells. (A) Top 20 hexamer sequences (ranked by p-value) enriched in the 3’UTR of genes found 
in 95th percentile and higher (bound) from the CUGBP1 RIP-Chip (signal-to-negative ratio). 
Matching sequence element from Figure 12, is given. (B) Corresponding sequence logo 
generated from the most-significant group of RIP-Chip hexamers after clustering. (C) Sequence 
logo from the hexamer analysis of the 88 immunoprecipitated and stabilized transcripts.  (D) Heat 
map comparing the half-life data from control myoblasts (y-axis) to the CUGBP1 RIP-Chip data 
(x-axis) where enrichment is shown in red and depletion in blue. 
CUGBP1 has been reported by us (Moraes et al., 2006; Zhang et al., 2008) and 
others (Paillard et al., 1998; Rattenbacher et al., 2010; Vlasova et al., 2008) to 
destabilize the mRNAs it binds. To address whether this is a general phenomenon in 
muscle cells, we compared our global half-life data from the control myoblasts to our 
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RIP-Chip data of “bound” mRNAs (Figure 15C). The half-life and RIP-Chip datasets 
were each divided at every 5th percentile, based on rank. Half-lives were assigned to the 
y-axis and Signal to negatives from the RIP-Chip were assigned to the x-axis. Each box 
of the resulting 20x20 matrix was assigned a color (red for enrichment, blue for 
depletion) based on the observed number of genes which fell in that box, versus number 
expected if the partitioning were random (Figure 15D). This reveals that short-lived 
transcripts in muscle (low on the y-axis) tend to be bound by CUGBP1 (far right on the x-
axis). The opposite is also true; long-lived transcripts (high on y-axis) are less likely to be 
bound by CUGBP1 (far left on x-axis). Overall, this shows that CUGBP1 binding 
correlates with instability in muscle cells. 
4.8 CUGBP1 and HuR bind common mRNA targets in muscle cells 
With a set of CUGBP1 target transcripts in hand we had achieved one of our 
primary goals. Upon examining the hexamers and sequence logos over-represented in 
CUGBP1 bound mRNAs, we noticed that they closely resembled those recognized by 
the stabilizing factor HuR (Dormoy-Raclet et al., 2007; Mukherjee et al., 2009; Ray et al., 
2009; Vlasova et al., 2008). To test whether the two proteins might bind common mRNA 
targets, a recently published HuR RIP-Chip dataset from human T-lymphocytes 
(Mukherjee et al., 2009) was compared to our list of  CUGBP1-bound mRNAs using 
Ingenuity Pathway Analysis (Figure 16A). Of our 881 identified targets, 640 could easily 
be compared to the HuR dataset as they had common gene identifiers in humans. 
Comparison of the 640 CUGBP1 targets with the 731 HuR targets revealed that 23% of 
mRNAs bound by CUGBP1 in C2C12 cells were bound by HuR in lymphocytes 
(Mukherjee et al., 2009). This result was perhaps not surprising, given the related nature 
of the sequences the two proteins recognize.  
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Figure 16.  
 
CUGBP1 and HuR bind common RNA targets. (A) Venn diagram showing the overlap of 
mRNAs bound by both CUGBP1 and HuR as determined by RIP-Chip experiments (Lee et al., 
2010; Mukherjee et al., 2009). (B) Sequence of the first 336nt of the p21 3’UTR, GU-rich 
sequences in green, and AU-rich sequences in red. (C) UV-crosslinking of radiolabeled p21 
3’UTR with recombinant HuR alone and with CUGBP1 protein. (D) Western blot of CUGBP1 
immunoprecipitates probed for CUGBP1 and HuR (top panels), and ethidium bromide stained 
formaldehyde agarose gel of RNA isolated from immunoprecipitated reaction supernatants 
(bottom panel). 
To follow up on this in silico result we utilized an in vitro approach to examine 
binding of HuR and CUGBP1 to one putative shared substrate mRNA –p21/Cdkn1a. 
Similar experiments were used to characterize the interactions of HuR and CUGBP2 
with the Cox2 ARE (Sureban et al., 2007). p21 is an important factor in muscle whose 
expression peaks early in the differentiation process and promotes cell cycle withdrawal 
(Parker et al., 1995). Moreover, the first 336nt of the p21 3’UTR harbors extensive AU 
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and GU-rich elements (Figure 16B). Radiolabeled p21 3’UTR RNA was incubated with 
200nM GST-CUGBP1 and increasing amounts of 6XHis-HuR, heparin was added, and 
stable complexes were cross-linked with 254nm light. This mixture was RNase treated 
and resolved by 10% SDS-PAGE. Both HuR and CUGBP1 could be cross-linked to the 
RNA efficiently (Figure 16C). However based on the loss of CUGBP1 cross-linking as 
the concentration of HuR is increased, the two proteins appear to compete for RNA-
binding in vitro (Figure 16B lanes 3 and 4).  This is consistent with these two factors 
sharing a binding site(s) within the p21 3’UTR. These results indicate that CUGBP1 may 
also compete with HuR for mRNA substrates during differentiation much like AUF1 does 
to regulate muscle differentiation (Lal et al., 2004). 
We next examined whether HuR and CUGBP1 also share substrate mRNAs in 
myoblasts. C2C12 lysates were immunoprecipitated with anti-CUGBP1 antibodies, and 
the immunoprecipitates were probed for CUGBP1 and HuR by western blotting (Figure 
16D). HuR was clearly detected in the CUGBP1 immunoprecipitates, but RNase 
treatment of the lysates prior to immunoprecipitation disrupted the interaction. The 
effectiveness of RNase treatment was confirmed by visualization of rRNA (lower panel 
Figure 16D). Therefore, although HuR and CUGBP1 probably do not interact directly, 
they are able to bind the same RNA simultaneously. 
4.9 CUGBP1 binds transcripts encoding factors involved in cell cycle and mRNA 
metabolism  
Given the target overlap between CUGBP1 and HuR (Figure 16), the well-
documented role for HuR in muscle differentiation (Figueroa et al., 2003; Lal et al., 
2004), and the involvement of CUGBP1 in muscle diseases, we speculated that 
CUGBP1 function was also critical in muscle specific processes. As with the global half-
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life experiments, GO analysis of the RIP-Chip dataset yielded insights into CUGBP1 
regulated processes. GO terms enriched in CUGBP1-associated transcripts were 
compiled. At first glance, the enriched GO terms that were most interesting were cell 
cycle and RNA processing (Table 4.2). 
Table 4.2  
 
CUGBP1 binds mRNAs encoding factors involved in the cell cycle and mRNA metabolism. 
Top 20 GO terms associated with CUGBP1 bound mRNAs (by P-value ranking). 
As the terms used in the NCBI GO database are vague and somewhat arbitrary, 
they were manually broken down into more descriptive terms (Table 4.3). For example, 
“RNA processing” from Table 4.2 was sub-divided into RNA Binding, RNA Splicing, and 
RNA Decay. The CUGBP1-bound transcripts that fell into these categories are listed. 
This table (Table 4.3) reveals that CUGBP1 binds to transcripts involved in muscle 
homeostasis, which is of great interest considering its role in DM1. Additionally, many of 
the RNAs bound by CUGBP1 encode other RNA-binding proteins. This cross-regulation 
amongst RNA-binding proteins has been documented previously and is likely a common 
P-value GO ID, GO Term
5.60E-15 GO:0007049, cell cycle
5.07E-13 GO:0046907, intracellular transport
6.51E-13 GO:0008104, protein localization
1.11E-12 GO:0051641, cellular localization
7.98E-11 GO:0048522, positive regulation of cellular process
1.01E-10 GO:0048523, negative regulation of cellular process
1.46E-10 GO:0050793, regulation of developmental process
1.02E-09 GO:0006996, organelle organization
3.66E-09 GO:0009887, organ morphogenesis
7.94E-09 GO:0007242, intracellular signaling cascade
1.72E-08 GO:0006915, apoptosis
1.05E-07 GO:0000278, mitotic cell cycle
1.31E-07 GO:0009790, embryonic development
2.20E-07 GO:0006396, RNA processing
2.22E-07 GO:0016192, vesicle-mediated transport
4.20E-07 GO:0040007, growth
6.54E-07 GO:0065008, regulation of biological quality
1.64E-06 GO:0008283, cell proliferation
3.66E-06 GO:0000087, M phase of mitotic cell cycle
1.73E-05 GO:0000279, M phase
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occurrence (Pullmann, Jr. et al., 2007). As we were interested in muscle differentiation 




CUGBP1 binds mRNAs encoding factors involved in mRNA metabolism, differentiation, 
and protein secretion. GO terms of interest from the standpoint of post-transcriptional control 
and muscle homeostasis found to be enriched in mRNAs that interact with CUGBP1 by RIP-Chip.  
 
One of the novel CUGBP1 regulated processes identified by this GO analysis is 


































and non-coding RNAs are also apparently regulated by CUGBP1. It will be interesting to 
learn how CUGBP1 is involved in all of these processes. 
4.10 CUGBP1 is required for muscle differentiation 
 A primary goal at the start of this project was to further characterize mRNA decay 
in muscle and determine the involvement of CUGBP1. The RIP-Chip experiment 
identified many CUGBP1-bound mRNAs encoding factors important for muscle 
differentiation (Table 4.3). We therefore sought to address the impact of CUGBP1 on 
myoblast differentiation. The process of muscle differentiation can be observed quite 
simply in C2C12 cultures by growing to near confluence and switching to a low-serum 
media (2% horse serum) triggering spontaneous differentiation to myotubes (Andres and 
Walsh, 1996). 
 Control and CUGBP1 KD myoblast cell pools were generated by lentiviral 
transduction and puromycin selection with empty vector and CUGBP1 targeting vector 
(see Materials and Methods 2.11). Knock-down was as effective as in the clonal cell line 
established previously (data not shown). Cells were induced to differentiate, and 
samples collected daily throughout the differentiation process. Immunofluorescence 
against the differentiation marker myosin heavy chain (MHC shown in green in Figure 
17A) was used to track differentiation (Andres and Walsh, 1996). Differentiation was 
quantified by calculating a fusion index. This involved counting MHC positive nuclei and 
dividing by total nuclei per field of view. As seen in Figure 17B, the CUGBP1 KD 
myoblasts showed MHC positive nuclei earlier, indicating that they initiated 
differentiation more rapidly (Days 1 and 2). Additionally, they displayed a disorganized 
differentiation phenotype. Instead of forming long thin myotubes with aligned nuclei (as 





CUGBP1 plays a role in muscle differentiation. (A) Immunofluorescence microscopy of day 5 
myotubes from control and CUGBP1 KD cell pools (nuclei were stained with DAPI and are 
colored blue, MHC was detected with monoclonal antibody MF20, and Cy-2 goat anti-mouse 
conjugated secondary antibody (colored green). (B) Fusion index in control and CUGBP1 KD 
cells (average of 3 independent experiments where error bars represent the standard error). (C) 
Average number of nuclei per MHC positive myotube compared between day 5 CUGBP1 KD and 
control cells (average of 3 random fields of view from 3 independent experiments, where error 
bars represent the standard error from the mean). 
organized syncytia or myosacs (Figure 17A). This is clearly quantified in Figure 17C, 




nuclei per myotube in the CUGBP1 KD compared to empty vector controls. As this 
phenotype occasionally arises spontaneously these results were confirmed by repeating 
these differentiation experiments in a different clonal cell line that utilized the same 1739 
shRNA, and in an alternatively transduced pool of cells made using the #1320 shRNA 
that targets a different region of the CUGBP1 mRNA (Appendix 10). Both of these cell 
lines gave a similar phenotype. 
There are many possible explanations for the myosac phenotype which likely 
reflects cytoskeletal disorganization. One CUGBP1 target mRNA Rnd3 (RhoE) encodes 
a small GTPase required for differentiation (Fortier et al., 2008). RhoE regulates RhoA 
which is responsible for organization of actin filaments during differentiation of C2C12 
myoblasts (Castellani et al., 2006). Thus one could imagine that aberrant expression of 
RhoE in CUGBP1 KD cells might lead to defects in the cytoskeleton.  In addition, TPA 
treatment of C2C12 cells, which we have shown induces CUGBP1 phosphorylation, also 
induces myosac formation (Mermelstein et al., 1996).  Finally, disruption of microtubules 
with nocodazole results in formation of myosacs, thus it may be relevant that CUGBP1 is 
associated with several tubulin mRNAs (Table 4.3). 
4.11 CUGBP1 plays an important role in muscle differentiation  
As the previous experiment indicated, the CUGBP1 KD cells appeared to be 
initiating differentiation more rapidly than the control myoblasts (see Figure 17B days 1 
and 2). To address this possibility differentiation was monitored by western blot to 
examine expression of myogenin, a marker of muscle differentiation. Whole cell lysates 
were collected from control and CUGBP1 KD myoblasts and probed for the 
differentiation markers MHC and myogenin. In good agreement with our microscopy 
data we observed that CUGBP1 KD cells expressed MHC at an earlier time during 
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differentiation (Figure 18). In addition, the transcription factor myogenin was also 
expressed at an earlier time. This result is significant, because expression of myogenin 
signals the end of myoblast proliferation (Katagiri et al., 1997). Premature expression of 
myogenic factors like myogenin results in depletion of progenitor cells necessary for 
maintenance of muscle in adult tissue, as well as muscle hypotrophy (Schuster-Gossler 
et al., 2007). 
Figure 18.  
 
CUGBP1 levels are important for appropriate expression of differentiation factors. 
(A)Western blot of whole cell lysates collected from myoblasts induced to differentiate in low-
serum media for the indicated number of days (number above lane). Samples were probed for 
the presence of the differentiation markers MHC and myogenin, as well as a GAPDH as loading 
control. (B) 35µg of whole cell lysate was resolved on 10%SDS-PAGE, blotted and probed for 
MHC and CUGBP1 during differentiation (day indicated at top of lane), GAPDH is a loading 
control. 
 
The relationship between onset of differentiation, and absence of CUGBP1 led 
us to wonder how CUGBP1 expression changed during the process of normal myoblast 
differentiation. To address this question, western blots of whole cell lysates from normal 
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myoblasts induced to differentiate were probed for CUGBP1 levels (Figure 18B). These 
showed that CUGBP1 protein levels decrease as the cells are differentiating, similar to a 
finding in a report published during the course of this study (Bland et al., 2010). qRT-
PCR analysis of CUGBP1 mRNA indicated that levels dropped ~80% between 
proliferating and 6-day differentiated cultures (J. Allredge personal communication). A 
previous report indicated that murine CUGBP1 is down-regulated by the miRNAs 
miR23a and miR23b in developing cardiac tissue (Kalsotra et al., 2008). This data 
provides a strong correlation between reduction in CUGBP1 protein levels, and 
increased expression of the differentiation markers MHC and myogenin. 
4.12 CUGBP1 is phosphorylated upon myotube formation 
 Finally, as the phosphorylation status of CUGBP1 is modulated upon expression 
of CUG repeat RNA or PKC activation (Figure 7) and in DM1 patients (Kuyumcu-
Martinez et al., 2007) we wondered if this were the case in differentiating muscle. To 
address this possibility C2C12 myoblast cultures were again induce to differentiate. Cells 
were collected and lysates prepared for isoelectric focusing, and 2nd dimension PAGE. 
Samples were blotted and probed for CUGBP1 and GAPDH as a loading control. 
Interestingly, CUGBP1 exhibits a shift in isoelectric point (pI) in the 5 day differentiated 
myotubes (Figure 19A lower panel). This phosphorylated species was not present in the 
proliferating cultures. GAPDH was multiply phosphorylated as was also shown in 
another study (Choudhary et al., 2000). To confirm that what we observed was indeed a 
phospho-state of CUGBP1, these same extracts were treated with phosphatase (CIP) 






Figure 19.  
 
CUGBP1 is phosphorylated in myotubes. (A) Western blot for CUGBP1 and GAPDH loading 
control from 2D-PAGE on whole cell lysates of proliferating myoblast cultures (top) and 5 day 
differentiated myotube cultures (bottom). (B) Western blot for CUGBP1 and GAPDH of 2D-PAGE 
on whole cell lysates from differentiated myotube cultures mock treated (top) or calf intestinal 
phosphatase treated (bottom).  
 
  
In addition, samples isolated at different times during differentiation were also 
subject to 2D-PAGE, revealing that the phosphorylated species appeared as myotubes 
formed (data not shown). These results indicate that phosphorylation of CUGBP1 occurs 
during the process of muscle differentiation. Interestingly, the relative amounts of 
phosphorylation observed here (Figure 19) and in response to TPA treatment or CUG 
repeat RNA expression seem to be rather distinct. During differentiation, only a small 
fraction of CUGBP1 is phosphorylated, whereas the other conditions appear to elicit 
phosphorylation of a much larger proportion of the protein. These results indicate that 
phosphorylation of CUGBP1 in DM1 is likely distinct from CUGBP1 phosphorylation 
during myotube formation. This is perhaps expected as DM1 conditions result in PKC 
activation and CUGBP1 phosphorylation (Kuyumcu-Martinez et al., 2007) while 
differentiation involves different kinase pathways from PKC (Akt/PI3, p38 MAPK, and 
Erk6; Lechner et al., 1996; Li et al., 2000; Xu and Wu, 2000) 
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 To summarize, a great deal has been learned about mRNA decay and CUGBP1. 
In these studies we have identified important elements for decay, and what RNA 
sequences CUGBP1 recognizes. Targets for CUGBP1 regulation have been identified in 
muscle, and CUGBP1 differentiation defects have been observed. Finally, we have 
documented the expression characteristics of CUGBP1 in normal myoblasts induced to 
differentiate. These studies will serve as a solid foundation for future endeavors looking 









Chapter 5: Global analysis reveals mRNA substrates for decay 
by PARN in myoblasts 
There is strong evidence that PARN is critical for survival in plants (Reverdatto et 
al., 2004), for oocyte maturation in Xenopus, (Kim and Richter, 2006) and in the 
response to DNA damage in mammalian cells (Cevher et al., 2010). Nevertheless, very 
few specific targets of this, or any other deadenylase have been identified. We 
hypothesized that PARN is recruited to a specific subset of mRNAs by RNA-binding 
proteins such as CUGBP1 (Moraes et al., 2006) and KSRP (Gherzi et al., 2004). A 
global approach to identify mRNAs that are dependent on PARN for their catabolism 
was undertaken. We chose to use C2C12 cells in order to allow comparison with the 
control and CUGBP1 KD datasets described in the previous sections. 
5.1 PARN knock-down disrupts decay rates for a subset of mRNAs in C2C12 cells 
 
Given that PARN had been implicated in the regulation of mRNA decay both on 
its own (Reverdatto et al., 2004) and in conjunction with CUGBP1 (Moraes et al., 2006), 
we carried out global half-life array experiments with our PARN KD cell line (Figure 6). 
These experiments were carried out in an identical manner to those described previously 
for the control and CUGBP1 KD cells. Briefly, transcription was inhibited by actinomycin-
D treatment and total RNA was collected at 0,10,40,100, and 230 minutes after 
transcriptional arrest. Lastly probes for array hybridization were generated from 300ng of 
total RNA. The results were analyzed by Drs. Bin Tian and Ju Youn Lee at UMDNJ-New 
Jersey Medical School. There were 19,385 transcripts detected in the PARN KD cells, 
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which is slightly more than the control (17,080) and CUGBP1 KD (14,619) datasets 
(13% and 32% more respectively). Half-lives were calculated for the 19,385 transcripts, 
those with a p-value greater than 0.05 were omitted, leaving 19,162 mRNAs. Ninety-five 
percent confidence intervals were calculated for these 19,162 half lives. Transcripts 
where the range of the confidence intervals was over 2 times the calculated half-life for 
two of the three replicates were omitted. This left 1,581 mRNAs with a “reliable” half-life. 
These transcripts were compared to the control dataset, leaving 1,389 genes with 
“reliable” half lives in both sets.  
Next we sought to identify mRNAs whose stability had changed significantly in 
the PARN KD cells. Half-lives were compared between the control and PARN KD 
myoblasts. As with the previous datasets, Student’s t-test was used to determine 
significant differences in decay rates between the control and PARN KD cells. 
Surprisingly, this yielded a mere 64 mRNAs whose half-lives had changed significantly 
(Table 5.1).  Forty of these mRNAs showed an increase in stability ranging from 2.4-fold 
to 1.2-fold stabilized. Many of the stabilized transcripts encode RNA-binding proteins 
(LIN37, ZFP36L2 (BRF2), TOE1 (CAF1Z) and EDC3) and transcription factors (GATA4, 
ZFP219, KLF14, and NUFIP1).This relatively small number of stabilized mRNAs is 
perhaps unsurprising when the number of cellular deadenylases is kept in mind (10 are 
predicted for humans). In the absence of PARN it is likely that other deadenylases 
substitute for its function to some degree, or that more transcripts undergo 
deadenylation-independent decay. This idea is supported by the fact that the greatest 



























Transcripts exhibiting altered decay rates in PARN knock-down myoblasts. Global half-life 
approach reveals 64 mRNAs exhibiting altered stability upon PARN KD. Impacted transcripts are 
listed with their corresponding half-lives. Transcripts shown in red were stabilized in the CUGBP1 









Adora2b 80 189 2.4 2.70E‐02
Lin37 107 240 2.2 4.32E‐02
Mrgprf 125 279 2.2 4.21E‐02
Mat2a 52 111 2.1 3.73E‐03
Gnb1l 73 145 2.0 1.94E‐02
Ptpn3 145 262 1.8 2.07E‐02
Ankrd54 112 201 1.8 7.00E‐03
Gpsm1 149 265 1.8 3.87E‐03
Klf16 102 176 1.7 3.24E‐02
1300010M03Rik 88 151 1.7 2.66E‐02
Caly 246 421 1.7 4.11E‐02
Nsun5 160 270 1.7 4.41E‐02
Zfp36l2 58 97 1.7 2.75E‐02
Xkr8 117 194 1.7 1.92E‐02
Kcnk5 89 146 1.6 3.88E‐02
Anapc7 129 208 1.6 1.84E‐02
Polm 220 340 1.5 4.56E‐02
Kcnn4 103 158 1.5 2.19E‐02
Rnf122 96 144 1.5 1.98E‐02
Jtv1 156 233 1.5 4.29E‐02
Tacc2 109 159 1.5 4.62E‐02
Rfxap 109 159 1.5 4.91E‐02
Toe1 71 102 1.4 6.02E‐03
Trip10 110 159 1.4 3.12E‐02
Nufip1 68 99 1.4 3.25E‐02
Sipa1l2 134 193 1.4 4.82E‐02
Zfp219 134 193 1.4 1.37E‐02
Cdk5r1 88 125 1.4 4.24E‐02
Itpripl1 179 251 1.4 4.57E‐02
Akirin2 75 106 1.4 2.05E‐02
Gata2 114 159 1.4 4.63E‐02
Traf2 71 98 1.4 3.60E‐02
Tbc1d10a 134 184 1.4 3.34E‐02
Dgcr14 97 133 1.4 2.88E‐02
Psrc1 115 158 1.4 3.50E‐02
Zbtb45 96 129 1.3 1.41E‐02
Edc3 76 100 1.3 9.91E‐03
Gfer 119 151 1.3 4.30E‐02
Fadd 128 153 1.2 9.53E‐03









Sema4f 410 153 ‐2.7 4.72E‐02
Tnfaip3 73 32 ‐2.3 2.04E‐02
Rnf144b 285 127 ‐2.3 1.94E‐02
Clk1 49 22 ‐2.2 2.83E‐02
Psg29 536 263 ‐2.0 1.52E‐02
Ccdc99 136 83 ‐1.6 2.20E‐02
Phlda1 52 32 ‐1.6 1.84E‐03
Ngf 83 52 ‐1.6 3.58E‐02
3010003L21Rik 214 138 ‐1.6 2.02E‐03
Gdf15 163 107 ‐1.5 3.95E‐03
Snapc1 150 101 ‐1.5 7.73E‐03
Foxc2 50 35 ‐1.4 1.22E‐03
Zcchc7 110 77 ‐1.4 2.75E‐02
Dusp16 92 66 ‐1.4 4.97E‐02
Chchd4 97 70 ‐1.4 6.61E‐03
Nanp 91 66 ‐1.4 1.22E‐02
Hist3h2a 55 40 ‐1.4 3.42E‐02
4732471D19Rik 80 60 ‐1.3 4.49E‐02
Eif1b 134 101 ‐1.3 1.41E‐02
2310057M21Rik 87 66 ‐1.3 3.94E‐02
Prmt6 125 98 ‐1.3 4.02E‐02
Thra 63 52 ‐1.2 3.94E‐02
Tmem171 132 115 ‐1.2 2.42E‐02




Unexpectedly, 24 mRNAs showed a significant decrease in stability ranging from 
1.1-fold to 2.5-fold destabilized in the PARN KD dataset. We speculate that this is due to 
indirect effects of PARN KD. For example PARN KD could result in stabilization of an 
mRNA encoding a destabilizing factor. In fact, this is observed for the Edc3 mRNA, 
which is stabilized 1.3-fold, and encodes a factor which recruits the decapping enzyme 
DCP1/2 to mRNA stubstrates (Badis et al., 2004; Fenger-Gron et al., 2005). Zfp36l2 
(Brf2) mRNA, is also stabilized (1.7-fold) in PARN KD cells (Table 5.1). Closely related 
homologues of BRF2 (TTP and BRF1) have been shown to mediate decay of ARE-
containing transcripts by recruiting CNOT6 and DCP2 (Lykke-Andersen and Wagner, 
2005). If this factor is limiting in normal myoblasts, but is increased in PARN KD cells, it 
might acquire additional targets, or act more effectively on its normal targets. In support 
of this idea, 11/24 destabilized transcripts harbor an ARE (Table 5.1  bold and 
underlined; Bakheet et al., 2006). 
Comparisons between the 40 genes exhibiting increased stability in the PARN 
KD and the 480 stabilized transcripts in the CUGBP1 KD cell line, showed little overlap 
(10 transcripts in total shown in red Table 5.1). This indicates that CUGBP1 and PARN 
are not exclusive partners in triggering deadenylation of CUGBP1-substrate RNAs in 
muscle. However, given the relatively small datasets for the two factors, the possibility of 
them co-regulating decay of a significant number of substrates has certainly not been 
ruled out. 
As before, we validated the findings from the microarrays. Transcription was shut 
off by actinomycin-D treatment and qRT-PCR was performed to monitor mRNA decay 
rates in control and PARN KD cells (Figure 20). Encouragingly, all four of the mRNAs 
tested upheld the trend predicted by the microarray results, and were stabilized in the 
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PCR-based assay. These stabilized mRNAs therefore represent the first reported 
endogenous targets for regulation by PARN in mammalian cells. 
 
Figure 20.  
 
 
Validation of mRNAs exhibiting PARN-dependent mRNA decay rates.  Decay rates in control 
and PARN KD myoblasts of mRNAs identified by global half-life approach measured by qRT-
PCR. Representative experiments are shown. Half-lives (T1/2) are reported with corresponding 
standard deviations. 
 
5.2 PARN knock-down alters poly(A) status  of Brf2 mRNA 
As demonstrated by the microarray experiments, and in Figure 20, PARN is 
necessary for normal decay rates of a subset of mRNAs. We next sought to address the 
mechanism for this regulation. As PARN has deadenylase activity, we chose to start with 
the simplest hypothesis: that PARN levels impact the poly(A) status of the Brf2 mRNA. 
Brf2 mRNA was chosen as it was over three-fold stabilized by qRT-PCR. In addition, as 




































































































members, BRF1 and BRF2 share homology at their N-termini, where the interactions 
with decay machinery (DCP1, DCP2, CNOT6)  likely occur (Lykke-Andersen and 
Wagner, 2005). BRF2 knockout mice die within two weeks of birth due to failed 
haematopoiesis (Stumpo et al., 2009) and cells lacking both BRF1 and BRF2 resemble 
T-lymphoblast leukemic cells  (Hodson et al., 2010). For these reasons we concluded 
that BRF2 is an important mediator of mRNA decay, and that disruption of PARN 
function may impact the expression of BRF2 and thereby affect expression of other 
genes. 
To test the poly(A) tail length of Brf2 mRNAs, an RNase H/northern blot was 
employed. Briefly, 10µg of total cellular RNA was annealed with a DNA oligonucleotide 
complementary to the 3’UTR of Brf2 and treated with RNaseH. Brf2 mRNA was detected 
by northern blotting using a probe specific for the 3’ UTR. As shown in Figure 21A, 
treatment with the Brf2-specific DNA oligo and oligo-dT18 generates a poly(A) minus 
band (A0) at ~170nt (see arrow). The expected length from the RefSeq database is 
168nt. The control lane (treated only with Brf2 specific oligo) shows a higher molecular 
weight smear corresponding to the last 168nt of the Brf2 message plus the poly(A) tail. 
When control and PARN KD samples are compared there is a greater proportion of 
poly(A)+ species with a long poly(A) tail in the PARN KD (see brackets in Figure 21A). 
This observation is further supported by profiles of the pixel density in each lane (Figure 
21B) and by quantitation of the proportion of poly(A)+ RNA to deadenylated RNA (Figure 
21C). Thus we conclude that the Brf2 poly(A)-status is dependent on levels of PARN.  
To confirm that the altered poly(A) status of the Brf2 mRNA observed in PARN 
knock-down myoblasts was specific to the Brf2 transcript, RNaseH/northern blots were 
repeated for the β-actin mRNA. As before, 10µg of total cellular RNA was annealed with 
a DNA oligonucleotide complementary to the 3’UTR of actin and treated with RNaseH. 
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The actin mRNA was detected by northern blotting using a probe specific for the 3’ UTR. 
The expected size for the A0 species was 232nt, which is consistent with what is shown 
in Figure 22A. The results from Figure 22A indicate that PARN KD has no effect on the 
overall poly(A) status of the actin mRNA, comparing the control and PARN KD lanes. 
This finding is confirmed by the lane profile counts in panel B, which also show no 
difference between control and PARN KD samples. The difference observed for the Brf2 
mRNA poly(A) status is likely specific to that mRNA, and not the result of a general 
disruption of poly(A) states in the PARN KD cells.   
Figure 21.  
 
 
PARN knock-down results in altered poly(A) status of the Brf2 mRNA. (A) Oligo 
annealing/RNaseH treatment followed by northern blot of the Brf2 mRNA in control and PARN KD 
myoblasts. Position of arrow indicates the A0 species, blue lines correspond with migration of 
molecular weight markers. (B) Profile of pixel density in control (red) and PARN KD (green) lanes 
indicate an increase proportion of poly(A)+ mRNA in PARN KD samples. (C) Quantitation of the 






PARN knock-down does not alter the poly(A) status of the actin mRNA. (A) Oligo 
annealing/RNaseH treatment followed by northern blot of the β-actin mRNA in control and PARN 
KD myoblasts. Position of black arrow indicates the A0 species, blue arrows and numbers 
correspond to the profile counts shown in B. (B) Profile of pixel density in control (green) and 
PARN KD (red) lanes indicate no change in the proportion of poly(A)+ mRNA in PARN KD 
samples compared with control samples.  
 
 
5.3 PARN knock-down disrupts deadenylation of Brf2 mRNA  
Encouraged by the finding that PARN levels impacted the poly(A) status of the 
Brf2 mRNA, we next investigated the impact on deadenylation rates. Rates of 
deadenylation for the Brf2 mRNA were examined by transcriptional arrest using 
actinomycin-D in control and PARN KD myoblasts. Total RNA samples were collected 
from the actinomycin-D treated time course. 10µg of total RNA from each sample was 
again treated with RNase H and the Brf2-specific oligo. As before there is a striking 
difference in poly(A) status of the mRNA between the control and PARN KD samples at 
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the 0 time point (Figure 23A and B). In the control, a large reduction in the levels of 
poly(A)+ Brf2 mRNA was evident by 40 minutes, with nearly all of the Brf2 mRNA 
migrating at a molecular weight consistent with a very short poly(A) tail species at that 
time (Figure 23A). This is in contrast to the PARN KD cells where the poly(A) tail is not 
completely shortened until the 80 minute time point (Figure 23A and B). Taken together 
these results support and extend those shown in Figure 21. We conclude that PARN 
impacts Brf2 mRNA decay by mediating poly(A) shortening. Interestingly, as the Brf2 
message is still deadenylated in the PARN KD cells there may be sufficient PARN 
remaining in this cell line to carry out some decay. Alternatively, a different deadenylase 
may be acting in its place (CCR4/NOT, or PARN-L). The fact that deadenylase enzymes 
may substitute for one another to some degree is indicative of the importance of mRNA 
decay. Post-transcriptional control of mRNA levels must be efficient for survival. (Stumpo 
et al., 2009; Williams et al., 2009).  
 This is the first time PARN has been show to impact the poly(A) status of an 
endogenous transcript in muscle cells and establishes PARN as significant initiator of 
mRNA decay in mammalian cells. Furthermore, as Brf2 is an ARE-binding protein that 
confers instability to bound transcripts, aberrant expression of Brf2 may in part explain 
why we had a subset of mRNAs that were destabilized in the PARN KD dataset. 
Therefore PARN deadenylase needs to be considered as an active contributor to 








Figure 23.  
 
 
PARN knock-down inhibits poly(A) tail removal of the Brf2 mRNA. (A) Oligo/RNaseH 
treatment of RNA isolated from control and PARN KD cells following actinomycin D addition was 
followed by northern blot for the Brf2 mRNA. Migration of A0 is marked with an arrowhead. 
Samples labeled 0 were not exposed to actinomycin-D. (B) Quantitation of poly(A)+ Brf2 mRNA 







Chapter 6: Discussion 
 
6.1 Regulation of TNF mRNA stability by CUGBP1 
Prior to this study, CUGBP1 and PARN had been demonstrated to be necessary 
for rapid deadenylation of TNF reporter RNA in vitro (Moraes et al., 2006). We 
hypothesized that this regulation might have biological impact in myoblasts, given the 
muscle-specific effects of CUGBP1 over-expression (Timchenko et al., 2004). Our 
experiments showed that CUGBP1 indeed regulates TNF mRNA decay in muscle cells 
(Figure 5; Zhang et al., 2008). However, PARN knock-down did not alter TNF mRNA 
stability (Figure 6). Interestingly, CUGBP1-mediated instability of TNF mRNA was 
disrupted by PKC activation (Figures 7 and 8). Lastly, interactions between CUGBP1and 
the Jun and Myogenin mRNAs were reduced by TPA treatment (Figure 9).  
 6.1.1 CUGBP1 targets the TNF mRNA for fast decay in muscle cells 
TNF mRNA exhibits rapid decay in myoblasts in a CUGBP1-dependent manner. 
This is perhaps surprising as TNF mRNA decay was shown previously to be promoted 
by four other ARE-binding factors: AUF1 (Lu et al., 2006), TIA1 (Piecyk et al., 2000), 
TIAR (Gueydan et al., 1999), and TTP (Sun et al., 2007). The half-life reported here (~10 
minutes) is even shorter than reported in immune cells (20-40 minutes), which are 
primary TNF producers (Garnon et al., 2005; Wang et al., 2006). In muscle cells, this 
very high decay rate may ensure that TNF production is tightly controlled. Such control is 
necessary as TNF can both induce and inhibit terminal differentiation of muscle 
dependent on its concentration (Chen et al., 2007). Chronic exposure of muscle to high 
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TNF levels causes muscle wasting and insulin resistance (Flores et al., 1989; 
Kewalramani et al., 2010). The relatively high rate of decay for TNF mRNA (~30 
minutes) even in the CUGBP1 KD cells is likely due to ARE recognition by one of the 
aforementioned factors.  Such extensive regulation of TNF mRNA is required because of 
the potency of the TNF cytokine (Kontoyiannis et al., 1999).  
The mechanism by which CUGBP1 induces TNF mRNA levels remains an open 
question, as PARN knock-down did not alter the rate of TNF mRNA decay (Figure 6). 
Although it is possible that PARN was not knocked down sufficiently, CUGBP1 could 
well recruit an alternate deadenylase in PARN KD myoblasts, or may act through a 
deadenylation-independent pathway. Although PARN is the only decay enzyme known 
to interact with CUGBP1, other RNA-binding proteins have been shown to interact with a 
multitude of cellular decay factors: TTP recruits the decapping machinery, the exosome, 
and CNOT6 (Lykke-Andersen and Wagner, 2005) to promote decay. The possibility of 
CUGBP1 interacting with other decay factors could be tested by co-immunoprecipitation 
assays. 
 6.1.2 PKC activation disrupts CUGBP1 function 
Phorbol ester treatment causes PKC activation, which resulted in stabilization of 
the TNF mRNA (Figure 8), phosphorylation of CUGBP1 and a reduction in 
CUGBP1/mRNA association (Figure 9). Hyperphosphorylation of CUGBP1 is observed 
in DM1, and in a mouse model expressing CUG-repeat transcripts (Kuyumcu-Martinez 
et al., 2007). Moreover, treatment of this DM1 mouse with PKC inhibitors reduces 
CUGBP1 phosphorylation and abundance, corrects CUGBP1-mediated mis-splicing, 
and improves muscle function (Wang et al., 2009a). This could indicate that the 
phosphorylation changes observed for CUGBP1 in TPA-treated myoblasts mirror those 
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observed in DM1 patients (Kuyumcu-Martinez et al., 2007). One question remains, do 
CUGBP1-dependent changes in TNF mRNA stability occur in DM1 patients and if so, 
are they sufficient to cause TNF over-expression? There is one published report of TNF 
over-expression in DM1 patients (Mammarella et al., 2002), but the mechanism is not 
known. Our results are encouraging and should be followed up by investigating TNF 
mRNA abundance in DM1 patient muscle cells and in mouse models of the disease. 
The immunoprecipitation experiments from cytoplasmic lysates demonstrated 
that mRNA associations with CUGBP1 were reduced upon TPA activation, which was 
correlated with CUGBP1 phosphorylation. Changes in the phospho-state of CUGBP1 
are also evident during differentiation. It is currently not clear how phosphorylation 
results in reduced affinity of CUGBP1 for RNA. It could result in CUGBP1 sequestration 
in the nucleus. However this appears not to be the case in TPA treated cells (Dr. L. 
Zhang unpublished observation). DM1 models seemingly indicate that phospho-
CUGBP1 retains affinity for RNA. In the DM1 mouse model (Kuyumcu-Martinez et al., 
2007), CUGBP1 is phosphorylated, and rates of exon inclusion in CUGBP1 targets are 
increased. This would seem to indicate that phospho-CUGBP1 retains affinity for RNA. 
However, in this mouse model nuclear levels of CUGBP1 are increased. Therefore, 
comparing rates of exon inclusion is not likely a reliable indicator of binding affinity. 
Phospho-CUGBP1 may have reduced affinity for RNA, but the increased concentration 
may offset that in the nucleus. In the cytoplasm, reduced affinity has a significant impact 
as less CUGBP1 is available. Phosphorylation could alter the binding preference of 
CUGBP1 for other proteins, like splicing factors, similar to TTP showing increased 
affinity for the 14-3-3 chaperone upon phosphorylation (Sun et al., 2007). In this instance 
the RNA-binding function of the complex would likely be influenced by other proteins in 
addition to CUGBP1.  
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To summarize findings from Chapter 3, we have determined that CUGBP1 
regulates the stability of TNF mRNA in muscle. Upon PKC activation, conditions similar 
to DM1, the destabilization is disrupted, and mRNA substrate association is reduced 
allowing TNF levels and half-life to increase. These findings establish a common link 
between disrupted CUGBP1 function and increased levels and stability of the TNF 
mRNA. Increased TNF levels have been shown to disrupt insulin signaling and promote 
muscle wasting (Li and Reid, 2001). Elevation of potent cytokine TNF, by disruption of 
CUGBP1 function in muscle cells, may be responsible for some unexplained symptoms 
of DM1 -muscle wasting and insulin resistance. 
 
6.2 mRNA decay and the role of CUGBP1 in muscle cells 
  
As CUGBP1 likely targets many mRNAs in addition to TNF, we sought to 
characterize mRNA decay in muscle, and identify CUGBP1 targets on a global scale. 
We reported half-lives for 7,398 mRNAs in C2C12 cells. Cell cycle and transcriptional 
regulation were identified as processes likely to be post-transcriptionally regulated in 
muscle, and AU-rich and GU-rich sequence elements were considered likely to mediate 
this regulation as they were over-represented in unstable mRNAs. We went on to 
identify over 800 CUGBP1-associated transcripts, and distinguish CUGBP1 binding 
motifs. RNA metabolism, protein targeting to the ER, and muscle differentiation were all 
identified as processes likely to be impacted by CUGBP1. CUGBP1 and HuR were 
found to share common mRNA targets. Finally CUGBP1 protein expression was 
essential for normal myogenesis and was down-regulated as cells completed the 





6.2.1 Unique attributes of mRNA decay in muscle cells 
The global half-life experiments revealed muscle-specific features of mRNA 
decay. GU-rich sequences were found to be more significant than AU-rich ones (Figure 
12A). Muscle cells were unique in this regard, as comparison of GU and AU-rich 
sequences with proliferative ES cells, neuronal-like ES cells, and immune-like ES cells 
identified AU-rich sequences as most significant in those three (Lee et al., 2010). This 
finding indicates that in muscle cells GREs are a more important regulatory element than 
AREs. This may in part explain why over-expression of CUGBP1 primarily causes 
symptoms in muscle (Kuyumcu-Martinez et al., 2007). 
For muscle cells, transcription factors and cell cycle regulators tend to be 
encoded by unstable mRNAs; as was noted by previous studies in other cell types 
(Miller et al., 2011; Raghavan et al., 2002; Sharova et al., 2009). In these studies it was 
hypothesized that mRNAs with short half-lives can most readily be induced in response 
to external cues. Stabilization in conjunction with transcriptional induction allows for 
synergistic effects on mRNA levels and corresponding increase in protein levels. In 
addition, keeping the mRNA half-life short for groups of transcripts, allows for a rapid 
induction of mRNA levels.  
6.2.2 CUGBP1 depletion has wide ranging effects on mRNA decay in muscle cells 
CUGBP1 knock-down significantly stabilized 480 mRNAs in myoblasts which 
represents more than half of the transcripts for which half-lives were obtained. 
Confirmation of these observations was obtained for 9/13 transcripts examined by qRT-
PCR. Hexamer analyses were not useful for identifying over-represented elements in 
CUGBP1-regulated mRNAs. This is partly due to the much smaller size of the dataset 
(924 mRNAs in total vs. 7,398 mRNAs in controls). In retrospect, the indirect effects of 
CUGBP1 on mRNA decay may be wide-ranging given that the protein binds to a large 
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number of mRNAs encoding proteins required for mRNA metabolism including 26 RNA-
binding proteins, 11 splicing factors, and 10 decay factors (Table 4.3).  All told, finding 
480 putative CUGBP1 targets represents a marked advance in characterizing the 
cytoplasmic roles of the protein.  
6.2.3 Direct CUGBP1 targets: substrate competition and differentiation   
As our initial attempts to identify CUGBP1 targets by half-life analysis did not give 
a clear result, direct CUGBP1 targets were identified by RIP-Chip. Stringent analysis of 
RIP-Chip data conservatively identified 881 targets for regulation by CUGBP1. GO 
analysis of this dataset indicated that regulation of transcription, muscle differentiation, 
protein secretion, and cytoskeletal genes are all likely to be post-transcriptionally 
regulated by CUGBP1 in muscle. Two CUGBP1 binding motifs were predicted from the 
hexamer analyses. Comparison of our CUGBP1 RIP-Chip dataset with a similar dataset 
of mRNAs associated with the human HuR protein in T-cells indicated a significant 
degree of overlap in the transcripts recognized by these two opposing mRNA stability 
factors. CUGBP1 and HuR were found to compete for RNA-binding in vitro, similar to the 
competition between CUGBP2 and HuR that was previously reported (Sureban et al., 
2007). During myoblast differentiation, HuR stabilizes the Myogenin, MyoD, and p21 
mRNAs (Lal et al., 2004; Figueroa et al., 2003). We found CUGBP1 bound to Myogenin, 
MyoD, and p21 mRNAs, and showed that CUGBP1 destabilizes the MyoD transcript 
(Figure 13). It now seems likely that CUGBP1 may be repressing the expression of 
these three factors in proliferative myoblasts. 
GO analysis of the CUGBP1 RIP-Chip dataset linked CUGBP1 with expression 
patterns of functionally related mRNAs in muscle. CUGBP1-bound mRNAs encode 
factors involved in cell cycle, transcription, and RNA metabolism, these findings were in 
agreement with previous reports where global approaches were applied to TTP targets, 
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PUM1 targets, HuR targets, and T-cell responses (Emmons et al., 2008; Morris et al., 
2008; Mukherjee et al., 2009; Vlasova et al., 2008). Our analysis has identified 
processes which are likely to be mis-regulated upon disruption of CUGBP1 function. 
Many of the short half-life mRNAs identified have an important role in muscle 
differentiation including: (1) CEBP/β a transcription factor that can repress myocyte 
growth (Bostrom et al., 2010), (2) Rnd3 (RhoE) constitutively active G-protein which 
when ablated in mice causes delayed neuromuscular maturation and very early mortality 
(Mocholi et al., 2011), (3) Jun, a transcription factor whose activity levels can promote 
myogenic differentiation of ES cells (Wu et al., 2010), and (4) MyoD a transcription factor 
that increases during muscle differentiation for transcription of muscle-specific genes 
(Rudnicki et al., 1993).The complete list of mRNAs now provides a large dataset for 
studies looking at mRNA regulation in muscle cells.  
It has been proposed that a single RNA-binding protein can regulate gene 
expression for hundreds of mRNA targets (Keene, 2007). This model is similar to 
transcriptional efficiency of related bacterial polycistronic genes being regulated by a 
common factor, in an operon. Extending this model to mRNA decay in eukaryotes, it is 
thought that functionally-related classes of messages are controlled by a common RNA-
binding protein, thus eliciting a concerted response. Our data strongly supports this 
model. We found CUGBP1 associated with mRNAs encoding factors involved in mRNA 
metabolism (including its own mRNA), muscle differentiation, cytoskeleton, and protein 
targeting to the ER. Finding an RNA-binding protein associated with many other mRNAs 
encoding other RNA-binding proteins supports the “regulator of regulators” idea. This is 
a concept that has emerged from several RIP-Chip studies which have found the RNA-
binding protein of interest associated with mRNAs which encode for RNA-binding 
proteins. This phenomenon likely represents a method of feedback by which mRNA-
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binding proteins exert far-reaching effects post-transcriptionally (Pullmann, Jr. et al., 
2007). 
6.2.4 Myoblast differentiation is regulated by CUGBP1 
As shown in Chapter 4, knock-down of CUGBP1 significantly alters myotube 
formation. We hypothesize this may be due to aberrant stabilization of one or more 
CUGBP1-regulated mRNAs.  Our work here demonstrated that TNF mRNA abundance 
and stability are elevated in CUGBP1 KD myoblasts. If we extend this finding to the 
protein level, then elevated TNF functioning in an autocrine fashion may be partly to 
blame for the precocious differentiation. A previous report demonstrated that: (1)TNF 
mRNA levels increase 3-fold upon initiation of differentiation, (2) depletion of TNF from 
culture media inhibits myotube formation, and (3) slightly elevated TNF levels promote 
differentiation of C2C12 cells (Li and Schwartz, 2001).  
 The finding that CUGBP1 depletion causes myosac formation upon 
differentiation is particularly interesting and could be linked with aberrant expression of 
any one of several mRNAs associated with CUGBP1. The RhoE mRNA encodes a 
factor important for cytoskeletal organization (Fortier et al., 2008; Mocholi et al., 2011). 
CUGBP1 also binds to four mRNAs that encode tubulins, and curiously, disruption of 
microtubules with drugs also causes a myosac phenotype (Saitoh et al., 1988). Finally, it 
is noteworthy that TPA treatment of differentiating C2C12 cells also induces formation of 
myosacs (Mermelstein et al., 1996). CUGBP1 binds to (Table 4.3) and regulates the 
mRNA stability of factors critical for protein targeting to the ER, and secretion (C. Lopez 
personal communication). Disruption of these processes in CUGBP1 knock-down cells 
may hamper the movement of proteins to the extracellular space. This is of note 
because mutations in extra cellular matrix (ECM) components cause Duchenne and 
other muscular dystrophies (Kanagawa and Toda, 2006) and effects on ECM were 
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recently documented in DM1 mouse models (Du et al., 2010). In addition, DM1 patient 
cells exhibit hallmarks of ER stress that could also be linked with defective CUGBP1 
function (Ikezoe et al., 2007). 
6.2.5 CUGBP1 is dynamically regulated during muscle differentiation 
 Differentiation of C2C12 cells from myoblast to myotubes required CUGBP1 for 
normal kinetics. We sought to characterize the expression profile of CUGBP1 in the 
differentiation process. CUGBP1 levels drop in C2C12 cultures (Figure 18) and murine 
cardiac tissues as differentiation proceeds (Kalsotra et al., 2010). Interestingly, 
phosphorylation of CUGBP1 also changes during differentiation, however the relative 
pattern may be distinct from that observed in TPA treatment or repeat RNA expression. 
As several pathways involving kinase signaling are activated upon muscle differentiation 
including PI3K/Akt (Xu and Wu, 2000) and p38/MAPK (Briata et al., 2005) it would be 
interesting to test which, if any, of these are responsible for CUGBP1 phosphorylation 
under normal differentiation conditions compared with the DM1/PKC activated 
conditions. 
 
6.3 Global approach identifies mRNA substrate for deadenylation by PARN 
 
Prior to this work no direct substrates of PARN had been characterized in 
mammalian cells. While this work was in progress, Gadd45α was found to be regulated 
by PARN at the level of stability in response to DNA damage (Reinhardt et al., 2010). 
PARN had been shown to interact with RNA-binding proteins including CUGBP1, TTP, 
KSRP, RHAU (Gherzi et al., 2004; Sandler and Stoecklin, 2008; Tran et al., 2004), and 
promote deadenylation in vitro (Moraes et al., 2006) but little evidence for a cytoplasmic 
role in living cells was available. Here we detected 64 mRNAs with significantly different 
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half-lives in PARN knock-down cells. One of these transcripts, Brf2, is directly affected at 
the level of deadenylation. This transcript, Brf2, encodes an RNA-binding protein which 
likely confers instability onto mRNA targets of its own (Lykke-Andersen and Wagner, 
2005). From the 40 mRNAs stabilized in the PARN knock-down cells, many may 
represent direct substrates for deadenylation by PARN. In addition, 24 of the mRNAs 
expressed in the PARN KD cells were in destabilized. As mentioned, this could be due 
to increased amounts of BRF2, an ARE-binding protein, as 11/24 destabilized transcripts 
were found to contain AREs (Bakheet et al., 2006). In addition, increases in the levels of 
the deadenylase TOE1 (CAF1Z) and/or the enhancer of decapping EDC3 could also 
promote mRNA decay of some of the 24 identified destabilized transcripts. 
6.3.1 PARN affects deadenylation in myoblasts 
Efforts here to implicate PARN deadenylase in the regulation of TNF mRNA 
stability were inconclusive. Interestingly, the PARN KD array data yields a plausible 
explanation. Upon PARN KD it was discovered that the Brf2 mRNA was stabilized. The 
closely related ARE-binding protein TTP has been shown previously to enhance decay 
of the TNF mRNA (Carballo et al., 1998). In addition TTP and BRF1 were both found to 
recruit DCP2 and CNOT6, but not PARN. No detectable changes in the overall 
abundance of the mRNA of Brf2 were detected in the PARN KD relative to controls, this 
is expected as BRF2 protein auto-regulates its own mRNA (Rabani et al., 2011). 
Nevertheless, Brf2 mRNA exhibits an increase in average poly(A) tail length in PARN 
KD cells, which might enhance translation. If excess BRF2 protein bound the ARE in the 
TNF mRNA, it might recruit DCP2 and/or CNOT6 thereby compensating for lack of 





6.3.2 Brf2 mRNA is subject to deadenylation by PARN 
 The relatively small number of mRNAs impacted by PARN knock-down is 
consistent with redundancy of targets between different deadenylases. Knock-down of 
the deadenylase CNOT6 in human breast adenocarcinoma cells (MCF7) resulted in no 
significant mRNA abundance changes. Double knock down of  CNOT6/CNOT6L 
resulted in 79 mRNA abundance changes of 1.5-fold or greater (up and down), and 
CNOT7/CNOT8 double knock down resulted in 229 abundance changes (up and down; 
Mittal et al., 2011). Analysis of the zero time point data from our PARN KD cells reveals 
263 abundance changes (68 increased, and 195 decreased 2-fold or greater). 
Intriguingly, the Mittal study indicates that different deadenylases examined regulate 
distinct classes of messages. This is somewhat surprising considering the deadenylases 
compared can all associate with the NOT scaffolding proteins. Further bioinformatic 
comparisons with the PARN KD abundance data may reveal whether distinct classes of 
mRNAs are targets for regulation by PARN. In addition, comparison of abundances from 
our global studies between PARN and CUGBP1 KD cells has revealed that the two 
proteins may cooperatively regulate a small subset (20 mRNAs) of transcripts which are 
involved in neuronal function (Appendix 11).  
Finally, to our knowledge this is the first data demonstrating that PARN 
modulates poly(A) tail status of an endogenous mRNA in the cytoplasm of mammalian 
cells. At this point it is unclear what features make Brf2 mRNA a PARN substrate in 
muscle, the 3’UTR has both AU- and GU-rich sequences. Future experiments will be 
directed towards looking at protein levels and translation rates of a Brf2 reporter RNA in 
control and PARN KD myoblasts. Future studies could be directed at elucidating what 




6.4 Concluding remarks 
 
At the inception of this study, the regulation of TNF mRNA decay in muscle was 
uncharacterized. The processes of mRNA decay and CUGBP1-mediated decay were 
uncharacterized in muscle. Finally, the role, if any, of PARN in mRNA decay in 
mammalian cells was unclear. TNF mRNA decay was characterized for the first time in 
muscle cells. CUGBP1 was demonstrated necessary for rapid decay of the TNF 
message (Zhang et al., 2008). This study provided a potential link between unexplained 
symptoms of DM1 and CUGBP1 overexpression. 
For the first time we have measured mRNA decay rates on a global scale in 
muscle cells, revealing important concepts about mRNA decay dynamics in muscle. We 
have identified a set of RNAs whose half-life is dependent of the presence of CUGBP1 
protein in muscle, identified direct mRNA targets of CUGBP1 (Lee et al., 2010), and 
differentiation defects dependent on CUGBP1 were characterized. Prior to these finding 
CUGBP1 was primarily characterized as a splicing factor in mammalian cells, and a 
mediator of translational activation/repression in transcriptionally silent oocytes (Kalsotra 
et al., 2008; Paillard et al., 1998). Our results have now firmly established CUGBP1 as 
an important post-transcriptional regulator in mammalian cells beyond splicing.  
Lastly we identified a subset of mRNAs whose decay rates are dependent on 
PARN levels, and have implicated PARN as an important deadenylase from the 
standpoint of transcript regulation in muscle cells. To conclude, these findings have 
significantly advanced the understanding mRNA decay in muscle cells, the role of 
CUGBP1 in muscle, and identified an endogenous mRNA substrate for deadenylation by 
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Only full-length CUGBP1 stably interacts with PARN in vitro. (A) Diagram of CUGBP1. RNA 
recognition motifs (RRM) are shown in blue and linker region is shown as a line. (B) Equal 
amounts of recombinant PARN were incubated with 5µg of the indicated GST-CUGBP1 protein 
immobilized on glutathione linked agarose resin in the presence of RNase A. After washing, the 
proteins were eluted by boiling in 1XSDS loading dye and separated on a 10% SDS 
polyacrylamide gel. PARN was detected by western blot. (C) Coomassie stained gel showing 







Knock-down of PARN by shRNA #1520 changes TNF mRNA abundance and half-life.  (A) 
Schematic of PARN mRNA, ORF as box, lines as UTRs, red line indicates position of targeting 
shRNA. (B) Western blot for PARN and GAPDH (loading control) of extracts from LKO-1 and 
PARN knock-down cell lines. (C) TNF mRNA levels assessed by qRT-PCR from LKO-1 and 
PARN KD cell lines normalized to GAPDH. (E) Rate of decay for TNF mRNA in the LKO-1 (solid 
line) and PARN KD cell line (dashed line) was assessed following actinomycin-D treatment. 



















Appendix 3. continued 
 
 
Hexamers enriched in the 3’UTRs of the most and least stable mRNAs. (A) Hexamers 
enriched in the least stable genes’ 3’UTRs and their corresponding sequence logo. (B) Hexamers 













64113 Moap1 86 458 5.3 3.57E‐02
22644 Rnf103 117 613 5.2 4.05E‐02
106200 Txndc11 103 418 4.0 1.11E‐02
320376 Bcorl1 132 531 4.0 4.36E‐02
101497 Plekhg2 142 571 4.0 1.83E‐02
11911 Atf4 66 258 3.9 7.80E‐03
217684 4933426M11Rik 114 448 3.9 1.92E‐04
118445 Klf16 102 395 3.9 3.59E‐02
268291 Rnf217 72 272 3.8 3.58E‐02
72655 2810026P18Rik 60 222 3.7 4.93E‐03
13716 Ell 100 373 3.7 1.16E‐02
11839 Areg 102 376 3.7 1.40E‐02
78266 Zfp687 134 494 3.7 4.92E‐05
100038535 ENSMUSG00000075516 117 431 3.7 4.34E‐02
29861 Dpf1 179 656 3.7 4.97E‐02
109019 Obfc2a 93 335 3.6 3.79E‐02
229004 Gmeb2 69 247 3.6 1.33E‐02
224118 1700021K19Rik 103 362 3.5 1.66E‐02
229543 Ints3 148 522 3.5 4.68E‐02
75273 Pelp1 139 489 3.5 3.09E‐02
235040 Atg4d 132 463 3.5 4.32E‐02
72469 Plcd3 104 361 3.5 1.60E‐02
239796 1600021P15Rik 99 340 3.4 5.33E‐05
13170 Dbp 91 308 3.4 2.22E‐02
170767 Rfxap 109 371 3.4 3.76E‐02
110524 Dgkq 220 745 3.4 3.07E‐02
74041 4632434I11Rik 77 259 3.4 3.12E‐02
72946 Lrrc47 106 356 3.4 2.26E‐02
74178 Stk40 96 323 3.3 2.52E‐02
52829 D4Bwg0951e 72 239 3.3 3.95E‐02
71955 2400003C14Rik 109 358 3.3 4.02E‐03
17131 Smad7 61 199 3.3 1.92E‐02
69612 2310037I24Rik 95 310 3.3 3.21E‐02
67246 2810474O19Rik 59 190 3.2 3.37E‐02
97484 Cog8 134 432 3.2 3.87E‐02
73122 Tgfbrap1 136 435 3.2 1.79E‐02
98402 Sh3bp4 73 232 3.2 3.27E‐02
227449 Zcchc2 94 298 3.2 1.92E‐02
209212 Osgin2 107 339 3.2 2.85E‐02
71254 Naif1 166 517 3.1 3.99E‐02
228869 Ncoa5 108 335 3.1 2.22E‐03
13557 E2f3 83 258 3.1 1.11E‐02
74194 Rnd3 34 106 3.1 1.27E‐03
72635 Lins2 126 391 3.1 7.36E‐03
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11854 Rhod 106 328 3.1 3.27E‐03
109136 Mmaa 135 414 3.1 3.46E‐02
207932 4921511H13Rik 110 337 3.1 4.46E‐02
381306 BC055324 106 322 3.0 5.16E‐06
13728 Mark2 100 304 3.0 1.61E‐02
242418 Wdr32 84 253 3.0 1.16E‐02
69612 2310037I24Rik 102 309 3.0 3.73E‐02
69601 Dab2ip 109 328 3.0 2.21E‐03
329003 Zfp516 87 260 3.0 3.56E‐03
18626 Per1 100 295 3.0 9.19E‐04
18844 Plxna1 103 306 3.0 1.68E‐02
114604 Prdm15 120 354 3.0 2.26E‐02
98999 Znfx1 107 318 3.0 6.30E‐03
26939 Polr3e 116 344 3.0 2.40E‐02
226182 Taf5 69 204 2.9 1.72E‐03
52504 Cenpo 127 373 2.9 9.08E‐03
319885 Zcchc7 110 322 2.9 2.22E‐02
64453 Zfp280b 75 219 2.9 1.54E‐03
230734 Yrdc 96 281 2.9 3.93E‐02
68778 1110038D17Rik 95 276 2.9 4.11E‐03
74094 Tjap1 85 246 2.9 4.50E‐02
99526 Usp53 120 349 2.9 8.81E‐03
107305 Vps37c 88 256 2.9 1.30E‐02
319583 Lig4 98 286 2.9 3.62E‐02
73233 3110048L19Rik 100 291 2.9 2.92E‐02
239555 Smcr7l 116 335 2.9 4.18E‐02
12296 Cacnb2 113 325 2.9 2.26E‐02
13803 Enc1 63 181 2.9 1.15E‐03
100978 Nfxl1 94 268 2.9 3.71E‐02
67123 Ubap1 75 214 2.8 4.51E‐02
56332 Amotl2 44 124 2.8 5.34E‐03
54006 Deaf1 118 333 2.8 4.54E‐02
71093 Atoh8 108 304 2.8 1.31E‐03
232944 Mark4 129 365 2.8 1.74E‐02
14312 Brd2 86 243 2.8 1.71E‐02
74035 Nol9 85 238 2.8 3.92E‐02
192652 Wdr81 143 402 2.8 6.39E‐03
80744 BC003993 77 215 2.8 9.07E‐03
67619 Nob1 112 313 2.8 3.42E‐04
66667 Hspbap1 142 397 2.8 4.32E‐02
21665 Tdg 98 275 2.8 2.08E‐02
641340 Nrbf2 93 259 2.8 2.28E‐02
14573 Gdnf 103 288 2.8 3.03E‐02
21665 Tdg 96 267 2.8 3.76E‐02
71799 Ptcd1 97 271 2.8 1.69E‐02
320790 Chd7 92 255 2.8 3.93E‐02
268783 Mtmr12 123 341 2.8 9.32E‐03
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20779 Src 136 377 2.8 3.03E‐02
320790 Chd7 78 218 2.8 2.34E‐02
75424 Zfp820 213 589 2.8 2.92E‐03
225339 Ammecr1l 109 301 2.7 2.10E‐02
227613 Tubb2c1 158 433 2.7 6.17E‐04
52552 Parp8 103 283 2.7 1.49E‐03
100169 Phactr4 87 238 2.7 1.97E‐02
74570 Zkscan1 64 175 2.7 3.41E‐02
668940 Myh7b 102 279 2.7 1.39E‐02
435684 Shf 128 347 2.7 4.58E‐02
15357 Hmgcr 108 294 2.7 2.10E‐02
269623 C030048B08Rik 107 289 2.7 4.54E‐02
15903 Id3 42 113 2.7 4.18E‐02
224648 Uhrf1bp1 110 298 2.7 9.84E‐03
14369 Fzd7 72 194 2.7 3.49E‐02
63856 Taf8 107 289 2.7 6.57E‐03
13875 Erf 119 320 2.7 3.91E‐02
14283 Fosl1 59 159 2.7 3.78E‐02
14287 Fpgs 116 311 2.7 4.32E‐02
72008 Zfyve19 177 472 2.7 3.07E‐02
386655 Eid2 189 503 2.7 4.76E‐03
75901 Dcp1a 99 263 2.7 2.23E‐02
66895 1300014I06Rik 91 241 2.7 4.68E‐02
107951 Cdk9 86 227 2.7 5.96E‐03
22145 Tuba4a 133 352 2.7 5.88E‐03
15117 Has2 48 127 2.6 9.08E‐03
77853 Msl2l1 49 129 2.6 3.75E‐02
21664 Phlda1 52 138 2.6 1.92E‐02
70573 Tbccd1 159 420 2.6 1.22E‐03
110816 Pwp2 149 392 2.6 4.78E‐02
229599 Gm129 88 233 2.6 3.94E‐02
66089 Rmnd5b 127 335 2.6 3.26E‐02
23849 Klf6 53 140 2.6 4.62E‐02
14200 Fhl2 80 210 2.6 5.06E‐03
57170 Dolpp1 117 309 2.6 1.12E‐02
66830 Btbd14b 127 334 2.6 1.40E‐02
260315 Nav3 126 331 2.6 2.59E‐02
69641 Wdr20a 65 169 2.6 3.92E‐03
102414 Clk3 93 241 2.6 4.96E‐04
12530 Cdc25a 60 156 2.6 4.53E‐02
58996 4933428G20Rik 110 286 2.6 2.44E‐02
100206 Adprhl2 116 301 2.6 1.49E‐02
19206 Ptch1 119 309 2.6 1.67E‐03
69577 Fastkd3 104 272 2.6 3.72E‐02
67109 Zfp787 132 343 2.6 1.37E‐03
217207 Dhx8 89 230 2.6 5.50E‐03
20482 Skil 79 205 2.6 2.34E‐02
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641340 Nrbf2 91 236 2.6 3.70E‐02
641340 Nrbf2 91 236 2.6 3.70E‐02
234138 BC019943 133 345 2.6 1.94E‐02
20623 Snrk 90 234 2.6 1.79E‐03
677593 LOC677593 94 244 2.6 1.69E‐02
21750 Terf2 109 281 2.6 2.80E‐02
30877 Gnl3 77 198 2.6 3.64E‐02
57438 7‐Mar 64 164 2.6 2.58E‐02
74349 4632419K20Rik 117 301 2.6 3.49E‐03
233276 Tubgcp5 129 331 2.6 1.21E‐03
52231 Ankzf1 156 401 2.6 2.78E‐02
16835 Ldlr 88 226 2.6 3.45E‐02
381022 Mll2 94 241 2.6 1.87E‐02
107765 Ankrd1 72 184 2.6 4.68E‐02
213990 Centg3 144 367 2.6 3.55E‐02
60532 Wtap 93 236 2.5 6.83E‐03
230700 Foxj3 79 202 2.5 3.36E‐02
211147 11‐Mar 146 371 2.5 3.87E‐03
223666 D15Wsu169e 125 317 2.5 5.33E‐04
545622 Ptpn3 145 368 2.5 1.05E‐02
102423 Mizf 134 339 2.5 1.37E‐02
22224 Usp10 86 218 2.5 2.74E‐02
72344 Usp36 84 214 2.5 8.68E‐04
56503 Ankrd49 81 205 2.5 1.14E‐02
223664 Lrrc14 95 238 2.5 2.39E‐02
68968 Cdan1 105 264 2.5 2.72E‐02
74386 Rmi1 73 184 2.5 2.85E‐02
16206 Lrig1 107 268 2.5 6.22E‐03
218613 Mier3 60 150 2.5 9.73E‐03
107607 Nod1 186 464 2.5 3.46E‐03
230661 Tesk2 93 232 2.5 1.24E‐02
71458 Bcor 95 237 2.5 2.99E‐02
20935 Surf6 110 273 2.5 2.80E‐04
29870 Gtse1 106 263 2.5 9.61E‐04
57912 Cdc42se1 102 254 2.5 3.10E‐02
71804 2610016C23Rik 97 240 2.5 4.84E‐02
240880 Scyl3 121 298 2.5 5.82E‐03
319719 4732471D19Rik 80 198 2.5 2.84E‐02
269060 Dagla 104 257 2.5 4.06E‐03
22390 Wee1 46 114 2.5 8.70E‐03
381801 Tatdn2 119 292 2.5 4.33E‐02
232196 C87436 71 174 2.5 3.25E‐02
54131 Irf3 132 325 2.5 7.51E‐03
228994 Ythdf1 103 251 2.5 7.76E‐03
12193 Zfp36l2 58 142 2.4 2.36E‐03
98710 Rabif 84 204 2.4 1.92E‐02
74549 9130404D08Rik 115 282 2.4 4.18E‐02
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238871 Pde4d 79 193 2.4 3.00E‐02
56632 Sphk2 126 307 2.4 1.89E‐02
233904 Setd1a 111 270 2.4 6.18E‐04
217039 Ggnbp2 75 181 2.4 1.01E‐02
22325 Vav2 131 316 2.4 2.49E‐02
228368 Slc35c1 113 271 2.4 3.68E‐04
269582 Clspn 125 300 2.4 9.99E‐03
21975 Top3a 98 237 2.4 1.34E‐02
268933 Wdr24 158 381 2.4 2.91E‐02
67164 2610209A20Rik 186 445 2.4 6.92E‐03
18130 Ints6 63 150 2.4 2.24E‐02
21847 Klf10 58 139 2.4 6.14E‐03
78246 Phf23 54 128 2.4 1.70E‐02
16319 Incenp 96 230 2.4 4.60E‐02
105351 AW209491 105 250 2.4 3.79E‐02
226049 Dmrt2 111 264 2.4 1.10E‐02
330474 Zc3h4 96 228 2.4 3.94E‐02
215748 Cnksr3 70 166 2.4 4.20E‐02
11350 Abl1 81 192 2.4 1.72E‐02
234678 D230025D16Rik 87 204 2.4 1.52E‐02
228140 Tnks1bp1 115 272 2.4 2.26E‐02
217127 Myst2 97 228 2.4 3.72E‐02
268749 Rnf31 141 331 2.4 1.20E‐03
74769 Pik3cb 120 283 2.3 1.93E‐02
66690 Tmem186 113 264 2.3 4.13E‐02
20677 Sox4 89 209 2.3 1.28E‐02
232798 Leng8 162 379 2.3 3.72E‐02
210973 Kbtbd2 70 164 2.3 3.78E‐02
108673 Ccdc86 93 217 2.3 1.91E‐02
22718 Zfp60 121 282 2.3 2.53E‐03
229055 Zbtb10 106 247 2.3 1.43E‐02
76969 Chst1 97 226 2.3 2.57E‐02
244666 Gm505 104 241 2.3 9.03E‐04
223642 Zc3h3 162 375 2.3 9.88E‐03
104445 Cdc42ep1 52 121 2.3 4.09E‐02
226153 Peo1 108 250 2.3 2.86E‐03
229584 Pogz 78 181 2.3 9.11E‐03
72726 Tbcc 123 283 2.3 1.45E‐02
240665 Ccnj 133 306 2.3 4.34E‐03
238330 6430527G18Rik 76 176 2.3 5.51E‐03
140629 Ubox5 106 243 2.3 1.40E‐02
18712 Pim1 87 201 2.3 3.97E‐02
235584 Dusp7 72 165 2.3 9.47E‐03
67655 Ctdp1 97 223 2.3 1.34E‐02
360216 Zranb1 106 244 2.3 8.56E‐03
67139 Mis12 82 189 2.3 9.49E‐03
65020 Zfp110 114 261 2.3 1.73E‐02
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320398 Lrig3 56 128 2.3 2.04E‐02
101612 Grwd1 93 212 2.3 2.39E‐02
81630 Zbtb22 99 226 2.3 3.30E‐04
20775 Sqle 95 217 2.3 5.68E‐03
240064 6030490I01Rik 127 290 2.3 3.91E‐02
276919 Gemin4 74 168 2.3 5.63E‐04
101095 Zfp282 86 196 2.3 7.31E‐03
320661 D5Ertd579e 80 181 2.3 5.69E‐03
109113 Uhrf2 82 185 2.3 4.30E‐02
76813 Armc6 123 279 2.3 2.50E‐03
24069 Sufu 84 190 2.3 9.02E‐03
13163 Daxx 93 210 2.3 3.37E‐02
72323 Asb6 86 194 2.3 3.19E‐02
101994 Zfp828 80 181 2.3 7.06E‐04
319520 Dusp4 39 89 2.2 8.24E‐03
112406 Egln2 142 318 2.2 1.55E‐02
21815 Tgif1 45 102 2.2 2.18E‐02
26889 Cln8 109 244 2.2 2.67E‐02
217779 Lysmd1 131 294 2.2 2.28E‐02
13548 Dyrk1a 78 174 2.2 3.99E‐02
56488 Nxt1 76 170 2.2 3.29E‐02
70024 Mcm10 102 227 2.2 1.41E‐02
381695 N4bp2l2 101 226 2.2 3.57E‐02
16172 Il17ra 81 180 2.2 2.38E‐02
20361 Sema7a 65 146 2.2 3.66E‐02
68114 Mum1 130 288 2.2 2.18E‐02
319594 Hif1an 74 163 2.2 9.58E‐03
57434 Xrcc2 117 260 2.2 3.93E‐02
231769 Sfrs8 120 267 2.2 2.57E‐03
75788 Smurf1 101 224 2.2 2.09E‐02
69582 Plekhm2 135 299 2.2 1.80E‐02
108961 E2f8 73 160 2.2 4.08E‐02
15547 Htf9c 139 305 2.2 2.01E‐02
22640 Zfp1 89 195 2.2 6.54E‐03
56381 Spen 93 204 2.2 2.72E‐03
17691 Snf1lk 62 135 2.2 3.02E‐02
625662 LOC625662 66 145 2.2 3.65E‐02
12750 Clk4 69 151 2.2 3.24E‐02
55942 Sertad1 49 107 2.2 2.33E‐02
239719 Mkl2 110 240 2.2 3.84E‐02
360216 Zranb1 92 199 2.2 1.03E‐02
20525 Slc2a1 127 276 2.2 4.82E‐02
209456 Trp53bp2 95 207 2.2 2.13E‐02
18044 Nfya 80 173 2.2 2.06E‐02
11541 Adora2b 80 174 2.2 2.41E‐02
66973 Mrps18b 117 253 2.2 4.12E‐03
22156 Tuft1 116 250 2.2 4.54E‐03
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232879 Zbtb45 96 208 2.2 1.71E‐02
231841 AA881470 163 351 2.2 4.60E‐02
12042 Bcl10 98 212 2.2 1.29E‐02
70052 Prpf4 93 202 2.2 1.07E‐02
245877 Mtap7d1 118 255 2.2 4.27E‐03
227522 Rpp38 41 89 2.2 2.29E‐02
73754 Thap1 127 272 2.1 4.84E‐03
215051 Bud13 98 211 2.1 5.17E‐03
18181 Nrf1 87 186 2.1 7.66E‐03
320790 Chd7 102 217 2.1 2.11E‐02
74133 1200011M11Rik 88 187 2.1 9.14E‐03
17127 Smad3 86 183 2.1 3.56E‐02
74211 14‐Sep 63 134 2.1 2.78E‐02
227731 Slc25a25 107 228 2.1 8.09E‐03
11845 Arf6 106 225 2.1 1.03E‐02
212427 A730008H23Rik 74 156 2.1 1.53E‐03
56371 Fzr1 81 172 2.1 4.56E‐02
17210 Mcl1 55 116 2.1 2.85E‐02
235682 Zfp445 87 183 2.1 4.07E‐03
57377 Gcs1 114 241 2.1 8.17E‐03
74155 Errfi1 38 79 2.1 2.41E‐02
30951 Cbx8 109 230 2.1 3.24E‐03
231798 Lrch4 116 244 2.1 2.15E‐02
17423 Ndst2 96 203 2.1 4.01E‐02
26909 Exo1 88 186 2.1 8.18E‐03
213499 Fbxo42 76 160 2.1 2.35E‐03
67131 Acbd4 183 385 2.1 4.02E‐02
243362 Stard13 64 134 2.1 4.36E‐03
71393 Kctd6 96 201 2.1 7.18E‐03
63953 Dusp10 49 102 2.1 4.03E‐02
78581 Utp23 108 227 2.1 2.45E‐04
101489 Ric8 168 351 2.1 4.98E‐02
59091 Jph2 143 299 2.1 2.91E‐02
320790 Chd7 110 230 2.1 1.94E‐03
99683 Sec24b 107 224 2.1 3.36E‐03
216805 Flcn 82 172 2.1 4.86E‐02
99696 Ankrd50 78 163 2.1 2.87E‐02
66953 Cdca7 79 164 2.1 2.57E‐02
100978 Nfxl1 96 201 2.1 4.21E‐02
67308 Mrpl46 139 289 2.1 4.20E‐02
20589 Ighmbp2 174 362 2.1 2.07E‐02
20893 Bhlhb2 42 87 2.1 2.50E‐03
77040 Atg16l1 118 245 2.1 7.14E‐03
231915 Uspl1 66 137 2.1 2.61E‐02
237859 Ccdc55 85 177 2.1 2.64E‐02
70686 Dusp16 92 192 2.1 4.86E‐02
66591 Mad2l1bp 70 145 2.1 1.99E‐03
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71865 Fbxo30 73 151 2.1 1.87E‐02
13666 Eif2ak3 113 233 2.1 4.19E‐02
109075 Exosc4 130 267 2.1 3.14E‐02
193796 Jmjd2b 110 226 2.1 1.31E‐02
13831 Epc1 80 164 2.0 6.86E‐03
93760 Arid1a 87 177 2.0 3.08E‐02
223642 Zc3h3 173 353 2.0 2.33E‐02
16468 Jarid2 100 203 2.0 1.90E‐02
72290 Lsm11 137 279 2.0 1.48E‐03
233210 Prr12 100 204 2.0 2.14E‐02
109305 Orai1 150 306 2.0 2.77E‐02
70044 Tut1 93 190 2.0 2.90E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
676142 LOC676142 74 150 2.0 3.50E‐02
192232 Hps4 118 240 2.0 7.00E‐03
103724 Tbc1d10a 134 271 2.0 4.63E‐03
14284 Fosl2 75 152 2.0 2.27E‐02
320119 Rps6kc1 112 226 2.0 1.68E‐02
72454 Ccdc71 104 209 2.0 1.12E‐02
66406 Sac3d1 140 281 2.0 4.86E‐02
64209 Herpud1 82 163 2.0 2.68E‐02
77011 5730590G19Rik 74 147 2.0 1.56E‐02
210029 Metrnl 178 355 2.0 1.37E‐02
74522 Morc2a 78 155 2.0 2.97E‐02
102098 Arhgef18 112 223 2.0 8.12E‐03
76793 Snip1 67 134 2.0 3.64E‐02
108954 Ppp1r15b 67 134 2.0 6.67E‐03
71640 4930422I07Rik 186 368 2.0 4.08E‐02
71878 2310007D09Rik 82 162 2.0 3.98E‐03
207952 Klhl25 121 240 2.0 3.46E‐03
97112 Nmd3 75 148 2.0 4.43E‐02
68550 1110002N22Rik 101 200 2.0 6.14E‐03
240442 Adnp2 57 113 2.0 6.43E‐03
68897 Disp1 94 185 2.0 3.05E‐03
211978 Zfyve26 149 295 2.0 7.34E‐04
94092 Trim16 87 171 2.0 3.44E‐02
12224 Klf5 86 170 2.0 3.18E‐02
20460 Stil 69 137 2.0 9.61E‐03
29815 Bcar3 63 125 2.0 7.98E‐03
72123 2010109K11Rik 132 261 2.0 2.81E‐02
67141 Fbxo5 33 65 2.0 1.81E‐02
50721 Sirt6 126 248 2.0 1.29E‐04
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12394 Runx1 108 211 2.0 3.60E‐02
20466 Sin3a 93 182 2.0 1.30E‐02
13836 Epha2 76 148 1.9 3.06E‐02
19671 Rce1 173 336 1.9 1.40E‐02
13846 Ephb4 134 260 1.9 5.68E‐03
68118 9430023L20Rik 93 180 1.9 8.64E‐03
213541 Ythdf2 108 209 1.9 3.26E‐02
67760 Slc38a2 71 136 1.9 4.71E‐03
11852 Rhob 43 82 1.9 8.25E‐03
22689 Zfp27 150 287 1.9 2.79E‐03
67311 Nanp 73 139 1.9 4.68E‐03
240263 Fem1c 65 123 1.9 2.02E‐02
12795 Plk3 125 238 1.9 4.02E‐03
80914 Uck2 107 204 1.9 4.74E‐03
217333 Trim47 88 167 1.9 4.90E‐02
52040 Ppp1r10 41 78 1.9 2.09E‐02
15902 Id2 55 105 1.9 1.06E‐04
75234 Rnf19b 106 202 1.9 2.37E‐02
54399 Bet1l 83 158 1.9 7.67E‐03
24001 Tiam2 76 143 1.9 3.95E‐03
15937 Ier3 55 105 1.9 3.28E‐02
232784 Zfp212 72 135 1.9 2.98E‐02
12053 Bcl6 89 166 1.9 2.55E‐04
67976 Trabd 166 311 1.9 4.19E‐02
106564 Ppcs 157 294 1.9 2.37E‐02
30945 Rnf19a 55 102 1.9 6.84E‐03
69534 Avpi1 133 247 1.9 3.05E‐02
98985 Clp1 58 107 1.9 3.90E‐02
72699 Lime1 153 284 1.9 3.18E‐02
319266 A130010J15Rik 103 190 1.8 3.68E‐02
108829 Jmjd1c 66 121 1.8 9.50E‐03
70208 Med23 97 180 1.8 1.68E‐02
83486 Rbm5 82 151 1.8 2.27E‐02
226154 Lzts2 120 221 1.8 3.06E‐02
67842 2610027L16Rik 133 245 1.8 3.27E‐02
212632 C79267 112 205 1.8 6.16E‐03
20471 Six1 56 102 1.8 1.33E‐02
28113 Tinf2 184 336 1.8 1.36E‐02
72046 2010005J08Rik 90 164 1.8 2.58E‐03
60532 Wtap 96 175 1.8 1.18E‐02
235036 Ppan 79 143 1.8 3.30E‐02
231872 Jtv1 156 282 1.8 1.44E‐02
75871 Zfp821 98 178 1.8 4.50E‐02
68295 0610011L14Rik 136 247 1.8 4.73E‐03
73338 Itpripl1 179 319 1.8 1.46E‐02
67311 Nanp 91 163 1.8 1.45E‐02
100213 Rusc2 100 177 1.8 4.94E‐02
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54343 Atf7ip 76 134 1.8 4.57E‐02
101471 Phrf1 89 156 1.8 3.17E‐02
353190 Edc3 76 134 1.8 1.33E‐02
276852 D11Wsu47e 178 312 1.8 1.03E‐03
78733 Troap 66 115 1.8 4.98E‐02
66617 Mettl11a 129 227 1.8 2.38E‐02
214791 Sertad4 78 136 1.7 1.35E‐02
217198 Plekhh3 103 179 1.7 1.39E‐02
218581 Depdc1b 92 160 1.7 4.09E‐02
16475 Jub 43 74 1.7 1.64E‐02
12449 Ccnf 45 79 1.7 2.28E‐02
22030 Traf2 71 124 1.7 1.28E‐02
72549 Reep4 120 208 1.7 1.95E‐02
20353 Sema4c 54 93 1.7 1.66E‐02
106894 A630042L21Rik 88 153 1.7 3.97E‐02
57815 Spata5 83 143 1.7 8.72E‐03
66597 Trim13 74 127 1.7 2.74E‐03
217331 Unk 101 174 1.7 4.83E‐02
53890 Sart3 119 204 1.7 1.44E‐02
59016 Thap11 123 211 1.7 2.58E‐02
68730 Dus1l 122 209 1.7 3.34E‐04
16190 Il4ra 68 116 1.7 4.52E‐02
228790 Asxl1 73 124 1.7 7.37E‐03
66513 Map3k7ip1 101 171 1.7 2.07E‐02
70427 Mier2 103 173 1.7 9.52E‐05
17165 Mapkapk5 124 208 1.7 5.87E‐03
66680 3230401D17Rik 63 106 1.7 3.63E‐02
320790 Chd7 113 187 1.7 1.47E‐03
74157 1300018I05Rik 99 164 1.6 5.52E‐04
53892 Ppm1d 70 114 1.6 1.82E‐02
68350 Mul1 88 144 1.6 2.96E‐02
72486 Rnf219 88 143 1.6 6.18E‐03
232855 BC023179 135 216 1.6 1.43E‐02
108912 Cdca2 79 127 1.6 9.08E‐03
209815 Tbc1d25 94 150 1.6 9.98E‐03
100047059 LOC100047059 102 164 1.6 8.51E‐03
16007 Cyr61 35 56 1.6 1.01E‐02
20620 Plk2 34 54 1.6 3.37E‐02
72171 Shq1 161 256 1.6 2.40E‐02
234582 Ccdc102a 131 204 1.6 4.32E‐02
67219 Med18 52 81 1.6 3.37E‐02
66680 3230401D17Rik 66 103 1.6 3.87E‐02
214855 Arid5a 143 221 1.5 2.35E‐02
319192 Hist2h2aa2 53 81 1.5 3.18E‐02
16362 Irf1 45 68 1.5 1.98E‐02
80838 Hist1h1a 45 68 1.5 1.06E‐03
78294 Rps27a 105 159 1.5 4.67E‐02
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17684 Cited2 65 98 1.5 5.11E‐03
67849 Cdca5 79 119 1.5 4.87E‐02
18654 Pgf 57 86 1.5 1.67E‐02
319192 Hist2h2aa2 65 96 1.5 3.24E‐02
22033 Traf5 83 122 1.5 3.72E‐02
665433 RP23‐480B19.10 51 75 1.5 1.05E‐02
66213 Med7 101 146 1.4 2.41E‐02
665433 RP23‐480B19.10 67 96 1.4 1.95E‐02
665433 RP23‐480B19.10 67 95 1.4 2.22E‐02
665433 RP23‐480B19.10 67 95 1.4 2.22E‐02
665433 RP23‐480B19.10 64 90 1.4 1.61E‐02
52521 Zfp622 89 123 1.4 3.61E‐02




























































































































































































































Appendix 5 continued 
 
Validation of novel mRNA targets of CUGBP1 in muscle cells. Half-lives of indicated mRNAs 
were determined in LKO-1 and CUGBP1 KD cell lines by qRT-PCR. Error bars represent the 
standard deviation.  Transcripts where no difference between LKO-1 and CUGBP1 KD was found 



































































































































Gene ID Gene Name
Signal-to-
Negative Rank (%) 
21771 Cirh1a 22.96 100.0
98258 Txndc9 20.70 100.0
68724 Arl8a 20.57 100.0
20443 St3gal4 20.33 100.0
109284 C030046I01Rik 18.72 100.0
11984 Atp6v0c 18.18 100.0
54208 Arl6ip1 17.97 100.0
56349 Net1 16.68 100.0
11984 Atp6v0c 16.08 100.0
13358 Slc25a1 16.07 99.9
98258 Txndc9 15.87 99.9
67141 Fbxo5 15.81 99.9
11984 Atp6v0c 15.42 99.9
13663 Ei24 15.12 99.9
12237 Bub3 14.55 99.9
67636 Lyrm5 14.40 99.9
22154 Tubb5 14.14 99.9
15374 Hn1 13.89 99.9
94280 Sfxn3 13.68 99.9
74194 Rnd3 13.66 99.9
12767 Cxcr4 13.41 99.9
209448 Hoxc10 13.40 99.9
76551 Ccdc6 13.15 99.9
66940 Shisa5 12.77 99.9
14467 Gbas 12.71 99.9
12111 Bgn 12.37 99.9
15081 H3f3b 12.34 99.9
100044509 LOC100044509 12.13 99.8
70088 2310005N01Rik 12.09 99.8
15081 H3f3b 11.96 99.8
246256 Fcgr4 11.68 99.8
66442 Spc25 11.62 99.8
68969 Eif1b 11.50 99.8
223922 Atf7 11.42 99.8
674164 LOC674164 11.33 99.8
13688 Eif4ebp2 11.31 99.8
213742 Xist 11.26 99.8
15081 H3f3b 11.24 99.8
223922 Atf7 11.20 99.8
15081 H3f3b 11.06 99.8
98711 Rdh10 10.89 99.8
434401 EG434401 10.72 99.8
384009 Glipr2 10.72 99.8
66094 Lsm7 10.68 99.8
Signal-to-negative ratios for RIP-chip experiment. 56398 1500003O03Rik 10.67 99.8
56457 Clptm1 10.64 99.7
66094 Lsm7 10.55 99.7
211488 Ado 10.53 99.7
105171 Arrdc3 10.46 99.7
71371 Arid5b 10.30 99.7
15368 Hmox1 10.26 99.7
20610 Sumo3 10.15 99.7
16848 Lfng 10.06 99.7
19108 Prkx 10.05 99.7
74648 S100pbp 10.02 99.7
68929 Mospd3 9.99 99.7
68066 Slc25a39 9.90 99.7
66799 Ube2w 9.89 99.7
22785 Slc30a4 9.87 99.7
51792 Ppp2r1a 9.74 99.7
67942 Atp5g2 9.69 99.7
22004 Tpm2 9.64 99.7
434401 EG434401 9.56 99.6
192662 Arhgdia 9.53 99.6
56693 Crtap 9.52 99.6
77889 Lbh 9.49 99.6
208228 Mobkl2a 9.46 99.6
11555 Adrb2 9.43 99.6
76987 Hdhd2 9.38 99.6
100127111 Snord22 9.32 99.6
114143 Atp6v0b 9.17 99.6
674164 LOC674164 9.17 99.6
67942 Atp5g2 9.11 99.6
26394 Lypla2 9.03 99.6
100048649 LOC100048649 9.03 99.6
97863 C78339 9.01 99.6
14368 Fzd6 9.01 99.6
12540 Cdc42 8.96 99.6
67942 Atp5g2 8.96 99.6
70310 Plscr3 8.79 99.6
20437 Siah1a 8.79 99.5
16647 Kpna2 8.76 99.5
19056 Ppp3cb 8.71 99.5
16647 Kpna2 8.70 99.5
21749 Terf1 8.69 99.5
16478 Jund 8.65 99.5
217558 6030408C04Rik 8.64 99.5
636070 EG636070 8.64 99.5
74868 Tmem65 8.63 99.5
18023 Nfe2l1 8.60 99.5
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16647 Kpna2 8.50 99.5
22240 Dpysl3 8.38 99.5
21366 Slc6a6 8.35 99.5
223455 6-Mar 8.32 99.5
18637 Pfdn2 8.30 99.5
17927 Myod1 8.30 99.5
66234 Sc4mol 8.19 99.4
73826 Poldip3 8.18 99.4
212111 Inpp5a 8.07 99.4
66508 2400001E08Rik 8.03 99.4
320267 Fubp3 8.00 99.4
17775 Laptm4a 7.98 99.4
22088 Tsg101 7.95 99.4
54401 Ywhab 7.86 99.4
68801 Elovl5 7.85 99.4
56473 Fads2 7.85 99.4
56371 Fzr1 7.83 99.4
68926 Ubap2 7.74 99.4
226178 D19Wsu162e 7.69 99.4
53817 Bat1a 7.65 99.4
26416 Mapk14 7.64 99.4
67393 Cxxc5 7.62 99.4
11777 Ap3s1 7.52 99.4
56351 Ptges3 7.52 99.4
11933 Atp1b3 7.49 99.3
56351 Ptges3 7.48 99.3
110454 Ly6a 7.47 99.3
19345 Rab5c 7.43 99.3
208715 Hmgcs1 7.41 99.3
17928 Myog 7.41 99.3
228005 Ppig 7.38 99.3
54351 Rai12 7.33 99.3
16476 Jun 7.29 99.3
53945 Slc40a1 7.28 99.3
19046 Ppp1cb 7.22 99.3
74747 Ddit4 7.16 99.3
68799 Rgmb 7.12 99.3
97820 4833439L19Rik 7.11 99.3
16835 Ldlr 7.10 99.3
11777 Ap3s1 6.96 99.3
68612 Ube2c 6.96 99.3
107732 Mrpl10 6.95 99.3
66522 Pgpep1 6.94 99.2
70296 Tbc1d13 6.93 99.2
56397 Morf4l2 6.93 99.2
11777 Ap3s1 6.90 99.2
71446 Wrb 6.86 99.2
107566 Arl2bp 6.83 99.2
71833 Wdr68 6.83 99.2
22196 Ube2i 6.82 99.2
230125 Mcart1 6.80 99.2
106248 Qtrtd1 6.77 99.2
239096 Cdh24 6.74 99.2
67515 Ttc33 6.74 99.2
20971 Sdc4 6.72 99.2
12443 Ccnd1 6.62 99.2
16319 Incenp 6.61 99.2
107513 Ssr1 6.56 99.2
11798 Xiap 6.55 99.2
83383 Tcfap4 6.53 99.1
56351 Ptges3 6.49 99.1
101142 Itfg2 6.49 99.1
665860 EG665860 6.49 99.1
71918 Zcchc24 6.48 99.1
14674 Gna13 6.47 99.1
22088 Tsg101 6.44 99.1
66290 Atp6v1g1 6.44 99.1
22196 Ube2i 6.43 99.1
20393 Sgk1 6.43 99.1
70546 Zdhhc2 6.38 99.1
214459 Fnbp1l 6.38 99.1
50918 Myadm 6.37 99.1
68564 Nufip2 6.33 99.1
104625 Cnot6 6.31 99.1
665860 EG665860 6.29 99.1
101185 Pot1a 6.28 99.1
12571 Cdk6 6.26 99.1
50784 Ppap2c 6.26 99.0
20652 Soat1 6.26 99.0
66632 Atpbd4 6.25 99.0
16323 Inhba 6.24 99.0
78541 Asb8 6.23 99.0
16533 Kcnmb1 6.22 99.0
216344 Rab21 6.21 99.0
17131 Smad7 6.19 99.0
192196 Luc7l2 6.17 99.0
101358 Fbxl14 6.17 99.0
382423 ENSMUSG000000 6.16 99.0
14062 F2r 6.14 99.0
19326 Rab11b 6.06 99.0
81489 Dnajb1 6.05 99.0
23992 Prkra 6.00 99.0
73469 Rnf38 6.00 99.0
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66290 Atp6v1g1 5.95 98.9
12934 Dpysl2 5.94 98.9
29812 Ndrg3 5.94 98.9
67554 Slc25a30 5.92 98.9
12527 Cd9 5.92 98.9
21750 Terf2 5.90 98.9
72999 Insig2 5.90 98.9
218793 Ube2e2 5.87 98.9
18787 Serpine1 5.84 98.9
226151 6030443O07Rik 5.82 98.9
224938 Pja2 5.79 98.9
26905 Eif2s3x 5.76 98.9
100040099 ENSMUSG000000 5.76 98.9
16828 Ldha 5.76 98.9
104318 Csnk1d 5.74 98.9
21416 Tcf7l2 5.73 98.9
114128 Laptm4b 5.72 98.9
170742 Sertad3 5.71 98.9
218975 Mapk1ip1l 5.70 98.8
20682 Sox9 5.68 98.8
12534 Cdc2a 5.65 98.8
67125 Tspan31 5.62 98.8
192657 Ell2 5.62 98.8
69065 Chac1 5.61 98.8
241296 Lrrc8a 5.59 98.8
54198 Snx3 5.57 98.8
19179 Psmc1 5.56 98.8
13990 Smarcad1 5.55 98.8
20877 Aurkb 5.54 98.8
76178 6330578E17Rik 5.54 98.8
67171 Tmem77 5.54 98.8
59090 Midn 5.53 98.8
80904 Dtx3 5.51 98.8
14026 Evl 5.51 98.8
12340 Capza1 5.47 98.8
11909 Atf2 5.45 98.8
74137 Nuak2 5.45 98.7
69288 Rhobtb1 5.43 98.7
11512 Adcy6 5.41 98.7
18453 P4hb 5.41 98.7
100043982 LOC100043982 5.40 98.7
12340 Capza1 5.37 98.7
73137 Prrc1 5.37 98.7
63959 Slc29a1 5.36 98.7
66578 2610039C10Rik 5.32 98.7
66511 2500003M10Rik 5.32 98.7
68581 Tmed10 5.31 98.7
224647 D17Wsu92e 5.30 98.7
19231 Ptma 5.26 98.7
209497 Tmem164 5.25 98.7
56737 Alg2 5.25 98.7
66618 2610209M04Rik 5.24 98.7
18648 Pgam1 5.23 98.7
18648 Pgam1 5.23 98.7
66390 Slmo2 5.22 98.6
640370 EG640370 5.22 98.6
100044416 LOC100044416 5.22 98.6
13972 Gnb1l 5.20 98.6
83797 Smarcd1 5.18 98.6
235072 7-Sep 5.18 98.6
640370 EG640370 5.18 98.6
14904 Gtpbp1 5.18 98.6
22390 Wee1 5.16 98.6
108705 Pttg1ip 5.16 98.6
27801 Zdhhc8 5.14 98.6
52398 11-Sep 5.13 98.6
240334 Pcyox1l 5.12 98.6
13728 Mark2 5.12 98.6
16784 Lamp2 5.11 98.6
26572 Cops3 5.09 98.6
12575 Cdkn1a 5.07 98.6
83486 Rbm5 5.06 98.5
68581 Tmed10 5.06 98.5
63953 Dusp10 5.06 98.5
105440 Kctd9 5.05 98.5
14567 Gdi1 5.03 98.5
68970 Wdr40a 5.02 98.5
381038 Parl 5.01 98.5
268490 Lsm12 4.99 98.5
70527 Stambp 4.99 98.5
23790 Coro1c 4.97 98.5
19231 Ptma 4.97 98.5
18648 Pgam1 4.96 98.5
70551 Tmtc4 4.96 98.5
19231 Ptma 4.96 98.5
77644 C330007P06Rik 4.95 98.5
66140 1110001A07Rik 4.95 98.5
67468 Mmd 4.94 98.5
52696 Zwint 4.94 98.5
675534 LOC675534 4.94 98.4
64453 Zfp280b 4.93 98.4
211347 Pank3 4.92 98.4
380959 Alg10b 4.91 98.4
109006 Ciapin1 4.90 98.4
184 
 




68911 Pygo2 4.89 98.4
228836 Dlgap4 4.88 98.4
15395 Hoxa10 4.88 98.4
56376 Pdlim5 4.85 98.4
19330 Rab18 4.84 98.4
52635 D12Ertd551e 4.83 98.4
22325 Vav2 4.83 98.4
72486 Rnf219 4.82 98.4
12444 Ccnd2 4.82 98.4
15200 Hbegf 4.80 98.4
56443 Arpc1a 4.79 98.4
56501 ENSMUSG000000 4.79 98.4
75869 Arl5b 4.78 98.3
11480 Acvr2a 4.77 98.3
56878 Rbms1 4.77 98.3
99151 Cercam 4.76 98.3
98415 Nucks1 4.76 98.3
20249 Scd1 4.74 98.3
19230 Twf1 4.71 98.3
76303 Osbp 4.71 98.3
103743 Tmem98 4.71 98.3
240028 Lnpep 4.70 98.3
68713 Ifitm1 4.70 98.3
12531 Cdc25b 4.70 98.3
18227 Nr4a2 4.70 98.3
12417 Cbx3 4.70 98.3
69085 Zcchc9 4.70 98.3
108954 Ppp1r15b 4.69 98.3
66059 Krtcap2 4.68 98.3
94275 Maged1 4.67 98.3
24075 Taf10 4.67 98.2
116940 Tgs1 4.66 98.2
19084 Prkar1a 4.65 98.2
19192 Psme3 4.65 98.2
14007 Cugbp2 4.65 98.2
18035 Nfkbia 4.64 98.2
70319 2600006K01Rik 4.63 98.2
20315 Cxcl12 4.62 98.2
107368 Pdzd8 4.62 98.2
19324 Rab1 4.61 98.2
675440 OTTMUSG0000001 4.61 98.2
59043 Wsb2 4.61 98.2
226251 Ablim1 4.61 98.2
675440 OTTMUSG0000001 4.60 98.2
18605 Enpp1 4.59 98.2
15939 Ier5 4.57 98.2
77853 Msl2l1 4.57 98.2
81535 Sgpp1 4.57 98.1
19230 Twf1 4.54 98.1
18708 Pik3r1 4.54 98.1
19156 Psap 4.53 98.1
16911 Lmo4 4.53 98.1
17134 Mafg 4.52 98.1
11842 Arf3 4.51 98.1
56233 Hdac7 4.51 98.1
78521 B230219D22Rik 4.51 98.1
19179 Psmc1 4.51 98.1
675440 OTTMUSG0000001 4.51 98.1
665155 Srp54b 4.50 98.1
19206 Ptch1 4.50 98.1
26442 Psma5 4.49 98.1
13874 Ereg 4.48 98.1
140499 Ube2j2 4.47 98.1
57339 Jph1 4.47 98.1
19139 Prps1 4.46 98.1
67145 Tomm34 4.45 98.0
11911 Atf4 4.45 98.0
22215 Ube3a 4.45 98.0
18475 Pafah1b2 4.45 98.0
20333 Sec22b 4.45 98.0
21973 Top2a 4.44 98.0
218581 Depdc1b 4.44 98.0
18174 Slc11a2 4.44 98.0
66206 1110059E24Rik 4.44 98.0
20474 Six4 4.43 98.0
66508 2400001E08Rik 4.42 98.0
229782 Slc35a3 4.42 98.0
12399 Runx3 4.40 98.0
67213 Cmtm6 4.39 98.0
30939 Pttg1 4.39 98.0
17387 Mmp14 4.38 98.0
71805 Nup93 4.38 98.0
15568 Elavl1 4.37 98.0
11908 Atf1 4.36 97.9
12848 Cops2 4.36 97.9
236848 BC023829 4.36 97.9
12417 Cbx3 4.35 97.9
19646 Rbbp4 4.34 97.9
12417 Cbx3 4.34 97.9
22318 Vamp2 4.34 97.9
101867 1500003O22Rik 4.34 97.9
268448 Phf12 4.33 97.9
56399 Akap8 4.33 97.9
319622 Itpripl2 4.33 97.9
185 
 




100201 Tmem64 4.32 97.9
319622 Itpripl2 4.32 97.9
214137 Arhgap29 4.32 97.9
665283 OTTMUSG0000000 4.32 97.9
13046 Cugbp1 4.31 97.9
215449 Rap1b 4.31 97.9
22151 Tubb2a 4.29 97.8
14595 B4galt1 4.29 97.8
100226 Stx12 4.29 97.8
545085 Wdr70 4.29 97.8
218460 Wdr41 4.28 97.8
68837 Foxk2 4.28 97.8
194655 Klf11 4.28 97.8
68842 Tulp4 4.28 97.8
638636 638636 4.27 97.8
107767 Scamp1 4.27 97.8
21423 Tcfe2a 4.27 97.8
20148 Dhrs3 4.26 97.8
230257 Rod1 4.26 97.8
327826 Frs2 4.26 97.8
667723 EG667723 4.25 97.8
675440 OTTMUSG0000001 4.24 97.8
12631 Cfl1 4.23 97.8
233724 Tmem41b 4.23 97.8
11652 Akt2 4.23 97.7
58523 Elp2 4.21 97.7
225339 Ammecr1l 4.19 97.7
19291 Purb 4.19 97.7
23849 Klf6 4.18 97.7
67219 Med18 4.18 97.7
71779 8-Mar 4.17 97.7
16430 Stt3a 4.17 97.7
19141 Lgmn 4.17 97.7
13557 E2f3 4.16 97.7
17684 Cited2 4.16 97.7
12449 Ccnf 4.16 97.7
12972 Cryz 4.16 97.7
17261 Mef2d 4.15 97.7
56494 Gosr2 4.15 97.7
16392 Isl1 4.14 97.7
54138 Atxn10 4.14 97.7
75734 Mff 4.14 97.6
67464 Entpd4 4.14 97.6
66700 Vps24 4.14 97.6
327900 Ubtd2 4.13 97.6
12520 Cd81 4.13 97.6
68441 Rraga 4.13 97.6
74102 Slc35a5 4.12 97.6
15251 Hif1a 4.12 97.6
223870 Senp1 4.12 97.6
233575 Frag1 4.11 97.6
14451 Gas1 4.11 97.6
11652 Akt2 4.10 97.6
74383 Ubap2l 4.10 97.6
19252 Dusp1 4.10 97.6
76789 2410129H14Rik 4.10 97.6
22234 Ugcg 4.09 97.6
225995 D030056L22Rik 4.09 97.6
76789 2410129H14Rik 4.09 97.6
21825 Thbs1 4.09 97.5
667723 EG667723 4.09 97.5
56356 Gltp 4.09 97.5
21859 Timp3 4.09 97.5
675440 OTTMUSG0000001 4.09 97.5
140499 Ube2j2 4.09 97.5
28042 D5Wsu178e 4.07 97.5
16011 Igfbp5 4.06 97.5
12330 Canx 4.04 97.5
76775 Slc10a7 4.04 97.5
75841 Rnf139 4.03 97.5
13002 Dnajc5 4.03 97.5
67501 Ccdc50 4.02 97.5
12469 Cct8 4.02 97.5
11966 Atp6v1b2 4.02 97.5
75219 Dusp18 4.02 97.5
12633 Cflar 4.02 97.5
107971 Frs3 4.01 97.5
56442 Serinc1 4.01 97.4
269987 2610024B07Rik 4.01 97.4
19042 Ppm1a 3.98 97.4
22146 Tuba1c 3.97 97.4
83673 Snhg1 3.97 97.4
223989 4921513D23Rik 3.96 97.4
667723 EG667723 3.96 97.4
13046 Cugbp1 3.96 97.4
54633 Pqbp1 3.95 97.4
29864 Rnf11 3.95 97.4
19664 Rbpj 3.95 97.4
72183 Snx6 3.94 97.4
667723 EG667723 3.94 97.4
19684 Rdx 3.93 97.4
98267 Stk17b 3.93 97.4
19826 Rnps1 3.93 97.4
14252 Flot2 3.93 97.4
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22344 Vezf1 3.92 97.3
74287 Kcmf1 3.92 97.3
11787 Apbb2 3.92 97.3
72124 Seh1l 3.89 97.3
381038 Parl 3.88 97.3
65960 Twsg1 3.87 97.3
74012 Rap2b 3.87 97.3
67443 Map1lc3b 3.87 97.3
228136 Zdhhc5 3.87 97.3
71801 Plekhf2 3.86 97.3
19826 Rnps1 3.85 97.3
108645 Mat2b 3.85 97.3
13713 Elk3 3.84 97.3
15481 Hspa8 3.84 97.3
15481 Hspa8 3.84 97.3
22631 Ywhaz 3.84 97.3
22146 Tuba1c 3.84 97.3
19872 Rny1 3.83 97.3
233812 BC030336 3.82 97.2
80795 Selk 3.82 97.2
100044642 LOC100044642 3.82 97.2
22196 Ube2i 3.82 97.2
110911 Cds2 3.81 97.2
15312 Hmgn1 3.81 97.2
100038401 ENSMUSG000000 3.81 97.2
13685 Eif4ebp1 3.81 97.2
68097 Dynll2 3.81 97.2
13684 Eif4e 3.81 97.2
226151 6030443O07Rik 3.80 97.2
108907 Nusap1 3.79 97.2
71949 Lass5 3.79 97.2
65103 Arl6ip6 3.79 97.2
237459 Pctk2 3.78 97.2
72972 Gcap14 3.78 97.2
224105 Pak2 3.78 97.2
229517 Slc25a44 3.77 97.2
56878 Rbms1 3.77 97.1
56332 Amotl2 3.77 97.1
50926 Hnrpdl 3.76 97.1
16589 Uhmk1 3.76 97.1
13803 Enc1 3.76 97.1
13798 En1 3.76 97.1
26442 Psma5 3.76 97.1
19087 Prkar2a 3.76 97.1
73067 Tmem192 3.75 97.1
71900 Tmem106b 3.75 97.1
68108 9430008C03Rik 3.75 97.1
56334 Tmed2 3.75 97.1
224903 Safb 3.75 97.1
26360 Angptl2 3.74 97.1
13135 Dad1 3.74 97.1
19777 C80913 3.73 97.1
21372 Tbl1x 3.73 97.1
433762 LOC433762 3.73 97.0
433762 LOC433762 3.73 97.0
20788 Srebf2 3.73 97.0
78755 4632404H22Rik 3.73 97.0
15234 Hgf 3.73 97.0
677333 677333 3.72 97.0
110213 Tegt 3.72 97.0
17188 Maz 3.72 97.0
72946 Lrrc47 3.72 97.0
12151 Bmi1 3.71 97.0
12306 Anxa2 3.71 97.0
108911 Rcc2 3.71 97.0
67898 Pef1 3.71 97.0
67760 Slc38a2 3.71 97.0
229542 Gatad2b 3.71 97.0
109270 Prr5 3.70 97.0
17449 Mdh1 3.70 97.0
277463 Gpr107 3.70 97.0
224170 Dzip3 3.69 96.9
28193 Reep3 3.69 96.9
545216 EG545216 3.69 96.9
321022 Cdv3 3.69 96.9
68916 Cdkal1 3.68 96.9
20878 Aurka 3.68 96.9
56334 Tmed2 3.68 96.9
72562 Pcbd2 3.68 96.9
67490 1810074P20Rik 3.67 96.9
100048094 LOC100048094 3.67 96.9
14825 Cxcl1 3.66 96.9
12417 Cbx3 3.66 96.9
209032 Zc3hav1l 3.66 96.9
22388 Wdr1 3.66 96.9
20729 Spin1 3.65 96.9
210992 Lpcat1 3.64 96.9
100048094 LOC100048094 3.64 96.9
68337 Crip2 3.63 96.8
236794 Slc9a6 3.63 96.8
18148 Npm1 3.63 96.8
215193 AA408296 3.62 96.8
68365 Rab14 3.62 96.8
11520 Adfp 3.62 96.8
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217653 C79407 3.61 96.8
110172 Slc35b1 3.61 96.8
67510 1810036I24Rik 3.60 96.8
19027 Sypl 3.60 96.8
19384 Ran 3.60 96.8
20583 Snai2 3.60 96.8
320213 Senp5 3.60 96.8
19353 Rac1 3.59 96.8
66661 Srp72 3.59 96.8
241576 Ldlrad3 3.58 96.8
67229 Prpf18 3.57 96.8
70620 Ube2v2 3.57 96.8
22319 Vamp3 3.57 96.7
72018 Fundc1 3.57 96.7
109154 2410014A08Rik 3.57 96.7
68151 Gpr177 3.57 96.7
67698 Fam174a 3.57 96.7
22099 Tsn 3.56 96.7
210998 D15Ertd621e 3.56 96.7
20750 Spp1 3.56 96.7
74026 4121402D02Rik 3.56 96.7
665155 Srp54b 3.55 96.7
22146 Tuba1c 3.55 96.7
69082 Zc3h15 3.55 96.7
381820 2700089E24Rik 3.54 96.7
20383 Sfrs3 3.54 96.7
12336 Capns1 3.54 96.7
66492 Zmat2 3.54 96.7
22381 Wbp5 3.53 96.7
67771 Arpc5 3.53 96.7
14958 H1f0 3.52 96.6
67958 2610101N10Rik 3.51 96.6
12417 Cbx3 3.51 96.6
12417 Cbx3 3.51 96.6
75553 Zc3h14 3.51 96.6
100048094 LOC100048094 3.51 96.6
22146 Tuba1c 3.51 96.6
71804 2610016C23Rik 3.51 96.6
100042180 LOC100042180 3.51 96.6
234663 Dync1li2 3.51 96.6
208292 9030612M13Rik 3.51 96.6
19821 Rnf2 3.50 96.6
229279 Hnrnpa3 3.49 96.6
18003 Nedd9 3.49 96.6
68024 Hist1h2bc 3.49 96.6
21413 Tcf4 3.49 96.6
56294 Ptpn9 3.48 96.6
100048094 LOC100048094 3.48 96.5
100042180 LOC100042180 3.48 96.5
22668 Sf1 3.48 96.5
18578 Pde4b 3.48 96.5
791412 OTTMUSG0000000 3.48 96.5
68473 Mobkl1a 3.47 96.5
68904 Abhd13 3.47 96.5
56217 Mpp5 3.47 96.5
72033 Tsc22d2 3.46 96.5
67704 1810037I17Rik 3.46 96.5
213491 D4Ertd22e 3.46 96.5
116891 Derl2 3.46 96.5
114716 Spred2 3.46 96.5
268697 Ccnb1 3.46 96.5
76179 Usp31 3.46 96.5
207521 Dtx4 3.45 96.5
97998 Depdc6 3.45 96.5
668347 EG668347 3.45 96.5
65112 Pmepa1 3.44 96.4
432537 OTTMUSG0000000 3.43 96.4
12371 Casp9 3.43 96.4
19352 Rabggtb 3.43 96.4
218203 Mylip 3.43 96.4
18515 Pbx2 3.43 96.4
329154 Ankrd44 3.42 96.4
13445 Cdk2ap1 3.42 96.4
56772 Mllt11 3.42 96.4
15257 Hipk1 3.42 96.4
21415 Tcf3 3.42 96.4
22221 Ubp1 3.42 96.4
56334 Tmed2 3.42 96.4
20397 Sgpl1 3.41 96.4
109154 2410014A08Rik 3.41 96.4
20454 St3gal5 3.41 96.4
13831 Epc1 3.41 96.4
226026 Smc5 3.41 96.3
268697 Ccnb1 3.41 96.3
226154 Lzts2 3.40 96.3
229279 Hnrnpa3 3.40 96.3
16653 Kras 3.40 96.3
268697 Ccnb1 3.40 96.3
238330 6430527G18Rik 3.40 96.3
11732 Ank 3.39 96.3
68713 Ifitm1 3.39 96.3
14234 Foxc2 3.39 96.3
103573 Xpo1 3.39 96.3
546080 EG546080 3.39 96.3
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72416 Lrpprc 3.39 96.3
433261 EG433261 3.39 96.3
18858 Pmp22 3.39 96.3
70420 2610034B18Rik 3.38 96.3
100043485 100043485 3.38 96.3
100043314 Vstm3 3.38 96.3
241311 Zbtb34 3.38 96.2
68051 Nutf2 3.38 96.2
65247 Asb1 3.38 96.2
27054 Sec23b 3.38 96.2
72265 Tram1 3.38 96.2
12417 Cbx3 3.37 96.2
70155 Ogfrl1 3.37 96.2
217337 Srp68 3.37 96.2
22152 Tubb3 3.37 96.2
71448 Tmem80 3.37 96.2
27984 Efhd2 3.37 96.2
319448 Fndc3a 3.37 96.2
66307 Isoc1 3.36 96.2
69568 Vkorc1l1 3.36 96.2
72542 Pgam5 3.36 96.2
20383 Sfrs3 3.36 96.2
107358 Tm9sf3 3.36 96.2
50721 Sirt6 3.36 96.2
83602 Gtf2a1 3.36 96.1
93730 Lztfl1 3.36 96.1
15405 Hoxa9 3.35 96.1
18391 Oprs1 3.35 96.1
14700 Gng10 3.35 96.1
271981 A630047E20Rik 3.35 96.1
321022 Cdv3 3.34 96.1
448987 Fbxl7 3.34 96.1
12317 Calr 3.33 96.1
72949 Ccnt2 3.33 96.1
14688 Gnb1 3.32 96.1
56386 B4galt6 3.32 96.1
101476 Plekha1 3.32 96.1
214597 Sidt2 3.32 96.1
73158 Larp1 3.32 96.1
59043 Wsb2 3.32 96.1
68137 Kdelr1 3.31 96.1
13589 Mapre1 3.31 96.0
13390 Dlx1 3.31 96.0
13445 Cdk2ap1 3.31 96.0
665250 OTTMUSG0000000 3.30 96.0
76073 Pcgf5 3.30 96.0
229279 Hnrnpa3 3.30 96.0
229279 Hnrnpa3 3.30 96.0
52626 Cdkn2aipnl 3.29 96.0
59125 Nek7 3.29 96.0
14470 Rabac1 3.29 96.0
57810 Cdon 3.29 96.0
56496 Tspan6 3.28 96.0
546032 EG546032 3.28 96.0
18701 Pigf 3.27 96.0
11793 Atg5 3.27 96.0
22763 Zfr 3.27 96.0
66143 Eef1e1 3.27 96.0
18647 Pftk1 3.26 96.0
20910 Stxbp1 3.26 95.9
69912 Nup43 3.26 95.9
218121 Mboat1 3.26 95.9
320063 B230354K17Rik 3.26 95.9
66078 Tsen34 3.26 95.9
53331 Stx7 3.25 95.9
20539 Slc7a5 3.25 95.9
80912 Pum1 3.25 95.9
14824 Grn 3.25 95.9
791412 OTTMUSG0000000 3.25 95.9
434356 EG434356 3.25 95.9
17758 Mtap4 3.25 95.9
15980 Ifngr2 3.25 95.9
14605 Tsc22d3 3.25 95.9
229279 Hnrnpa3 3.25 95.9
27494 Amot 3.24 95.9
66074 Tmem167 3.24 95.9
19652 Rbm3 3.24 95.9
321022 Cdv3 3.24 95.8
15387 Hnrnpk 3.24 95.8
625801 EG625801 3.24 95.8
68051 Nutf2 3.24 95.8
68051 Nutf2 3.24 95.8
69554 Klhdc2 3.24 95.8
66817 Tmem170 3.24 95.8
170791 Rbm39 3.24 95.8
20362 8-Sep 3.23 95.8
226551 AI848100 3.23 95.8
67966 Zcchc10 3.23 95.8
67048 2610030H06Rik 3.23 95.8
67048 2610030H06Rik 3.23 95.8
56612 Pfdn5 3.23 95.8
56314 Zfp113 3.23 95.8
13498 Atn1 3.23 95.8
20384 Sfrs5 3.22 95.8
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69860 Eif1ad 3.22 95.7
14284 Fosl2 3.22 95.7
26939 Polr3e 3.22 95.7
13207 Ddx5 3.22 95.7
668063 EG668063 3.22 95.7
270066 Slc35e1 3.22 95.7
67006 Cisd2 3.22 95.7
20623 Snrk 3.22 95.7
232313 Glt8d4 3.21 95.7
56418 Ykt6 3.21 95.7
622469 OTTMUSG0000000 3.21 95.7
20168 Rtn3 3.21 95.7
100048094 LOC100048094 3.21 95.7
64164 Ifrg15 3.20 95.7
12048 Bcl2l1 3.20 95.7
57436 Gabarapl1 3.20 95.7
67248 Rpl39 3.20 95.7
17309 Mgat3 3.20 95.7
67963 Npc2 3.20 95.6
66439 2010012O05Rik 3.20 95.6
13852 Stx2 3.19 95.6
67710 Polr2g 3.19 95.6
329506 Ctdspl2 3.19 95.6
13929 Amz2 3.19 95.6
14230 Fkbp10 3.19 95.6
68041 Mid1ip1 3.18 95.6
18005 Nek2 3.18 95.6
17691 Snf1lk 3.18 95.6
101148 B630005N14Rik 3.18 95.6
108946 Zzz3 3.18 95.6
67039 Rbm25 3.17 95.6
100042107 100042107 3.17 95.6
72462 Rrp1b 3.17 95.6
14955 H19 3.17 95.6
15382 Hnrnpa1 3.16 95.6
622845 EG622845 3.16 95.5
100042289 100042289 3.16 95.5
268396 Sh3pxd2b 3.16 95.5
54196 Pabpn1 3.16 95.5
100434 Slc44a1 3.16 95.5
66624 Spcs2 3.15 95.5
13196 Ddef1 3.15 95.5
19652 Rbm3 3.15 95.5
192285 Phf21a 3.15 95.5
19225 Ptgs2 3.15 95.5
14462 Gata3 3.15 95.5
272589 Tbcel 3.15 95.5
229279 Hnrnpa3 3.14 95.5
209416 Gpkow 3.14 95.5
102098 Arhgef18 3.14 95.5
20024 Sub1 3.13 95.5
57437 Golga7 3.13 95.5
56468 Socs5 3.13 95.5
66915 Myeov2 3.13 95.4
54667 Atp8b2 3.12 95.4
22193 Ube2e3 3.12 95.4
67248 Rpl39 3.12 95.4
70533 Btf3l4 3.12 95.4
69563 2310015B20Rik 3.12 95.4
230779 Serinc2 3.11 95.4
97487 Cmtm4 3.11 95.4
17344 Pias2 3.11 95.4
277010 Marveld1 3.11 95.4
23983 Pcbp1 3.11 95.4
246103 Atxn7 3.11 95.4
20810 Srm 3.11 95.4
107765 Ankrd1 3.11 95.4
13178 Dck 3.10 95.4
107975 Pacs1 3.10 95.4
230761 Zfp362 3.09 95.4
67876 Coq10b 3.09 95.4
66258 Mrps17 3.09 95.3
229279 Hnrnpa3 3.09 95.3
15387 Hnrnpk 3.09 95.3
72881 Zdhhc4 3.09 95.3
59021 Rab2a 3.09 95.3
67070 Lsm14a 3.08 95.3
17118 Marcks 3.08 95.3
242291 Impad1 3.07 95.3
74585 Sppl3 3.07 95.3
433702 AU014645 3.07 95.3
66818 9130011J15Rik 3.07 95.3
78832 2700078E11Rik 3.07 95.3
100040260 Gm1862 3.06 95.3
78651 Lsm6 3.06 95.3
67857 Ppp6c 3.06 95.3
70144 Lrch3 3.06 95.3
20364 Sepw1 3.06 95.3
78825 5830417C01Rik 3.06 95.2
16562 Kif1c 3.05 95.2
26949 Vat1 3.05 95.2
21769 Zfand3 3.05 95.2
110809 Sfrs1 3.05 95.2
19652 Rbm3 3.05 95.2
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12798 Cnn2 3.05 95.2
15931 Ids 3.05 95.2
13865 Nr2f1 3.04 95.2
18148 Npm1 3.04 95.2
13345 Twist2 3.04 95.2
14593 Ggps1 3.04 95.2
215335 Slc36a1 3.04 95.2
22724 Zbtb7b 3.04 95.2
229279 Hnrnpa3 3.03 95.2
12868 Cox8a 3.03 95.2
72454 Ccdc71 3.03 95.2
108735 Sft2d2 3.03 95.2
23854 Def8 3.03 95.1
208968 Zfp280c 3.03 95.1
107260 Otub1 3.03 95.1
67733 Itgb3bp 3.03 95.1
219024 Tmem55b 3.03 95.1
20918 Eif1 3.02 95.1
12995 Csnk2a1 3.02 95.1
70510 Rnf167 3.02 95.1
69568 Vkorc1l1 3.01 95.1
56444 Actr10 3.01 95.1
70681 Fam175a 3.00 95.1
22682 Zfand5 3.00 95.1
103583 Fbxw11 3.00 95.1
72640 Mex3a 3.00 95.1
671652 Trav7-1 3.00 95.1
74168 Zdhhc16 3.00 95.1
13205 Ddx3x 3.00 95.1
69082 Zc3h15 3.00 95.0
230721 Pabpc4 2.99 95.0
18226 Nup62 2.99 95.0
16906 Lmnb1 2.99 95.0
11435 Chrna1 2.99 95.0
75747 Sesn3 2.99 95.0
12995 Csnk2a1 2.98 95.0
53424 Tsnax 2.98 95.0
53380 Psmd10 2.98 95.0
22629 Ywhah 2.98 95.0
69875 Ndufa11 2.98 95.0
74919 4930471M23Rik 2.98 95.0
101187 Parp11 2.97 95.0
18712 Pim1 2.97 95.0
545622 Ptpn3 2.97 95.0
20520 Slc22a5 2.97 95.0
76522 Lsm8 2.97 95.0






Clustering of the top 50 hexamers enriched in CUGBP1 IP dataset reveals binding site. 
(A.)The top 50 hexamers (by P-value ranking) from CUGBP1 bound mRNA 3’UTRs, clustered by 
relatedness of sequence. (B) Box and whisker plot of p-value ranges for the clustered groups of 












68904 Abhd13 98 2.4 1.8E‐05
50721 Sirt6 97 2.0 1.3E‐04
69860 Eif1ad 97 3.3 5.2E‐04
100043982 LOC100043982 99 2.6 8.4E‐04
13803 Enc1 98 2.9 1.1E‐03
68799 Rgmb 99 2.4 1.2E‐03
74194 Rnd3 100 3.1 1.3E‐03
64453 Zfp280b 99 2.9 1.5E‐03
19206 Ptch1 99 2.6 1.7E‐03
20877 Aurkb 99 4.6 1.7E‐03
20623 Snrk 97 2.6 1.8E‐03
13345 Twist2 97 3.1 3.3E‐03
105171 Arrdc3 100 3.2 3.8E‐03
67760 Slc38a2 98 1.9 4.7E‐03
17684 Cited2 98 1.5 5.1E‐03
56332 Amotl2 98 2.8 5.3E‐03
238330 6430527G18Rik 97 2.3 5.5E‐03
226178 D19Wsu162e 100 3.5 5.8E‐03
72486 Rnf219 99 1.6 6.2E‐03
26416 Mapk14 100 2.5 6.6E‐03
108954 Ppp1r15b 99 2.0 6.7E‐03
68911 Pygo2 99 3.3 6.7E‐03
114716 Spred2 98 3.0 6.7E‐03
13831 Epc1 97 2.0 6.9E‐03
11911 Atf4 99 3.9 7.8E‐03
102098 Arhgef18 97 2.0 8.1E‐03
75841 Rnf139 98 2.1 8.2E‐03
22390 Wee1 99 2.5 8.7E‐03
241296 Lrrc8a 99 1.8 9.2E‐03
16007 Cyr61 95 1.6 1.0E‐02
109263 Rlf 96 3.0 1.1E‐02
102193 Zdhhc7 96 1.9 1.1E‐02
13557 E2f3 95 3.1 1.1E‐02
72454 Ccdc71 97 2.0 1.1E‐02
11555 Adrb2 100 3.2 1.4E‐02
56772 Mllt11 97 3.0 1.5E‐02
13728 Mark2 99 3.0 1.6E‐02
381085 Tbc1d22b 96 3.0 1.8E‐02
76522 Lsm8 96 2.3 1.8E‐02
67141 Fbxo5 100 2.0 1.8E‐02
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16468 Jarid2 96 2.0 1.9E‐02
17131 Smad7 99 3.3 1.9E‐02
72549 Reep4 96 1.7 1.9E‐02
140482 Zfp358 95 2.7 2.0E‐02
68041 Mid1ip1 97 3.6 2.0E‐02
13990 Smarcad1 99 3.1 2.0E‐02
225339 Ammecr1l 98 2.7 2.1E‐02
72946 Lrrc47 98 3.4 2.3E‐02
14284 Fosl2 97 2.0 2.3E‐02
83486 Rbm5 99 1.8 2.3E‐02
12449 Ccnf 98 1.7 2.3E‐02
75234 Rnf19b 96 1.9 2.4E‐02
12531 Cdc25b 99 2.3 2.4E‐02
22325 Vav2 99 2.4 2.5E‐02
76969 Chst1 99 2.3 2.6E‐02
210106 Pols 95 2.3 2.6E‐02
268697 Ccnb1 97 4.0 2.8E‐02
21750 Terf2 99 2.6 2.8E‐02
17691 Snf1lk 97 2.2 3.0E‐02
226154 Lzts2 97 1.8 3.1E‐02
14739 S1pr2 96 2.6 3.2E‐02
219024 Tmem55b 97 1.7 3.3E‐02
67219 Med18 98 1.6 3.4E‐02
68970 Wdr40a 99 2.8 3.4E‐02
16835 Ldlr 99 2.6 3.5E‐02
27058 Srp9 96 2.7 3.5E‐02
20937 Suv39h1 96 2.7 3.6E‐02
232798 Leng8 95 2.3 3.7E‐02
77853 Msl2l1 99 2.6 3.7E‐02
18712 Pim1 96 2.3 4.0E‐02
63953 Dusp10 99 2.1 4.0E‐02
218581 Depdc1b 99 1.7 4.1E‐02
19822 Rnf4 95 3.0 4.1E‐02
66140 1110001A07Rik 99 3.1 4.1E‐02
210982 BC032203 95 2.7 4.3E‐02
12064 Bdnf 96 3.2 4.5E‐02
56371 Fzr1 100 2.1 4.6E‐02
16319 Incenp 99 2.4 4.6E‐02
66665 5730528L13Rik 96 2.9 4.6E‐02
23849 Klf6 98 2.6 4.6E‐02
107765 Ankrd1 97 2.6 4.7E‐02
170742 Sertad3 99 2.3 4.7E‐02
73847 5430432M24Rik 96 2.7 4.7E‐02
230761 Zfp362 97 2.9 4.8E‐02
71804 2610016C23Rik 98 2.5 4.8E‐02





Top 50 hexamers from transcripts stabilized  in the CUGBP1 knock-down dataset and  in 
the top 5% of the CUGBP1 IP dataset. (A.)The top 50 hexamers (by P-value ranking) from 
CUGBP1 bound mRNA 3’UTRs, and the stabilized in the CUGBP1 KD half-life array clustered by 
relatedness of sequence, and the corresponding sequence logo. (B) Box and whisker plot of p-
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CUGBP1 knock-down cell line and alternative shRNA (#1320) result in myosac formation 
and enhanced differentiation. (A) Immunofluorescence microscopy of 6 day differentiated 
myotubes from LKO-1and CUGBP1 KD cell lines from Chapter 3. (B) Immunofluorescence 
microscopy of 5 day differentiated myotubes from control and CUGBP1 KD cell pools sh1320 
(nuclei were stained with DAPI and are colored blue, MHC was detected with monoclonal 
antibody MF20 (colored green). (C) Fusion index of myoblast differentiation in control and 
CUGBP1 KD cell pools sh1320 (average of 3 independent experiments) where error bars 







A significant number of mRNAs are increased in abundance in both PARN and CUGBP1 
knock-down cells. Of the 144 mRNAs whose abundance was increased in the CUGBP1 KD 
cells, 20 were also elevated >2-fold in the PARN KD cells. This was significantly more than 
expected at random (number indicated in parentheses). GO terms enriched in the shared mRNAs 
are shown.  
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“axon guidance” p value =4.9x10-3
